MX2008003347A

MX2008003347A - Novel 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity.

Info

Publication number: MX2008003347A
Application number: MX2008003347A
Authority: MX
Inventors: Kenji Kawashima; Minoru Yamamoto; Mamoru Matsuda; Toshiyuki Mori; Masato Nagatsuka; Sachiko Kobayashi; Masatomo Kato; Miwa Takai; Tomoko Oda
Original assignee: Santen Pharma Co Ltd
Priority date: 2005-09-14
Filing date: 2006-09-14
Publication date: 2008-03-27

Abstract

The present invention aims to synthesize a novel 1,2-dihydroquinoline derivative and to find pharmacological effects of such a derivative. A compound represented by the general formula (1) below or a salt thereof is effective for treating diseases associated with a glucocorticoid receptor. In the formula below, ring X represents a benzene ring or a pyridine ring; R1 represents a halogen atom, an alkyl group, a hydroxy group, an alkoxy group, an amino group or the like; p represents an integer of 0-5; R2 represents a halogen atom, an alkyl group, a hydroxy group or the like; q represents an integer of 0-2; R3 represents a hydrogen atom, an alkyl group, an alkenyl group or the like; R4 and R5 respectively represent a hydrogen atom or the like; R6 represents a hydrogen atom or the like; A represents an alkylene group or the like; and R7 represents OR8, NR8R9, SR8, S(O)R8 or S(O)2R8, wherein R8 represents an aryl group, a heterocyclic group or the like and R9 represents a hydrogen atom or the like.

Description

NOVEDOUS 1, 2-DIHYDROQUINOLINE DERIVATIVE THAT HAS GLUCOCORTICOID RECEIVER UNION ACTIVITY TECHNICAL FIELD The present invention relates to a novel derivative of 1,2-dihydroquinoline or a salt thereof, which is useful as a pharmaceutical substance. The derivative has glucocorticoid receptor binding activity and is useful as a glucocorticoid receptor modulator having a non-steroidal structure (a glucocorticoid receptor agonist and / or a glucocorticoid receptor antagonist).

BACKGROUND OF THE ART The glucocorticoid receptor is a 94 kDa ligand-activated intracellular transcriptional factor that is a member of the nuclear receptor subfamily. It is known that this receptor regulates the metabolism of carbohydrates, proteins, fats and the like, suppresses immune or inflammatory responses, activates the central nervous system, regulates cardiovascular function and affects basal and tension-related homeostasis and the like due to its regulatory action transcriptional As metabolic disorders related to the glucocorticoid receptor, metabolic disorders such as diabetes and obesity, inflammatory diseases such as enteritis and chronic obstructive pulmonary diseases, autoimmune diseases such as co-active tissue diseases, allergic diseases such as asthma, atopic dermatitis and allergic rhinitis, central nervous system diseases such as psychiatric disorders, Alzheimer's disease and drug use, cardiovascular diseases such as hypertension, hypercalcemia, hyperinsulinamia and hyperlipidemia, diseases related to homeostasis that cause an abnormality of the neuro-immunological-endocrine balance, glaucoma and the like (SOUGOU RINSYOU, 54 (7), 1951-2076 (2005) and JP-A-2002-193955). Therefore, a compound having glucocorticoid receptor binding activity is considered to be useful as a preventive and / or therapeutic agent for these diseases. As such compound having glucocorticoid receptor binding activity, glucocorticoid receptor agonists synthesized in the living body such as corticosterone, synthetic glococorticoid receptor agonists such as dexamethasone, prednisone and prednisolone, antagonists of non-selective glucocorticoid receptors such as RU486 are known. (JP-a-2002-193955). On the other hand, compounds that have a structure 1, 2-dihydroquinoline have been described as steroid receptor modulators in WO 2004/018429, JP-T-10-0510840 and the like. The compounds described in WO 2004/018429 and JP-T-10-0510840 have a 1,2-dihydroquinoline structure, however, a compound in which any of the various substituents which have been introduced in the 5-position of the 1,2-dihydroquinoline structure have not been specifically described herein.

DESCRIPTION OF THE INVENTION It is a very interesting object of study the synthesis of a novel derivative of 1,2-dihydroquinoline and find pharmacological action of the derivative. The present inventors conducted synthesis studies of 1,2-dihydroquinoline derivatives having a novel chemical structure and succeeded in producing a large number of novel compounds. In addition, the present inventors studied the pharmacological actions of the derivatives and as a result found that the derivatives having glucocorticoid receptor binding activity are useful as a pharmaceutical substance and therefore the present invention has been completed. That is, the present invention relates to a compound represented by the following general formula (1) or a salt thereof (hereinafter referred to as "the present compound") and a pharmaceutical composition containing the same. Furthermore, a preferred invention in its pharmaceutical use is related to a glucocorticoid receptor modulator and its target diseases are glucocorticoid receptor-related diseases., ie, metabolic disorders such as diabetes and obesity, inflammatory diseases such as enteritis and chronic obstructive pulmonary diseases, autoimmune diseases such as congenital tissue diseases, allergic diseases such as asthma, atopic dermatitis and allergic rhinitis, diseases of the central nervous system such such as psychiatric disorders, Alzheimer's disease and drug use disorders, cardiovascular diseases such as hypertension, hypercalcemia, hyperinsulinaemia and hyperlipidemia, diseases related to homeostasis that cause an abnormality of the neuro-immunological-endocrine balance, glaucoma and the like. A particularly preferred invention is an invention that relates to a preventive or therapeutic agent for these diseases.

[Ring X represents a benzene ring or a pyridine ring; R1 represents a halogen atom, a lower alkyl group which may have at least one substituent, a hydroxy group, a lower alkoxy group which may have at least one substituent, a lower alkenyloxy group which may have at least one a substituent, a lower alkylcarbonyl group, an amino group, a nitro group or a cyano group; p represents an integer from 0 to 5; in the case where p is 2 to 5, each R1 may be the same or different; R 2 represents a halogen atom, a lower alkyl group which may have at least one substituent, a hydroxy group, an ester of a hydroxy group or a lower alkoxy group which may have at least one substituent; q represents an integer from 0 to 2; in the case where q is 2, each R2 can be same or different; R3 represents a hydrogen atom, a lower alkyl group which may have at least one substituent, a lower alkenyl group which may have at least one substituent, a lower alkynyl group which may have at least one substituent, aryl group which may have at least one substituent, a lower alkylcarbonyl group which may have at least one substituent, a lower alkenylcarbonyl group which may have at least one substituent, a lower alkynylcarbonyl group which may therefore have minus one substituent or an arylcarbonyl group which may have at least one substituent; R4 and R5 may be the same or different and represent a hydrogen atom or a lower alkyl group; R4 and R5 can be combined together to form a lower cycloalkane ring of 3 to 8 members; R6 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or a carbonyl group; R7 represents OR8, NR8R9, SR8, S (0) R8 or S (0) 2R8; R8 represents a lower alkyl group which may have at least one substituent, a lower alkenyl group which may have at least one substituent, a lower alkynyl group which may have at least one substituent, a lower cycloalkyl group which may have at least one substituent, an aryl group which may have at least one substituent, a heterocyclic group which may have at least one substituent, a formyl group, a lower alkylcarbonyl group which may have at least one substituent, a lower alkenylcarbonyl group which may have at least one substituent, a lower alkynylcarbonyl group which may have at least one substituent, a lower cycloalkylcarbonyl group which may have at least one substituent, an arylcarbonyl group which may have at least one substituent, heterocyclic carbonyl group which may have at least one substituent, a carboxy group, a lower alkoxycarbonyl group which ede having at least one substituent, a lower alkenyloxycarbonyl group which may have at least one substituent, a lower alkynyloxycarbonyl group which may have at least one substituent, a lower cycloalkyloxycarbonyl group which may have at least one substituent, an aryloxycarbonyl group which may have at least one substituent, a group heterocyclic oxycarbonyl which may have at least one substituent, a lower alkynylsulfonyl group which may have at least one substituent, a lower alkenylsulfonyl group which may have at least one substituent, a lower alkynylsulfonyl group which may therefore have minus one substituent, a lower cycloalkylsulfonyl group which may have at least one substituent, an arylsulfonyl group which may have at least one substituent, a heterocyclic sulfonyl group which may have at least one substituent, an aminocarbonyl group, a lower alkylaminocarbonyl group which may have at least one substituent, a lower alkenylaminocarbonyl group which may have at least one substituent, a lower alkynylaminocarbonyl group which may have at least one substituent, a lower cycloalkylaminocarbonyl group which may having at least one substituent, an arylaminocarbonyl group which may have at least one substituent or a heterocyclic aminocarbonyl group which may have at least one substituent, - R9 represents a hydrogen atom, a lower alkyl group which may have at least one substituent, a lower alkenyl group which may have at least one substituent, an alkynyl group lower which may have at least one substituent, a lower cycloalkyl group which may have at least one substituent, an aryl group which may have at least one substituent, a heterocyclic group which may have at least one substituent , a formyl group, a lower alkylcarbonyl group which may have at least one substituent, a lower alkenylcarbonyl group which may have at least one substituent, a lower alkynylcarbonyl group which may have at least one substituent, a cycloalkylcarbonyl group lower which can have at least one substituent, an arylcarbonyl group which can have at least one substituent, a heterocyclic carbonyl group which can have at least one substituent, a carboxy group, a lower alkoxycarbonyl group which can have at least one substituent, a lower alkenyloxycarbonyl group which may have at least one substituent, a group at lower quiniloxycarbonyl which may have at least one substituent, a lower cycloalkyloxycarbonyl group which may have at least one substituent, an aryloxycarbonyl group which may have at least one substituent, a heterocyclic oxycarbonyl group which may have at least one a substituent, a lower alkylsulfonyl group which may have at least a substituent, a lower alkenylsulfonyl group which may have at least one substituent, a lower alkynylsulfonyl group which may have at least one substituent, a lower cycloalkylsulfonyl group which may have at least one substituent, an aryisulfonyl group which may have at least one substituent, a heterocyclic sulfonyl group which may have at least one substituent, an aminocarbonyl group, a lower alkylaminocarbonyl group which may have at least one substituent, a lower alkenylaminocarbonyl group which may therefore have less a substituent, a lower alkynylaminocarbonyl group which may have at least one substituent, a lower cycloalkylaminocarbonyl group which may have at least one substituent, an arylaminocarbonyl group which may have at least one substituent or a heterocyclic aminocarbonyl group on the which may have at least one substituent; furthermore, in the case where R7 is NR8R9, R8 and R9 can be combined together to form a 3 to 8 membered nitrogen containing heterocyclic ring which may have a substituent. The same will apply here]. The present invention provides a 1,2-dihydroquinoline derivative or a salt thereof, which is useful as a pharmaceutical substance. The present compound has excellent glucocorticoid receptor binding activity and is useful as a glucocorticoid receptor modulator. In particular, the present compound is useful as a preventive or therapeutic agent for diseases related to the glucocorticoid receptor, i.e., metabolic disorders such as diabetes and obesity, inflammatory diseases such as enteritis and chronic obstructive pulmonary diseases, autoimmune diseases such as diseases of conactive tissue, allergic diseases such as asthma, atopic dermatitis and allergic rhinitis, central nervous system diseases such as psychiatric disorders, Alzheimer's disease and drug use disorders, cardiovascular diseases such as hypertension, hypercalcemia, hyperinsulinamia and hyperlipidemia, related diseases with homeostasis that cause an abnormality of the neuro-immunological-endocrine balance, glaucoma and the like.

BEST MODE FOR CARRYING OUT THE INVENTION In the following, definitions of the terms and phrases (atoms, groups and the like) will be used in this specification and will be described in detail. The term "halogen atom" refers to a fluorine atom, chlorine, bromine or iodine. The term "lower alkyl group" refers to a linear or branched chain alkyl group having 1 to 8 carbon atoms. Specific examples thereof include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, isopropyl, isobutyl, sec-butyl, tertbutyl and isopentyl groups and the like. The term "lower alkenyl group" refers to a linal or branched chain alkenyl group having 2 to 8 carbon atoms. Specific examples thereof include vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, isopropenyl, 2-methyl-1-propenyl and 2-methyl-2-butenyl groups and the like. The term "lower alkynyl group" refers to a linear or branched alkynyl group having 2 to 8 carbon atoms. Specific examples thereof include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, isobutynyl and isopentynyl groups and the like. The term "lower cycloalkyl group" refers to a cycloalkyl group having 3 to 8 carbon atoms. Specific examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl groups.

The term "lower cycloalkane ring" refers to a cycloalkane ring having 3 to 8 carbon atoms. Specific examples thereof include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane and cyclooctane rings. The term "aryl group" refers to a residue formed by separating a hydrogen atom from a monocyclic aromatic hydrocarbon group or a bicyclic or tricyclic condensed polycyclic aromatic hydrocarbon having 6 to 14 carbon atoms. Specific examples thereof include phenyl, naphthyl, anthryl and phenanthryl groups and the like. The term "heterocyclic group" refers to a residue that is formed by removing a hydrogen atom from a saturated or unsaturated monocyclic heterocyclic ring or a bicyclic or tricyclic fused polycyclic heterocyclic ring having one or a plurality of heteroatoms which is selected from a Nitrogen atom, an oxygen atom and a sulfur atom in the ring. Specific examples of the saturated monocyclic heterocyclic ring include pyrrolidine, pyrazolidine, imidazolidine, triazolidine, piperidine, hexahydropyridazine, hexahydropyrimidine, piperazine, homopiperidine and homopiperazine rings and the like having at least one nitrogen atom in the ring, tetrahydrofluoride rings. and tetrahydropyran and the like having at least one oxygen atom in the ring, tetrahydrothiophene and tetrahydrothiopyran rings and the like having a sulfur atom in the ring, oxazolidine, isoxazolidine and morpholine rings and the like having a nitrogen atom and a Oxygen atom in the ring and thiazolidine rings, iso-thiazolidine and thiomorpholine and the like having a nitrogen atom and a sulfur atom in the ring. In addition, said saturated monocyclic heterocyclic ring can be condensed with a benzene ring or the like to form a fused, bicyclic or tricyclic polycyclic heterocyclic ring such as a dihydroindole, dihydroindazole, dihydrobenzimidazole, tetrahydroquinoline, tetrahydroisoquinoline, tetrahydrocinnoline, tetrahydrophthalazine, tetrahydroquinazoline, tetrahydroquinoxaline ring. , dihydrobenzofuran, dihydroisobenzofuran, chroman, isochroman, dihydrobenzothiophene, dihydroisobenzothiophene, thiochroman, isothiochroman, dihydrobenzoxazole, dihydrobenzisoxazole, dihydrobenzoxazine, dihydrobenzothiazole, dihydrobenzisothiazole, dihydrobenzothiazine, xanthene, 4a-carbazole or perimi-dine. Specific examples of the unsaturated monocyclic heterocyclic ring include the dihydropyrrole, pyrrole, dihydropyrazole, pyrazole, dihydroimidazole, imidazole, dihydrotriazole, triazole, tetrahydropyridine, dihydropyridine, pyridine, tetrahydropyridazine, dihydropyridazine, pyridazine, tetrahydropyrimidine, dihydropyrimidine, pyrimidine, tetrahydropyrazine, dihydropyrazine and pyrazine and the like having at least one nitrogen atom in the ring, dihydrofuran, furan, dihydropyran and pyran rings and the like having at least one less an oxygen atom in the ring, dihydrothiophene, thiophene, dihydrothiopyran and thiopyran rings and the like having a ring sulfur atom, dihydrooxazole rings, oxazole, dihydroisoxazole, isoxazole, dihydrooxazine and oxazine and the like having a nitrogen atom and an oxygen atom in the ring, dihydrothiazole, thiazole, dihydroisothiazole, isothiazole, dihydrothiazine and thiazine rings and the like having a nitrogen atom and a sulfur atom in the ring. In addition, said unsaturated monocyclic heterocyclic ring can be fused with a benzene ring or the like to form a bicyclic or tricyclic fused polycyclic heterocyclic ring such as an indole ring, indazole, benzimidazole, benzotriazole, dihydroquinoline, quinoline, dihydroisoquinoline, isoquinoline, phenanthridine, dihydrocinnoline, cinnoline, dihydrophthalazine, phthalazine, dihydroquinazoline, quinazoline, dihydroquinoxaline, quinoxaline, benzofuran, isobenzofuran, chromene, isocromen, benzothiophene, isobenzothiophene, thiochromen, isothiochromen, benzoxazole, benzisoxazole, benzoxazine, benzothiazole, benzisothiazole, benzothiazine, phenoxanthin, carbazole, beta-carboline, phenanthridine, acridine, phenanthroline, phenazine, phenothiazine or phenoxazine. The "lower alkoxy group" refers to a group formed by the substitution of the hydrogen atom of a hydroxy group with a lower alkyl group. Specific examples of these include methoxy, ethoxy, n-propoxy, n-butoxy, n-pentoxy, n-hexyloxy, n-heptyloxy, n-octyloxy, isopropoxy, isobutoxy, secbutoxy, terbutoxy and isopentoxy groups and the like. The term "lower alkenyloxy group" refers to a group formed by substituting the hydrogen atom of a hydroxy group with a lower alkenyl group. Specific examples thereof include the vinyloxy, propenyloxy, butenyloxy, pentenyloxy, hexenyloxy, heptenyloxy, octenyloxy, isopropenyloxy, 2-methyl-1-propenyloxy and 2-methyl-2-butenyloxy groups and the like. The term "lower alkynyloxy group" refers to a group formed by substituting the hydrogen atom of a hydroxy group with a lower alkynyl group. Specific examples thereof include the ethynyloxy, propynyloxy, butynyloxy, pentynyloxy, hexynyloxy, heptynyloxy, octynyloxy, isobutynyloxy and isopentynyloxy groups and the like.

The term "lower cycloalkyloxy group" refers to a group formed by replacing the hydrogen atom of a hydroxy group with a lower cycloalkyl group. Specific examples thereof include cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy and cyclooctyloxy groups and the like. The term "aryloxy group" refers to a group formed by substituting the hydrogen atom of a hydroxy group with an aryl group. Specific examples thereof include phenoxy, naphthoxy, anthryloxy and phenanthryloxy groups and the like. The term "heterocyclic oxy group" refers to a group formed by substituting the hydrogen atom of a group with a heterocyclic group. The term "lower alkylthio group" refers to a group formed by substituting the hydrogen atom of a mercapto group with a lower alkyl group. Specific examples thereof include methylthio, ethylthio, n-propylthio, n-butylthio, n-penththio, n-hexylthio, n-heptylthio, n-octylthio, isopropylthio, isobutylthio, sec-butylthio, tert-butylthio and isopentylthio groups and Similar. The term "lower cycloalkylthio group" refers to a group formed by substituting the hydrogen atom of a mercapto group with a lower cycloalkyl group. Specific examples thereof include the cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio, cycloheptylthio and cyclooctylthio groups and the like. The term "arylthio group" refers to a group formed by substituting the hydrogen atom of a mercapto group with an aryl group. Specific examples thereof include phenylthio, naphthylthio, anthrylthio and phenanthylthio groups and the like. The term "heterocyclic thio group" refers to a group formed by substituting the hydrogen atom for a mercapto group with a heterocyclic group. The term "lower alkylamino group" refers to a group formed by replacing one or both hydrogen atoms of an amino group with a lower alkyl group. Specific examples thereof include methylamino, ethylamino, propylamino, dimethylamino, diethylamino and ethyl (methyl) amino groups and the like. The term "lower alkenylamino group" refers to a group formed by replacing one or both hydrogen atoms of an amino group with a lower alkenyl group, or a group formed by substituting one of the hydrogen atoms of an amino group with a group lower alkenyl and the other hydrogen atom with a lower alkyl group. Examples thereof include vinylamino, propenylamino, butenylamino, pentenylamino groups, hexenylamino, heptenylamino, octenylamino, isopropenylamino, 2-methyl-1-propenylamino, 2-methyl-2-butenylamino, divinylamino and methyl (vinyl) amino and the like. The term "lower alkynylamino group" refers to a group formed by replacing one or both hydrogen atoms of an amino group with a lower alkynyl group or a group formed by substituting one of the hydrogen atoms of an amino group with an alkynyl group lower and the other hydrogen atom with a lower alkyl group or a lower alkenyl group. Specific examples thereof include ethynylamino groups, propynylamino, butylamino, pentynylamino, hexylamino, heptinylamino, octylamino, isobutylamino, isopentylamino, diethylamino, ethynyl (methyl) amino, ethyl (vinyl) amino and the like. The term "lower cycloalkylamino group" refers to a group formed by substituting one or both hydrogen atoms of an amino group with a lower cycloalkyl group or a group formed by substituting one of the hydrogen atoms of an amino group with a cycloalkyl group lower and the other hydrogen atom with a lower alkyl group, a lower alkenyl group or a lower alkynyl group. Specific examples thereof include cyclopropylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino, cycloheptylamino, cyclooctylamino groups, dicyclohexylamino, cyclohexyl (methyl) amino, cyclohexyl (vinyl) amino and cyclohexyl (ethynyl) amino and the like. The term "arylamino group" refers to a group formed by substituting one or both hydrogen atoms of an amino group with an aryl group or a group formed by substituting one of the hydrogen atoms of an amino group with an aryl group and the another hydrogen atom with a lower alkyl group, a lower alkenyl group, a lower alkynyl group or a lower cycloalkyl group. Specific examples thereof include phenylamino, naphthylamino, anthrylamino, phenanthrylamino, diphenylamino, methyl (phenyl) amino, ethyl (phenyl) amino, phenyl (vinyl) amino, ethynyl (phenyl) amino and cyclohexyl (phenyl) amino groups and the like. The term "heterocyclic amino group" refers to a group formed by substituting one or both hydrogen atoms of an amino group with a heterocyclic group or a group formed by substituting one of the hydrogen atoms of an amino group with a heterocyclic group and the other hydrogen atom with a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower cycloalkyl group or an aryl group. The term "lower alkylcarbonyl group" refers to a group formed by substituting the hydrogen of a formyl group with a lower alkyl group. Specific examples thereof include the methylcarbonyl, ethylcarbonyl, n-propylcarbonyl, n-butylcarbonyl, n-pentylcarbonyl, n-hexylcarbonyl, n-heptylcarbonyl, n-octylcarbonyl, isopropylcarbonyl, isobutylcarbonyl, sec-butylcarbonyl, tert-butylcarbonyl and isopentylcarbonyl and the like. The term "lower alkenylcarbonyl group" refers to a group formed by substituting the hydrogen atom of a formyl group with a lower alkenyl group. Specific examples thereof include vinylcarbonyl, propenylcarbonyl, butenylcarbonyl, pentenylcarbonyl, hexenylcarbonyl, heptenylcarbonyl, octenylcarbonyl, isopropenylcarbonyl, 2-methyl-1-propenylcarbonyl and 2-methyl-2-butenylcarbonyl groups and the like. The term "lower alkynylcarbonyl group" refers to a group formed by substituting the hydrogen atom of a formyl group with a lower alkynyl group. Specific examples thereof include the ethynylcarbonyl, propynylcarbonyl, butynylcarbonyl, pentynylcarbonyl, hexynylcarbonyl, heptynylcarbonyl, octynylcarbonyl, isobutynylcarbonyl and isopentynylcarbonyl groups and the like. The term "lower cycloalkylcarbonyl group" refers to a group formed by substituting the hydrogen atom of a formyl group with a lower cycloalkyl group. Specific examples thereof include the cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, cycloheptylcarbonyl and cyclooctylcarbonyl groups. The term "lower arylcarbonyl group" refers to a group formed by substituting the hydrogen atom of a formyl group with an aryl group. Specific examples thereof include the phenylcarbonyl, naphthylcarbonyl, anthrylcarbonyl and phenanthylcarbonyl groups and the like. The term "heterocyclic carbonyl group" refers to a group formed by substituting the hydrogen atom of a formyl group with a heterocyclic group. The term "lower alkoxycarbonyl group" refers to a group formed by substituting the hydrogen atom of a formyl group with a lower alkoxy group. Specific examples thereof include the groups methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, n-butoxycarbonyl, n-pentyloxycarbonyl, n-hexyloxycarbonyl, n-heptyloxycarbonyl, n-octyloxycarbonyl, isopropoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl and isopentyloxycarbonyl and the like.

The term "lower alkenylcarbonyl group" refers to a group formed by substituting the hydrogen atom of a formyl group with a lower alkenyloxy group. Specific examples thereof include vinyloxycarbonyl groups, propenyloxycarbonyl, butenyloxycarbonyl, pentenyloxycarbonyl, hexenyloxycarbonyl, heptenyloxycarbonyl, octenyloxycarbonyl, isopropenyloxycarbonyl, 2-methyl-1-propenyloxycarbonyl and 2-methyl-2-butenyloxycarbonyl and the like. The term "lower alkynyloxycarbonyl group" refers to a group formed by substituting the hydrogen atom of a formyl group with a lower alkynyloxy group. Specific examples thereof include the ethynyloxycarbonyl, propynyloxycarbonyl, butynyloxycarbonyl, pentynyloxycarbonyl, hexynyloxycarbonyl, heptynyloxycarbonyl, octynyloxycarbonyl, isobutynyloxycarbonyl and isopentynyloxycarbonyl groups and the like. The term "lower cycloalkyloxycarbonyl group" refers to a group formed by substituting the hydrogen atom of a formyl group with a lower cycloalkoxy group. Specific examples thereof include the cyclopropyloxycarbonyl, cyclobutyloxycarbonyl, cyclopentyloxycarbonyl, cyclohexyloxycarbonyl, cycloheptyloxycarbonyl and cyclooctyloxycarbonyl groups.

Bonilo and similar. The term "aryloxycarbonyl group" refers to a group formed by substituting the hydrogen atom of a formyl group with an aryloxy group. Specific examples thereof include the phenoxycarbonyl, naphthoxycarbonyl, anthryloxycarbonyl and phenanthryloxycarbonyl groups and the like. The term "heterocyclic oxycarbonyl group" refers to a group formed by substituting the hydrogen atom of a formyl group with a heterocyclic oxy group. The term "lower alkylaminocarbonyl group" refers to a group formed by substituting the hydrogen atom of a formyl group with a lower alkylamino group. Specific examples thereof include the methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, dimethylaminocarbonyl, diethylaminocarbonyl and ethylmethylaminocarbonyl groups and the like. The term "lower alkenylaminocarbonyl group" refers to a group formed by substituting the hydrogen atom of a formyl group with a lower alkenylamino group. Specific examples thereof include the vinylaminocarbonyl, propenylaminocarbonyl, butenylaminocarbonyl, pentenylaminocarbonyl, hexenylaminocarbonyl, heptenylaminocarbonyl, octenylamino- nocarbonyl, isopropenylaminocarbonyl, 2-methyl-1-propenylaminocarbonyl, 2-methyl-2-butenylaminocarbonyl, divinylaminocarbonyl and methyl (vinyl) aminocarbonyl and the like. The term "lower alkynylaminocarbonyl group" refers to a group formed by substituting the hydrogen atom of a formyl group with a lower alkynylamino group. Specific examples thereof include the ethynylaminocarbonyl, propylaminocarbonyl, butylaminocarbonyl, pentynylaminocarbonyl, hexylaminocarbonyl, heptinylaminocarbonyl, octylaminocarbonyl, isobutylaminocarbonyl, isopentylaminocarbonyl, diethylaminocarbonyl, ethynyl (methyl) -aminocarbonyl and ethynyl (vinyl) aminocarbonyl groups and the like. The term "lower cycloalkylaminocarbonyl group" refers to a group formed by substituting the hydrogen atom of a formyl group with a lower cycloalkylamino group. Specific examples thereof include the cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, cyclohexylaminocarbonyl, cycloheptylaminocarbonyl, cyclooctylaminocarbonyl, dicyclohexylaminocarbonyl, cyclohexyl (methyl) aminocarbonyl, cyclohexyl (vinyl) aminocarbonyl and cyclohexyl (ethynyl) aminocarbonyl groups and the like. The term "arylaminocarbonyl group" refers to to a group formed by replacing the hydrogen atom of a formyl group with an arylamino group. Specific examples thereof include the phenylaminocarbonyl, naphthylaminocarbonyl, anthrylamidocarbonyl, phenanthylaminocarbonyl, diphenylaminocarbonyl, methylphenylaminocarbonyl, ethylphenylaminocarbonyl, phenyl (vinyl) aminocarbonyl, ethynyl (phenyl) minocarbonyl and cyclohexyl (phenyl) -aminocarbonyl groups and the like. The term "heterocyclic aminocarbonyl group" refers to a group formed by substituting the hydrogen atom of a formyl group with a heterocyclic amino group. The term "lower alkylsulfinyl group" refers to a group formed by substituting the hydroxy of a sulfinic acid group with a lower alkyl group. Specific examples thereof include the groups methylsulfinyl, ethylsulfinyl, n-propylsulfinyl, n-butylsulfinyl, n-pentylsulfinyl, n-hexylsulfinyl, n-heptylsulfinyl, n-octylsulfinyl, isopropylsulfinyl, isobutylsulfinyl, sec-butylsulfinyl, tert-butylsulfinyl and isopentylsulfinyl and the like. The term "arylsulfinyl group" refers to a group formed by substituting the hydroxy of a sulfinic acid group with an aryl group. Specific examples thereof include phenylsulfinyl groups, naphthylsulfinyl, anthrylsulfinyl and phenanthrylsulfinyl and the like. The term "lower alkylsulfonyl group" refers to a group formed by substituting the hydroxy of a sulfonic acid group with a lower alkyl group. Specific examples thereof include the methylsulfonyl groups, ethylsulfonyl, n-propylsulfonyl, n-butylsulfonyl, n-pentylsulfonyl, n-hexylsulfonyl, n-heptylsulfonyl, n-octylsulfonyl, isopropylsulfonyl, isobutylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl and isopentylsulfonyl and the like. The term "lower alkenylsulfonyl group" refers to a group formed by substituting the hydroxy of a sulfonic acid group with a lower alkenyl group. Specific examples thereof include the vinylsulfonyl, propenylsulfonyl, butenylsulfonyl, pentenylsulfonyl, hexenylsulfonyl, heptenylsulfonyl, octenylsulfonyl, isopropenylsulfonyl, 2-methyl-1-propenylsulfonyl and 2-methyl-2-butenylsulfonyl groups and the like. The term "lower alkynylsulfonyl group" refers to a group formed by substituting the hydroxy of a sulfonic acid group with a lower alkynyl group. Specific examples thereof include the ethynylsulfonyl, propynylsulfonyl, butynylsulfonyl, pentynylsulfonyl, hexynylsulfonyl, heptylsulfonyl groups, octynylsulfonyl, isobutynylsulfonyl and isopentinylsulfonyl and the like. The term "lower cycloalkylsulfonyl group" refers to a group formed by substituting the hydroxy of a sulfonic acid group with a lower cycloalkyl group. Specific examples thereof include cyclopropylsulfonyl, cyclobutylsulfonyl, cyclopentylsulfonyl, cyclohexylsulfonyl, cycloheptylsulfonyl and cyclooctylsulfonyl groups and the like. The term "heterocyclic sulfonyl group" refers to a group formed by substituting the hydroxy of a sulfonic acid group with a heterocyclic group. The term "arylsulfonyl group" refers to a group formed by substituting the hydroxy of a sulfonic acid group with an aryl group. Specific examples thereof include the phenylsulfonyl, naphthylsulfonyl, antrisulphonyl and phenanthrylsulfonyl groups and the like. The term "lower alkoxycarbonyloxy group" refers to a group formed by substituting the hydrogen atom of a hydroxy group with a lower alkoxycarbonyl group. Specific examples thereof include the methoxycarbonyloxy, ethoxycarbonyloxy, n-propoxycarbonyloxy, n-butoxycarbonyloxy, n-pentoxycarbonyloxy, n-hexyloxycarbonyloxy groups, n- heptyloxycarbonyloxy, n-octyloxycarbonyloxy, isopropoxy-carbonyloxy, isobutoxycarbonyloxy, sec-butoxycarbonyloxy, tert-butoxycarbonyloxy and isopentoxycarbonyloxy and the like. The term "aryloxycarbonyloxy group" refers to a group formed by substituting the hydrogen atom of a hydroxy group with an alkoxycarbonyl group. Specific examples thereof include the phenoxycarbonyloxy, naphthoxycarbonyloxy, anthryloxycarbonyloxy and phenanthyloxycarbonyloxy groups and the like. The term "lower alkylsulfonyloxy group" refers to a group formed by substituting the hydrogen atom of a hydroxy group with a lower alkylsulfonyl group. Specific examples thereof include the methylsulphonyloxy, ethylsulphonyloxy, n-propylsulphonyloxy, n-butylsulphonyloxy, n-pentylsulphonyloxy, n-hexylsulphonyloxy, n-heptylsulphonyloxy, n-octylsulphonyloxy, isopropylsulphonyloxy, isobutylsulphonyloxy, sec-butylsulphonyloxy groups, tert-butylsulfonyloxy and isopentylsulfonyloxy and the like. The term "arylsulfonyloxy group" refers to a group formed by substituting the hydrogen atom of a hydroxy group with an aryisulfonyl group. Specific examples thereof include the phenylsulfonyloxy, naphthylsulfonyloxy, anthrylsulfonyloxy and phenanthrylsulfonyloxy groups and the like.

The term "lower alkylaminocarbonyloxy group" refers to a group formed by substituting the hydrogen atom of a formyloxy group with a lower aralkylamino group. Specific examples thereof include the methylaminocarbonyloxy, ethylaminocarbonyloxy, propylaminocarbonyloxy, dimethylamidocarbonyl, diethylaminocarbonyloxy and ethyl (methyl) aminocarbonyloxy groups and the like. The term "arylaminocarbonyloxy group" refers to a group formed by substituting the hydrogen atom of a formyloxy group with an arylamino group. Specific examples thereof include the phenylaminocarbonyloxy, naphthylaminocarbonyloxy, anthrylaminocarbonyloxy, phenanthylaminocarbonyloxy, diphenylaminocarcarbyloxy, methyl (phenyl) aminocarbonyloxy, ethyl (phenyl) aminocarbonyloxy, phenyl (vinyl) aminocarbonyloxy, ethynyl (phenyl) a- (4-methoxycarbonyloxy) groups and cyclohexyl (phenyl) aminocarbonyloxy and the like. The term "nitrogen-containing 3 to 8-membered heterocyclic ring" refers to a saturated monocyclic heterocyclic ring containing one or two nitrogen atoms in the ring. Specific examples thereof include aziridine, azetidine, pyrrolidine, piperidine, imidazolidine, pyrazolidine, piperazine and morpholine rings and the like.

The term "alkylene group" refers to a straight or branched chain alkylene group having 1 to 8 carbon atoms. Specific examples thereof include methylene groups, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene, methylmethylene and ethylmethylene and the like. The term "ester of a hydroxy group" refers to an ester formed by a hydroxy group and a carboxylic acid. The term "ester of a mercapto group" refers to a thioester formed from a hydroxy group and a carboxylic acid. The term "amide of an amino group" refers to an amide formed of an amino group and a carboxylic acid. The term "amide of a lower alkylamino group" refers to an amide formed of a lower alkylamino group and a carboxylic acid. The term "amide of an arylamino group" refers to an amide formed of an arylamino group and a carboxylic acid. The term "amide of a heterocyclic amino group" refers to an amide formed of a heterocyclic amino group and a carboxylic acid. The term "carboxylic acid" refers to a saturated aliphatic monocarboxylic acid, an acid saturated aliphatic dicarboxylic acid, an unsaturated aliphatic carboxylic acid, a carbocyclic carboxylic acid, a heterocyclic carboxylic acid or the like represented by RaCOOH (Ra represents a hydrogen atom, a lower alkyl group which may have at least one substituent, a lower alkenyl group which may have at least one substituent, an aryl group which may have at least one substituent, a heterocyclic group which may have at least one substituent, a lower alkoxy group which may have at least one substituent or Similary) . Specific examples thereof include saturated aliphatic monocarboxylic acids such as formic, acetic, propionic, butyric, isobutyric, valeric, isovaleric and pivalic acids; saturated aliphatic dicarboxylic acids such as the oxalic, malonic, succinic, glutaric and adipic acids; unsaturated aliphatic carboxylic acids such as the acids: acrylic, propionic, crotonic and cinnamic; carbocyclic carboxylic acids such as benzoic, phthalic, isophthalic, terephthalic, naphthoic, toluic, cydohexane carboxylic and cydohexane dicarboxylic acids; heterocyclic carboxylic acids such as the acids: furancarboxylic, thiophenecarboxylic, nicotinic and isonicotinic; and similar. In addition, acid anhydrides of these carboxylic acids [(RaCO) 20] and the acid halides of these carboxylic acids (RaCOX, X represents a halogen atom) are also included in the term "carboxylic acid". The term "ester of a carboxy group" refers to an ester formed from a carboxy group and an alcohol or a phenol. The term "ester of a sulfinic acid group" refers to an ester formed from a sulfinic acid group and an alcohol or a phenol. The term "ester of a sulfonic acid group" refers to an ester formed from a sulfonic acid group and an alcohol or a phenol. The term "alcohol" refers to a saturated aliphatic hydroxy compound, an unsaturated aliphatic hydroxy compound or the like represented by ROH (Rb represents a lower alkyl group which may have at least one substituent, an alkenyl group which may have at least one less a substituent or the like). Specific examples thereof include saturated aliphatic hydroxy compounds such as methanol, ethanol, propanol, butanol and isopropanol; unsaturated aliphatic hydroxy compounds such as vinyl alcohol; saturated aliphatic hydroxy compounds substituted by at least one aryl group such as benzyl alcohol and phenethyl alcohol; and similar.

The term "phenol" refers to a carbocyclic hydroxy compound or the like represented by RcOH (Rc represents an aryl group which may have at least one substituent or the like). Specific examples thereof include phenol, naphthol, antrol, fenantrol and the like. The term "amide of a carboxy group" refers to an acid amide that is formed from a carboxy group and an amine. The term "amide of a sulfinic acid group" refers to an acid amide that is formed from a sulfinic acid group and an amine. The term "amide of a sulfonic acid group" refers to an acid amide that is formed from a sulfonic acid group and an amine. The term "amine" refers to ammonia, a saturated aliphatic amine compound, a carbocyclic amine compound, a heterocyclic amine compound, a saturated cyclic amine compound or the like represented by NHRdRe (Rd and Re may be the same or different and represent a hydrogen, a lower alkyl group which may have at least one substituent, an aryl group which may have at least one substituent, a heterocyclic group or the like, or Rd and Re may be combined together to form a cyclic amine saturated). Specific examples thereof include ammonia; saturated aliphatic amine compounds such as methylamine, ethylamine, propylamine, pentylamine, dimethylamine, diethylamine and ethylmethylamine; saturated aliphatic amine compounds having a substituent such as benzylamine; carbocyclic amine compounds such as phenylamine, naphthylamine, anthrylamine, phenanthrylamine, diphenylamine, methylphenylamine, ethylphenylamine and cyclohexylamine, heterocyclic amine compounds such as furylamine, thienylamine, pyrrolidylamine, pyridylamine, quinolylamine and methylpyridylamine; saturated cyclic amine compounds such as aziridine, azetidine, pyrrolidine, piperidine and 4-methylpiperidine and the like. The term "lower alkyl group which may have at least one substituent", "lower alkenyl group which may have at least one substituent", "lower alkynyl group which may have at least one substituent", "alkoxy group" lower which may have at least one substituent "," lower alkylcarbonyl group which may have at least one substituent "," lower alkenylcarbonyl group which may have at least one substituent "," lower alkynylcarbonyl group which may have at least one substituent "," lower alkoxycarbonyl group which may have at least one substituent "," alkenyloxycarbonyl group lower which may have at least one substituent "," lower alkynyloxycarbonyl group which may have at least one substituent "," lower alkylaminocarbonyl group which may have at least one substituent "and" lower alkylsulfonyloxy group which may have at least one substituent "refers to a" lower alkyl group ", a" lower alkenyl group ", a" lower alkynyl group ", a" lower alkoxy group ", a" lower alkylcarbonyl group ", a" lower alkenylcarbonyl group " , a "lower alkynylcarbonyl group", a "lower alkoxycarbonyl group", a "lower alkenyloxycarbonyl group", a "lower alkynyloxycarbonyl group", a "lower alkylaminocarbonyl group" and a "lower alkylsulfonyloxy group" which may have one or a plurality of substituents that are selected from the following group a1, respectively.

[Group a1] A halogen atom, a lower cycloalkyl group, an aryl group, an aryl group substituted by at least one halogen atom, an aryl group substituted by at least one lower alkyl group, an aryl group substituted by at least one hydroxy group, an aryl group substituted by at least one lower alkoxy group, a heterocyclic group, a hydroxy group, an ester of a group hydroxy, a lower alkoxy group, a lower alkoxy group substituted by at least one halogen atom, a lower alkenyloxy group, a lower alkynyloxy group, a lower cycloalkyloxy group, an aryloxy group, a heterocyclic oxy group, a mercapto group, an ester of a mercapto group, a lower alkylthio group, a lower alkenylthio group, a lower alkynylthio group, a lower cycloalkylthio group, an arylthio group, a heterocyclic thio group, an amino group, an amide of an amino group, a lower alkylamino group, an amide of a lower alkylamino group, an arylamino group, an amide of an arylamino group, a heterocyclic amino group, an amide of a heterocyclic amino group, a formyl group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group, a lower alkynylcarbonyl group , a lower cycloalkylcarbonyl group, an arylcarbonyl group, a heterocyclic carbonyl group, a carboxy group, an ester of a carboxy group, a amide of a carboxy group, a lower alkoxycarbonyl group, a lower alkenyloxycarbonyl group, a lower alkynyloxycarbonyl group, a lower cycloalkyloxycarbonyl group, an aryloxycarbonyl group, a heterocyclic oxycarbonyl group, a lower alkylsulfinyl group, an arylsulfinyl group, a lower alkylsulfonyl group, an arisulphonyl group, a sulfinic acid group, an ester of a sulfinic acid group, an amide of a sulfinic acid group, a sulfonic acid group, an ester of a sulfonic acid group, an amide of a sulfonic acid group, a nitro group and a cyano group. The terms "lower cycloalkyl group which may have at least one substituent", aryl group which may have at least one substituent "," heterocyclic group which may have at least one substituent "," lower cycloalkylcarbonyl group which may have at least one substituent "," arylcarbonyl group which may have at least one substituent "," heterocyclic carbonyl group which may have at least one substituent "," lower cycloalkyloxycarbonyl group which may have at least one substituent "," aryloxycarbonyl group which may have at least one substituent "," heterocyclic oxycarbonyl group which may have at least one substituent "," arylaminocarbonyl group which may have at least one substituent ", and" aminocarbonyl group " heterocyclic which may have at least one substituent "refers to a" lower cycloalkyl group ", an" aryl group ", a" heterocyclic group ", a" cycloalkyl group " "lower alkylcarbonyl", an "arylcarbonyl group", a "heterocyclic carbonyl group", a "lower cycloalkyloxycarbonyl group", a "lower alkyl aryloxycarbonyl "a" heterocyclic oxycarbonyl group ", an" arylaminocarbonyl group "and" heterocyclic aminocarbonyl group "which may have one or a plurality of substituents selected from the following group ss1, respectively.

[Group ß1] A halogen atom, a lower alkyl group substituted with at least one halogen atom, a lower alkyl group substituted by at least one hydroxy group, a lower alkyl substituted lower alkyl by at least one alkoxy group lower, substituted by at least one amino group, a lower alkyl group substituted by at least one lower alkylamino group, a lower alkyl substituted by at least one carboxy group, a lower alkyl substituted lower alkyl by at least one alkoxycarbonyl group lower, a lower alkenyl group, an alkynyl group, a lower cycloalkyl group, an aryl group, a heterocyclic group, a hydroxy group, an ester of a hydroxy group, a lower alkoxy group, a lower alkoxy group substituted by at least one halogen atom, a lower alkenyloxy group, a lower alkynyloxy group, a lower cycloalkyloxy group, an aryloxy group, a heterocyclic oxy group co, a mercapto group, an ester of a group mercapto, a lower alkylthio group, an alkenylthio group lower an alkynylthio group, a lower cycloalkylthio group, an arylthio group, a heterocyclic thio group, an amino group, an amide of an amino group, a lower alkylamino group, an amide of a lower alkylamino group, an arylamino group, an amide of an arylamino group, a heterocyclic amino group, an amide of a heterocyclic amino group, a formyl group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group, a lower alkynylcarbonyl group, lower cycloalkylcarbonyl, arylcarbonyl group, heterocyclic carbonyl group, a carboxy group, an amide of a carboxy group, a lower alkoxycarbonyl group, a lower alkenyloxycarbonyl group, a lower alkynyloxycarbonyl group, a cycloalkyloxy group carbonyl lower, an aryloxycarbonyl group, heterocyclic oxycarbonyl, a lower alkylsulfinyl group, an arylsulfinyl group, an alkyl group lower uilsulfonilo a ariisulfonilo group, a sulfinic acid group, an ester of a sulfinic acid group, an amide of a sulfinic acid group, a sulfonic acid group, an ester of a sulfonic acid group, an amide of a sulfonic acid group, nitro group, a cyano group, an aminocarbonyloxy group, a lower alkylaminocarbonyloxy group and an arylaminocarbonyloxy group.

The term "a plurality of groups" as used herein means that each group may be the same or different and the number of groups preferably is 1, 2 or 3 and particularly preferably 2. In addition, a hydrogen atom and a Halogen atom are also included in the concept of "group". The term "glucocorticoid receptor modulator" as used herein refers to a modulator that exhibits a pharmaceutical action by glucocorticoid receptor binding. Examples thereof include glucocorticoid receptor agonists, glucocorticoid receptor antagonists and the like. The "salt" of the present compound is not particularly limited insofar as it is a pharmaceutically acceptable salt and examples thereof include salts with an inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, sulfuric acid or phosphoric acid; salts with an organic acid such as acids: citric lactic 1, 2-ethanedisulfonic acetic, fumalic, maleic, succinic, tartaric, adipic, gluconic, glucoheptonic, glucuronic, terephthalic, methanesulfonic, hippuric, isethionic, lactobionic, oleic, pamoic, polygalacturonic, stearic, tannic, trifluoromethanesulfonic, benzenesulphonic, p-toluenesulfonic, lauryl sulfate ester, methyl sulfate, naphthalenesulfonic acid or sulfosalicylic acid; quaternary ammonium salts with methyl bromide, methyl iodide or the like; salts with a halogen ion such as a bromine ion, a chlorine ion or an iodine ion; salts with an alkali metal such as lithium, sodium or potassium; salts with an alkaline earth metal such as calcium or magnesium; salts with a metal such as iron or zinc; salts with ammonia; salts with an organic amine such as triethylenediamine, 2-aminoethanol, 2, 2-iminobis (ethanol), 1-deoxy-l- (methylamino) -2-D-sorbitol, 2-amino-2- (hydroxymethyl) -1, 3-propanediol, procaine or N, N-bis (phenylmethyl) -1,2-ethanediamine; and similar. In the case where there are geometric isomers or optical isomers in the present compound, these isomers are also included within the scope of the present invention. In addition, the present compound may be in the form of a hydrate or a solvate. In addition, in the case where there is proton tautomerism in the present compound, the tautomeric isomers thereof are also included in the present invention. In case where crystalline polymorphism exists in the present compound, the crystalline polymorphisms thereof are also included in the present invention. (a) The preferred examples of the present compounds include compounds in which the respective groups are groups as defined in the following and salts thereof in the compounds represented by the general formula (1) and salts thereof. In the general formula (1), (a) the ring X represents a benzene ring or a pyridine ring; and / or (a2) R1 represents a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group, a lower alkenyloxy group, a lower alkylcarbonyl group, an amino group, a nitro group or a cyano group; in the case where R1 is a lower alkyl group or a lower alkoxy group, the lower alkyl group or the lower alkoxy group may have one or a plurality of groups which are selected from a halogen atom, an aryl group, an aryl group substituted by at least one halogen atom, an aryl group substituted by at least one lower alkyl group, an aryl group substituted by at least one hydroxy group, an aryl group substituted by at least one lower alkoxy group, a hydroxy group, an ester of a hydroxy group, a lower alkoxy group, an aryloxy group, a carboxy group and an ester of a carboxy group as one or more substituents; or (a3) p represents an integer from 0 to 3; in the case where p is 2 or 3, each R1 may be the same or different; or (a4) R2 represents a halogen atom, a lower alkyl group, a hydroxy group, an ester of a hydroxy group or a lower alkoxy group; or (a5) q represents an integer from 0 to 2; in the case where q is 2, each R2 can be the same or different; or (a6) R3 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, an aryl group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group, a lower alkynylcarbonyl group or an arylcarbonyl group; in the case where R3 is a lower alkyl group or a lower alkylcarbonyl group, the lower alkyl group or the lower alkylcarbonyl group may have one or a plurality of aryl groups as substituents; in the case where R3 is an aryl group or an arylcarbonyl group, the aryl group or the arylcarbonyl group may have one or a plurality of groups which are selected from a halogen atom and a lower alkyl group as substituents; or (a7) R4 and R5 may be the same or different and they represent a hydrogen atom or a lower alkyl group; or (a8) R6 represents a hydrogen atom or a lower alkyl group; or (a9) A represents a lower alkylene group or a carbonyl group; or (alO) R7 represents OR8, NR8R9 or SR8; or (all) R8 represents a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower cycloalkyl group, an aryl group, a heterocyclic group, a formyl group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group, a lower alkynylcarbonyl group, a lower cycloalkylcarbonyl group, an arylcarbonyl group, a heterocyclic carbonyl group, a carboxy group , a lower alkoxycarbonyl group, a lower alkenyloxycarbonyl group, a lower alkynyloxycarbonyl group, a lower cycloalkyloxycarbonyl group, an aryloxycarbonyl group, a heterocyclic oxycarbonyl group, a lower alkylsulfonyl group, a lower alkenylsulfonyl group, a lower alkynylsulfonyl group, a lower cycloalkylsulfonyl group, an arylsulfonyl group, a heterocyclic sulfonyl group, an aminocarbonyl group, a lower alkylaminocarbonyl group, a lower alkenylamino-carbonyl group, an alkynylaminocarbonyl group lower, a lower cycloalkylaminocarbonyl group, an arylaminocarbonyl group or a heterocyclic aminocarbonyl group; or (al2) R9 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower cycloalkyl group, an aryl group, a heterocyclic group, a formyl group, a lower alkylcarbonyl group, a group lower alkenylcarbonyl, an alkynylcarbonyl group, a lower cycloalkylcarbonyl group, an arylcarbonyl group, a heterocyclic carbonyl group, a carboxy group, a lower alkoxycarbonyl group, a lower alkenyloxycarbonyl group, a lower alkynyloxycarbonyl group, a lower cycloalkyloxycarbonyl group, an aryloxycarbonyl group, oxycarbonyl heterocyclic group, a lower alkylsulfonyl group, a lower alkenylsulfonyl group, a lower alkynylsulfonyl group, a lower cycloalkylsulfonyl group, an ariisulfonilo group, a sulfonyl group heterocyclic aminocarbonyl group, a lower alkylaminocarbonyl group, a lower alkenylaminocarbonyl group, alq lower alkylaminocarbonyl, a lower cycloalkylaminocarbonyl group, an arylaminocarbonyl group or a heterocyclic aminocarbonyl group; or (al3) in the case where R8 or R9 is a group , a lower alkenyl group, a lower alkynyl group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group, a lower alkynylcarbonyl group, a lower alkoxycarbonyl group, a lower alkenyloxycarbonyl group, a lower alkynyloxycarbonyl group, a lower alkylsulfonyl group, an alkyl group lower alkenylsulfonyl an alkynylsulfonyl group, a lower alkylaminocarbonyl group, a lower alkenylaminocarbonyl group or a lower alkynylaminocarbonyl group, the lower alkyl group, lower alkenyl group, lower alkynyl group, lower alkylcarbonyl group, lower alkenylcarbonyl group, the group lower alkynylcarbonyl, lower alkoxycarbonyl group, lower alkenyloxycarbonyl group, lower alkynyloxycarbonyl group, lower alkylsulfonyl group, lower alkenylsulfonyl group, lower alkynylsulfonyl group, lower alkylaminocarbonyl group, lower alkenylaminocarbonyl or the lower alkynylaminocarbonyl group may have one or a plurality of groups which are selected from a halogen atom, a lower cycloalkyl group, an aryl group, a heterocyclic group, a hydroxy group, an ester of a hydroxy group, a group lower alkoxy, a lower alkoxy group substituted by at least one halogen atom, a a lower alkenyloxy group, a lower alkynyloxy group, a lower cycloalkyloxy group, an aryloxy group, an oxyheterocyclic group, a mercapto group, an ester of a mercapto group, a lower alkylthio group, a lower alkenylthio group, a lower alkynylthio group, a group lower cocloalkylthio, an arylthio group, a thioheterocyclic group, an amino group, an amide of an amino group, a lower alkylamino group, an amide of a lower alkylamino group, an arylamino group, an amide of an arylamino group, a heterocyclic amino group , an amide of an aminoheterocyclic group, a formyl group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group, a lower alkynylcarbonyl group, a lower cycloalkylcarbonyl group, an arylcarbonyl group, a heterocyclic carbonyl group, a carboxy group, an amide of a group carboxy, a lower alkoxycarbonyl group, a lower alkenyloxycarbonyl group, a lower alkynyloxycarbonyl group, a lower cycloalkyloxycarbonyl group, an aryloxycarbonyl group, a heterocyclic oxycarbonyl group, a lower alkylsulfinyl group, an arylsulfinyl group, a lower alkylsulfonyl group, ariisulfonilo group, a sulfinic acid group, an ester of a sulfinic acid group, an amide of an acid group sulfinic, a sulfonic acid group, an ester of a sulfonic acid, an amide of a sulfonic acid group, a nitro group and a cyano group as substituents; or (al4) in the case where R8 or R9 is a lower cycloalkyl group, an aryl group, a heterocyclic group, a lower cycloalkylcarbonyl group, an arylcarbonyl group, a heterocyclic carbonyl group, lower cycloalkyloxycarbonyl group, an aryloxycarbonyl group, a oxycarbonyl heterocyclic group, a lower cycloalkylsulfonyl group, an ariisulfonilo group, a heterocyclic sulfonyl group, lower cycloalkylaminocarbonyl group, an arylaminocarbonyl group or heterocyclic aminocarbonyl group, the lower cycloalkyl group, aryl group, heterocyclic group, lower cycloalkylcarbonyl group, arylcarbonyl group, heterocyclic carbonyl group, lower cycloalkyloxycarbonyl group the the aryloxycarbonyl group, heterocyclic oxycarbonyl group, lower cycloalkylsulfonyl group the the ariisulfonilo group, heterocyclic sulfonyl group, lower cycloalkylaminocarbonyl group the the arylaminocarbonyl group or the ami heterocyclic nocarbonyl may have one or a plurality of groups selected from a halogen atom, a lower alkyl group, a lower alkyl group substituted by at least one halogen atom, a substituted lower alkyl group by at least one hydroxy group, a lower alkyl group substituted by at least one lower alkoxy group, a lower alkyl group substituted by at least one amino group, a lower alkyl group substituted by at least one lower alkylamino group, a substituted lower alkyl group by at least one carboxy group, a lower alkyl group substituted by at least one lower alkoxycarbonyl group, a lower alkenyl group, a lower alkynyl group, a lower cycloalkyl group, an aryl group, a heterocyclic group, a hydroxy group, an a hydroxy group, a lower alkoxy group, a lower alkoxy group substituted by at least one halogen atom, a lower alkenyloxy group, a lower alkynyloxy group, a lower cycloalkyloxy group, an aryloxy group, an oxyheterocyclic group, a mercapto group, a ester of a mercapto group, a lower alkylthio group, a lower alkenylthio group, a lower alkynylthio group, a lower cycloalkylthio group or, an arylthio group, a heterocyclic thio group, an amino group, an amide of an amino group, a lower alkylamino group, an amide of a lower alkylamino group, an arylamino group, an amide of an arylamino group, a heterocyclic amino group , an amide of an aminoheterocyclic group, a formyl group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group, a lower alkynylcarbonyl group, a group lower cycloalkylcarbonyl, arylcarbonyl group, heterocyclic carbonyl group, a carboxy group, an amide of a carboxy group, a lower alkoxycarbonyl group, an alkenyloxycarbonyl group lower, an alkynyloxy-carbonyl group, a lower cycloalkyloxycarbonyl group, an aryloxycarbonyl group, a oxycarbonyl heterocyclic group, a lower alkylsulfinyl group, an arylsulfinyl group, a lower alkylsulfonyl group, ariisulfonilo group, a sulfinic acid group, an ester of a sulfinic acid group, an amide of a sulfinic acid group, a sulfonic acid group, an ester of a sulfonic acid group, an amide of a sulfonic acid group, a nitro group, a cyano group, an aminocarbonyloxy group, a lower alkylaminocarbonyloxy group and an arylaminocarbonyloxy group as substituents; or (al5) additionally, in the case where R7 is NR8R9, R8 and R9 can be combined together to form a 5- to 6-membered nitrogen containing heterocyclic ring. That is, in the compounds represented by the general formula (1), the preferred examples include compounds comprising one or a combination of two or more that are selected from the above (a), (a2), (a3), (a4), (a5), (a6), (a7), (a8), (a9), (alO), (all), (al2), (al3), (al4) ) and (al5) and salts thereof. (b) the most preferred examples of the present compound include compounds in which the respective groups are groups as defined in the following and salts thereof in the compounds represented by the general formula (1) and salts thereof. In the general formula (1), (bl) the ring X represents a benzene ring or a pyridine ring; or (b2) R1 represents a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group, a lower alkenyloxy group, a lower alkylcarbonyl group, an amino group or a nitro group; in the case where R1 is a lower alkyl group or a lower alkoxy group, the lower alkyl group or the lower alkoxy group may have one or a plurality of groups which are selected from a halogen atom, an aryl group, an aryl group substituted by at least one halogen atom, an aryl group substituted by at least one lower alkyl group, an aryl group substituted by at least one lower alkoxy group, a hydroxy group, a lower alkoxy group, an aryloxy group, a carboxy group and. an ester of a carboxy group as substituents; or (b3) p represents an integer from 0 to 3; In the case where p is 2 or 3, each R1 can be same or different; or (b4) R2 represents a halogen atom, a lower alkyl group, a hydroxy group or a lower alkoxy group; or (b5) q represents an integer from 0 to 2; in the case where q is 2, each R2 can be the same or different; or (b6) R3 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, an aryl group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group or an arylcarbonyl group; in the case where R3 is a lower alkyl group or a lower alkylcarbonyl group, the lower alkyl group or the lower alkylcarbonyl group may have one or a plurality of aryl groups as substituents; in the case where R3 is an aryl group or an arylcarbonyl group, the aryl group or the arylcarbonyl group may have one or a plurality of groups which are selected from a halogen atom and a lower alkyl group as substituents; or (b7) R4 and R5 may be the same or different and represent a hydrogen atom or a lower alkyl group; or (b8) R6 represents a hydrogen atom or a lower alkyl group; or (b9) A represents a lower alkylene group or a carbonyl group; or (blO) R7 represents OR8, NR8R9 or SR8; or (bll) R8 represents a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower cycloalkyl group, an aryl group, a heterocyclic group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group, a lower alkynylcarbonyl group, an lower cycloalkylcarbonyl group, an arylcarbonyl group or a heterocyclic carbonyl group; or (bl2) R9 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower cycloalkyl group, an aryl group, a heterocyclic group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group, an lower alkynylcarbonyl group, a lower cycloalkylcarbonyl group, an arylcarbonyl group, or a heterocyclic carbonyl group; or (bl3) in the case where R8 or R9 is a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group or a lower alkynylcarbonyl group, the lower alkyl group, the group lower alkenyl, the lower alkynyl group, the lower alkylcarbonyl group, lower alkenylcarbonyl group or lower alkynylcarbonyl group may have one or a plurality of groups which are selected from an aryl group, a hydroxy group and a lower alkoxy group as substituents; or (bl4) in the case where R8 or R9 is a lower cycloalkyl group, an aryl group, a heterocyclic group, a lower cycloalkylcarbonyl group, an arylcarbonyl group or a carbonylheterocyclic group, the lower cycloalkyl group, the aryl group, the heterocyclic group, the lower cycloalkylcarbonyl group, the arylcarbonyl group or the carbonylheterocyclic group can have one or a plurality of groups that are selected from a halogen atom, a lower alkyl group, a group lower alkyl substituted by at least one halogen atom, a lower alkyl group substituted by at least one hydroxy group, a lower alkyl group substituted by at least one lower alkoxy group, a lower alkyl group substituted by at least one amino group, a group lower alkyl substituted by at least one lower alkylamino group, a lower alkyl group substituted by at least one carboxy group, a lower alkyl group substituted by at least one lower alkoxycarbonyl group, a lower alkenyl group, a lower alkynyl group, an aryl group, a heterocyclic group, a hydroxy group, an ester of a hydroxy group, a lower alkoxy group, a lower alkoxy group substituted by at least one halogen atom, an aryloxy group, a mercapto group, a lower alkylthio group, an amino group, an amide of an amino group, an lower alkylamino group, an amide of a lower alkylamino group, a formyl group, a lower alkylcarbonyl group, a carboxy group, an amide of a carboxy group, a lower alkoxycarbonyl group, a nitro group, a cyano group, an aminocarbonyloxy group and a alkylaminocarbonyloxy group as a substituent; or (bl5) additionally, in the case where R7 is NR8R9, R8 and R9 can be combined together to form a 5- or 6-membered heterocyclic ring containing nitrogen. That is, in the compounds represented by the general formula (1), the most preferred examples include compounds comprising one or a combination of two or more that are selected from the preceding paragraphs (bl), (b2), (b3), (b4), (b5), (b6), (b7), (b8), (b9), (blO), (bll), (bl2), (bl3), (bl4) ) and (bl5) and salts thereof. (c) further preferred examples of the present compounds include compounds in which the respective groups are groups as defined in the following and salts thereof in the compounds represented by the general formula (1) and salts of the same. In the general formula (1), (cl) the X ring represents a benzene ring or a pyridine ring; or (c2) R1 represents a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group, a lower alkenyloxy group, a lower alkylcarbonyl group, an amino group or a nitro group; in the case where R1 is a lower alkyl group or a lower alkoxy group, the lower alkyl group or the lower alkoxy group may have one or a plurality of groups which are selected from a halogen atom, an aryl group, an aryl group substituted with at least one halogen atom, an aryl group substituted with at least one lower alkyl group, an aryl group substituted with at least one lower alkoxy group, a hydroxy group, a lower alkoxy group and an ester of a carboxy group as substituents; or (c3) p represents an integer from 0 to 3; in the case where p is 2 or 3, each R1 may be the same or different; or (c4) R2 represents a halogen atom, a lower alkyl group or a lower alkoxy group; or (c5) q represents O or l; or (c6) R3 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group or an arylcarbonyl group; in the case where R3 is a lower alkyl group, the lower alkyl group may have one or a plurality of aryl groups as substituents; in the case where R3 is an arylcarbonyl group, the arylcarbonyl group can have one or a plurality of groups that are selected from a halogen atom and a lower alkyl group as a substituent; or (c7) R4 and R5 both represent a lower alkyl group; or (c8) R6 represents a lower alkyl group; or (c9) A represents a lower alkylene group or a carbonyl group; or (clO) R7 represents OR8, NR8R9 or SR8; or (cll) R8 represents a lower alkyl group, a lower cycloalkyl group, an aryl group, a heterocyclic group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group, a lower cycloalkylcarbonyl group, an arylcarbonyl group or a heterocyclic carbonyl group; or (cl 2) R 9 represents a hydrogen atom, a lower alkyl group, a lower cycloalkyl group, an aryl group, a heterocyclic group, an arylcarbonyl group or a heterocyclic carbonyl group; or (cl3) in the case where R8 or R9 is a lower alkyl group, the lower alkyl group may have one or a plurality of groups which are selected from a lower alkoxy group and an aryl group as a substituent; or (cl4) in the case where R8 or R9 is an aryl group, an arylcarbonyl group or a heterocyclic carbonyl group, the aryl group, the arylcarbonyl group or the heterocyclic carbonyl group may have one or a plurality of groups which are selected from a halogen atom, a lower alkyl group, a lower alkyl group substituted by at least one halogen atom, a group lower alkyl substituted by at least one hydroxy group, a lower alkyl group substituted by at least one amino group, a lower alkyl group substituted by at least one lower alkylamino group, a lower alkyl group substituted by at least one carboxy group, an alkyl group lower substituted by at least one lower alkoxycarbonyl group, a lower alkenyl group, a lower alkynyl group, an aryl group, a hydroxy group, an ester of a hydroxy group, a lower alkoxy group, a lower alkoxy group substituted by at least one atom of halogen, an aryloxy group, a lower alkylthio group, an amino group, an amide of an amino group, a lower alkylamino group, an amide of a group or alkylaminolower, a formyl group, a lower alkylcarbonyl group, a carboxy group, an amide of a carboxy group, a lower alkoxycarbonyl group, a nitro group, a cyano group and a lower alkylaminocarbonyloxy group as a substituent; or (cl5) additionally, in the case where R7 is NR8R9, R8 and R9 can be combined together to form a 5- or 6-membered heterocyclic ring containing nitrogen. That is, in the compounds represented by the general formula (1), the further more preferred examples include compounds comprising one or a combination of two or more that are selected from the above items (cl), (c2), (c3) , (c4), (c5), (c6), (c7), (c8), (c9), (clO), (cll), (cl2), (cl3), (cl4) and (cl5) and salts thereof. (d) the most preferred examples of the present compound include compounds in which the respective groups are groups as defined in the following and salts thereof in the compounds represented by the general formula (1) and salts thereof. In the general formula (1), (di) the ring X represents a benzene ring; or (d2) R1 represents a halogen atom, a lower alkyl group, a hydroxy group, an alkoxy group lower, a lower alkenyloxy group, an amino group or a nitro group; in the case where R1 is a lower alkyl group, the lower alkyl group may have one or a plurality of halogen atoms as substituents; in the case where R1 is a lower alkoxy group, the lower alkoxy group may have one or a plurality of groups which are selected from an aryl group, an aryl group substituted by at least one halogen atom, an aryl group substituted by minus a lower alkyl group; an aryl group substituted by at least one lower alkoxy group and a lower alkoxy group as substituents; or (d3) p represents 2 or 3, and at this time each R1 may be the same or different; or (d4) R 2 represents a halogen atom, a lower alkyl group or a lower alkoxy group; or (d5) q represents O or l; or (d6) R3 represents a hydrogen atom; or (d7) R4 and R5 both represent a lower alkyl group; or (d8) R6 represents a lower alkyl group; or (d9) A represents a lower alkylene group; or (dlO) R7 represents OR8, NR8R9 or SR8; or (dll) R8 represents an aryl group, a group arylcarbonyl or a heterocyclic carbonyl group; or (dl2) R9 represents a hydrogen atom or a lower alkyl group; or (dl3) in the case where R8 is an aryl group, an arylcarbonyl group or a heterocyclic carbonyl group, the aryl group, the arylcarbonyl group or the heterocyclic carbonyl group may have one or a plurality of groups selected from an atom of halogen, a lower alkyl group, a lower alkyl group substituted by at least one halogen atom, a lower alkyl group substituted by at least one hydroxy group, a lower alkyl group substituted by at least one amino group, a substituted lower alkyl group by at least one lower alkylamino group, a lower alkyl group substituted by at least one carboxy group, a lower alkyl group substituted by at least one lower alkoxycarbonyl group, a lower alkenyl group, a lower alkynyl group, an aryl group, a hydroxy group , an ester of a hydroxy group, a lower alkoxy group, a lower alkoxy group substituted by at least one halogen atom, an aryloxy group, an alkyl group lower thio, an amino group, an amide of an amino group, a lower alkylamino group, an amide of a lower alkylamino group, a formyl group, a lower alkylcarbonyl group, a carboxy group, an amide of a carboxy group, an alkoxycarbonyl group lower, a nitro group, a cyano group and a lower alkylaminocarbonyloxy group as substituents. That is, in the compounds represented by the general formula (1), the further most preferred examples include compounds comprising one or a combination of two or more that are selected from the preceding paragraphs (di), (d2), (d3), (d4), (d5), (d6), (d7), (d8), (d9), (dlO), (dll), (dl2) and (dl3), and salts of them. (e) further preferred examples of the present compound include compounds that satisfy the following requirement and salts thereof. A compound which satisfies the requirement of the above subparagraphs a, b, cody in which R7 is OR8 in the general formula (1) or a salt thereof is preferred, and at this time, a compound in which R8 is a phenyl group, a phenylcarbonyl group or a thiophenecarbonyl group or a salt thereof. Incidentally, this R8 may have a substituent and in the case where R8 is a phenyl group, the phenyl group may be substituted by one or a plurality of groups (particularly one, two or three groups) that are selected from an atom of halogen, a lower alkyl group, an alkyl group substituted by at least one halogen atom, a lower alkyl group substituted by at least one hydroxy group, an alkyl group lower substituted by at least one lower alkylamino group, a lower alkyl group substituted by at least one carboxy group, a lower alkyl group substituted by at least one lower alkoxycarbonyl group, a lower alkenyl group, a lower alkynyl group, an aryl group, an hydroxy group, a lower alkoxy group, a lower alkylthio group, an amino group, an amide of an amino group, a lower alkylamino group, an amide of a lower alkylamino group, a formyl group, a lower alkylcarbonyl group, a carboxy group, an amide of a carboxy group, a lower alkoxycarbonyl group, a nitro group and a cyano group. In the case where R8 is a phenylcarbonyl group, the phenylcarbonyl group can be substituted by one or a plurality of groups (particularly one, two or three groups) which are selected from a halogen atom, a lower alkyl group, an alkyl group lower substituted by at least one halogen atom, a lower alkyl group substituted by at least one hydroxy group, an aryl group, a hydroxy group, an ester of a hydroxy group, a lower alkoxy group, a lower alkoxy group substituted by minus one halogen atom, an aryloxy group, a lower alkylthio group, an amino group, a lower alkylamino group, a lower alkylcarbonyl group, a nitro group and a cyano group. In addition, in the case where R8 is a thiophene group carbonyl, the thiophene carbonyl group may be substituted by one or a plurality of groups (particularly one, two or three groups) which are selected from a halogen atom, a lower alkyl group, an aryl group, a lower alkoxy group, a group lower alkylthio, an amide of an amino group and a lower alkylcarbonyl group. (f) Still further preferred examples of the present compound include compounds that satisfy the following requirement and salts thereof. A compound which satisfies the requirement of the above items (a), (b), (c) or (d) and in which R7 is NR8R9 in the general formula (1) or a salt thereof is preferred, and in at this time, a compound in which R8 is a phenyl group or a salt thereof is particularly preferred. Incidentally, this R8 may have a substituent and, in the case where R8 is a phenyl group, the phenyl group may be substituted by one or a plurality of groups (particularly one, two or three groups) which are selected from a halogen atom, a lower alkyl group, a lower alkyl group substituted by at least one hydroxy group, a heterocyclic group, a lower alkoxy group, a lower alkylthio group, an amide of an amino group, an alkylamino group lower, an amide of a lower alkylamino group, a lower alkylaminocarbonyloxy group and a cyano group. (g) Still further preferred examples of the present compound include compounds that satisfy the following requirement and salts thereof. A compound which satisfies the requirement of the preceding paragraphs (a), (b), (c) or (d) and in which R7 is SR8 in the general formula (1) or a salt thereof is the one that is preferred . (h) Additional, more preferred examples of the present compound include compounds that satisfy the following requirement and salts thereof. A compound which satisfies the requirement of the preceding paragraphs (a), (b), (c), (d), (e), (f) or Y in which the ring X is a benzene ring in the general formula (1) or a salt thereof. (i) Additional, more preferred examples of the present compound include compounds that satisfy the following requirement and salts thereof. A compound which satisfies the requirement of the preceding paragraphs (a), (b), (c), (d), (e), (f), (g) or (h) and in which it is preferred that A is a lower alkylene group of the general formula (1) or a salt thereof, and at this time a compound in which the lower alkylene group is a methylene group or a salt of it. (j) Further even more preferred examples of the present compound include compounds that satisfy the following requirement and salts thereof. A compound which satisfies the requirement of the preceding paragraphs (a), (b), (c), (d), (e), (f), (g), (h) or (i) and in which R3 is a hydrogen atom of the general formula (1) or a salt thereof. (k) Particularly preferred examples of the present compound include compounds satisfying the following requirement and salts thereof. A compound is preferred which satisfies the requirement of the preceding paragraphs (a), (b), (c), (d), (e), (f), (g), (h), (i) or ( j) and in which R4, R5 and R6 are a lower alkyl group in the general formula (1) or a salt thereof and at this time a compound in which each of the lower alkyl groups is a group is particularly preferred methyl or a salt thereof. (1) Particularly preferred specific examples of the present compound include the following compounds and salts thereof. 5-Acetoxymethyl-6- (2-methoxyphenyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 5-benzoyloxymethyl-6- (2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (2-methoxyphenyl) -5- [(thiophen-2-yl) carbonyloxymethyl] 2,2,4-trimethyl-1,2-dihydroquinoline 5- (4-tert-butylbenzoyloxymethyl) -6- (2-methoxyphenyl) -2 2, 4-trimethyl-1,2-dihydroquinoline 5-benzoyloxymethyl-6- (4-fluoro-2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2- methoxyphenyl) -5- (3-methoxybenzoyloxymethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-Fluoro-2-methoxyphenyl) -5- (2-methoxybenzoyloxymethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (4-methoxybenzoyloxymethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- [(thiophen-2-yl) carbonyloxymethyl] -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) - 5- (4-methylbenzoyloxymethyl) 2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (3-methylbenzoyloxymethyl) 2,2,4-trimethyl-2, -dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (2-methylbenzoyloxymethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5-phenoxymethyl-2, 2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (4-methoxyphenoxymethyl) -2 , 2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (4- fluorophenoxymethyl) -2,2, 4-trimethyl-l 2 -dihydroquinoline 6- (4-fluoro-2-methoxyphenyl; -5- (3-fluorophenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (2-fluorophenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (3-methoxyphenoxymethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (2-methoxyphenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- ( 4,5-difluoro-2-methoxyphenyl) -5- (3-fluorophenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (4-methylphenoxymethyl) ) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (3-methylphenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (2-methylphenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (2-hydroxymethylphenoxymethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (5-fluoro-2-methyl-phenoxymethyl) -2,2, 4-trimethyl-1 , 2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (5-chloro-2-methyl-phenoxymethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4,5) difluoro-2-methoxyphenyl) -5- (5-fluoro-2- methylphenoxymethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (2-methoxy-5-nitrophenoxymethyl) -2,2,4-trimethyl-1, 2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- [2- (2-hydroxyethyl) -phenoxymethyl] -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2) -methoxyphenyl) -5- (2-methyl-5-nitrophenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (2-allylphenoxymethyl) -2, 2,4-trimethyl-1,2-dihydroquinoline 6- (5-chloro-2-methoxyphenyl) -5- [2- (2-hydroxyethyl) -phenoxymethyl] -2,2,4-trimethyl-1,2- dihydroquinoline 5- (5-fluoro-2-methylphenoxymethyl) -6- (4-hydroxy-2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline 5- (5-fluoro-2-methylphenoxymethyl) - 6- (5-hydroxy-2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-hydroxy-2-methoxyphenyl) -5- (4-methylbenzoyloxymethyl) 2,2,4- trimethyl-1,2-dihydroquinoline 6- (2-methoxyphenyl) -5-phenylaminomethyl-2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5-phenylaminomethyl-2, 2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (4-methoxyphenylaminomethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (4-fluorophenylaminomethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (3-fluorophenylaminomethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (2-fluorophenylaminomethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (3-methoxyphenylaminomethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-Fluoro-2-methoxyphenyl) -5- (2-methoxyphenylaminemethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4,5-difluoro-2-methoxyphenyl) -5- (2-methoxyphenyl-aminomethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5 - (2-hydroxymethylfe-nilaminomethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (2-methoxy-5-methylphenylaminomethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (5-fluoro-2-methylphenylaminomethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (5 -chloro-2-methoxyphenyl) -5- (2-methoxyphenylaminomethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (5-Chloro-2-methoxyphenyl) -5- (5-fluoro-2-methylphenylaminomethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (2-methoxyphenyl) -5-phenylthiomethyl-2 , 2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5-phenylthiomethyl-2, 2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2 - methoxyphenyl) -5- (2- methoxyphenylthiomethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5 - [(5-methylthiophen-2-yl) carbonyloxymethyl] -2,2, 4-trimethyl -l, 2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5 - [(4-methylthiophen-2-yl) carbonyloxymethyl] -2,2,4-trimethyl-1,2-dihydroquinoline 5- [( 5-chlorothiophen-2-yl) carbonyloxymethyl] -6- (4-fluoro-2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- [(3-methylthiophen-2-yl) carbonyloxymethyl] -2,2,4-trimethyl-1,2-dihydroquinoline 5- [(5-bromothiophen-2-yl) carbonyloxymethyl] -6- (4-fluoro-2 - methoxyphenyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5 - [(5-methoxythiophen-2-yl) carbonyloxymethyl] -2,2, 4-trimethyl -l, 2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- [(thiophen-3-yl) carbonyloxymethyl] -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4,5) -difluoro-2-methoxyphenyl) -5- [(5-methylthiophen-2-yl) carbonyloxymethyl] -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (5-chloro-2-methoxyphenyl) -5- (5-methylthiophen-2-ylcarbonyloxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (5-chloro-2-methoxyphenyl) -5 - (4-methoxybenzoyloxymethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (5-chloro-2-methoxyphenyl) -5- (2-methyl-5-nitrophenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (5-chloro-2-methoxyphenyl) -5 - (5-fluoro-2-methylphenoxymethyl) -2, 2, 4-trimethyl-1,2-dihydroquinoline 6- (5-chloro-2-methoxyphenyl) -5- (2-methoxy-5-nitrophenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (5-chloro-2-methoxyphenyl) -5 - (5-chloro-2-methylphenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (5-chloro-2-methoxyphenyl) -5- (5-fluoro-2-methoxyphenoxymethyl) -2, 2, 4-trimethyl-1,2-dihydroquinoline 6- (5-chloro-2-methoxyphenyl) -5- (2,5-dimethylphenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 5- (2 -alphaphenoxymethyl) -6- (5-chloro-2-methoxyphenyl) 2,2,4-trimethyl-1,2-dihydroquinoline 5- (5-fluoro-2-methylphenoxymethyl) -6- (2-methoxy-5-nitrophenyl) ) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-allyloxy-2-methoxyphenyl) -5- (5-fluoro-2-methylphenoxymethyl) -2,2,4-trimethyl-2, -dihydroquinoline 6- (5-allyloxy-2-methoxyphenyl) -5- (5-fluoro-2-methylphenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (5-amino-2-methoxyphenyl) -5- (5-fluoro-2-methylphenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 5- (2-fluorobenzoyloxymethyl) -6- (4-fluoro-2-methoxyphenyl) -2,2, 4-trimethyl-1,2-dihydroquinone 5- (3-fluorobenzoyloxymethyl) -6- (4-fluoro-2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline 5- (4-fluorobenzoyloxymethyl) -6- (4-fluoro-2) -methoxyphenyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (4- methylphenylaminomethyl) -2,2, 4-trimethyl-l, 2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (3-methylphenylaminomethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5 - (2-methylphenylaminomethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (2-methylphenylthiomethyl) 2,2,4-trimethyl-2, -dihydroquinoline. The present compound can be synthesized according to the following procedures. The individual concrete preparation procedures are explained in detail in the following examples [preparation examples]. These examples are designed to make the present invention more clear and understandable and do not limit the scope of the present invention. The term hal shown in the synthesis routes that follow represents a halogen atom. The present compounds (I) - (a) (the compound wherein A is a methylene group, R3 is H, R4, R5 and R6 is a methyl group, R7 is OR8a, R8a is such as an alkylcarbonyl group, a cycloalkylcarbonyl group , an arylcarbonyl group, a carbonylheterocyclic group of the general formula (1)) and (I) - (b) (the compound wherein A is a methylene group, R3 is such as an alkylcarbonyl group, a cycloalkylcarbonyl group, an arylcarbonyl group , a heterocyclic carbonyl group, R4, R5 and R6 is a group methyl, R7 is OR8a, R8a is such as an alkylcarbonyl group, a cycloalkylcarbonyl group, an arylcarbonyl group, a heterocyclic carbonyl group in the general formula (1)) can be synthesized according to synthesis route 1. Specifically, the compound (I) - (a) or (I) - (b) can be supplied by the reaction of the compound (II) with a corresponding acid chloride (III) - (a) in an organic solvent such as tetrahydrofuran (hereinafter referred to as as the TF), 1,4-dioxane, N, -dimethylformamide (hereinafter referred to as DMF), methylene dichloride in the presence of a base such as triethylamine, diisopropylethylamine (hereinafter referred to as DIEA) at 0 ° C at room temperature for 12 hours to 2 days.

Synthesis Route 1 The present compound (I) - (a) (the compound wherein A is a methylene group, R3 is H, R4, R5 and R6 is a methyl group, R7 is OR8a, R8 is such as a carbonyl group, a cycloalkylcarbonyl group, an arylcarbonyl group, a heterocyclic carbonyl group in the general formula (1)) can also be synthesized according to the synthesis route 2. Specifically, the compound (IV) can be supplied by the reaction of the compound (II) ) with methanesulfonyl chloride in an organic solvent such as methylene dichloride DMF in the presence of a base such as triethylamine, DIEA at 0 ° C to room temperature for 30 minutes to 3 days. The compound (I) - (a) can be supplied by the reaction of the compound (IV) with a corresponding carboxylic acid (III) - (b) in an organic solvent such as DMF, methylene dichloride in the presence of a base such as potassium carbonate, DIEA, sodium hydride at 50 ° C up to 100 ° C for 1 hour to 2 days.

Synthesis Route 2 The present compound (I) - (a) (the compound wherein A is a methylene group, R3 is H, R4, R5 and R6 is a methyl group, R7 is OR8a, R8 is such as an alkylcarbonyl group, a cycloalkylcarbonyl group, an arylcarbonyl group, a heterocyclic carbonyl group in the general formula (1)) can also be synthesized according to synthesis route 3. Specifically, the compound (I) - (a) can be supplied by the reaction of the compound (II) with a corresponding carboxylic acid (III) - (b) in an organic solvent such as benzene, toluene in the presence of a phosphine such as triphenylphosphine, tributylphosphine and a reagent such as diethyl azodicarboxylate, diisopropyl azodicarboxylate, 1, 1'- (azodicarbonyl) dipepridine at room temperature during 1 hour to 2 days.

Synthesis Route 3 The present compound (I) - (c) (the compound wherein A is a methylene group, R3 is H, R4, R5 and R6 is a methyl group, R7 is 0R8a, NR8R9 or SR8 in the general formula (1)) It can be synthesized according to the synthesis route 4. Specifically, the compound (I) - (c) can be supplied by the reaction of the compound (IV) with a corresponding alcohol or phenol (V), an amine (VI) thiol or thiophenol (VII) in an organic solvent such as DMF methylene dichloride in the presence of a base such as potassium carbonate, DIEA, sodium hydride at 50 ° C to 100 ° C for 1 hour to 2 days.

Synthesis route 4 HO-R8 (V) The present compound (I) - (d) (the compound wherein A is a methylene group, R3 is H, R4, R5 and R6 is a methyl group, R7 is OR8a, R8a is an aryl group in the general formula (1 )) can be synthesized according to the synthesis route 5. Specifically, the compound (I) - (d) can be supplied by the reaction of the compound (II) with a corresponding phenol (V) in an organic solvent such as benzene , toluene in the presence of a phosphine such as triphenylphosphine, tributylphosphine and a reagent such as diethyl azodicarboxylate, azodicarboxylate diisopropyl, 1,1'- (azodicarbonyl) dipiperidine at room temperature for 1 hour to 2 days.

Synthesis Route 5 The present compound (I) - (e) (the compound wherein A is a carbonyl group, one of R1 is a hydroxyl group in the 2-position, R3 is H, R4, R5 and R6 is a methyl group, R7 is OR8a, p 'is an integer from 0 to 4 in the general formula (1)) and (I) - (f) the compound wherein A is a carbonyl group, one of R1 is OR10 at the 2-position (R10 is such as a lower alkyl group, a lower alkylcarbonyl group), R3 is H, R4, R5 and R6 is a methyl group, R7 is NR8R9, p ' is an integer from 0 to 4 in the general formula (1)) and can be synthesized according to the synthesis route 6. Specifically, the compound (I) - (e) can be supplied by the reaction of the compound (VIII ) with a corresponding amine (VI) in an organic solvent such as diethyl ether, TF in the presence of a base such as butyl lithium at 0 ° C to room temperature for 30 minutes up to 2 hours. The compound (I) - (f) can be synthesized from by the reaction of the compound (I) - (e) with a corresponding halide (IX) in an organic solvent such as DMF, ethanol, in the presence of a base such as carbonate of potassium, DIEA at room temperature up to 100 ° C for 1 hour to 24 hours.

Synthesis Route 6 The compound (II) - (a) (the compound wherein one of R1 is OR10 at position 2, p1 is an integer from 0 to 4 in the above compound (II)) can be synthesized according to the route of synthesis 7. Specifically, the compound (II) - (b) can be supplied by the treatment of the compound (VIII) in an organic solvent such as diethyl ether, TF and in the presence of a reducing agent such as lithium aluminum hydride from 0 ° C up to 50 ° C for 1 hour to 1 day. The compound (II) - (a) can be provided by the reaction of the compound (II) - (b) with a corresponding halide (IX) in an organic solvent such as DMF, ethanol in the presence of a base such as potassium carbonate, DIEA at room temperature up to 100 ° C for 1 hour. hour to 24 hours.

Synthesis Route 7 (VI) < m- (b) (p) - (a) The compound (II) - (c) (the compound wherein one of R1 is H at the 2-position, p 'is an integer from 0 to 4 in the above compound (II)) can be synthesized according to the synthesis route 8. Specifically, the compound (II) - (d) can be supplied by the reaction of the compound (II) - (b) with trifluoromethanesulfonyl in an organic solvent such as methylene dichloride in the presence of a base such as triethylamine at -30 ° C until 0 ° C for 30 minutes to 12 hours. The compound (II) - (c) can be synthesized by the treatment of the compound (II) - (d) in an organic solvent such as DMF in the presence of a catalyst such as tetrakis (triphenylphosphine) palladium (0), a base such as triethylamine and formic acid at 60 ° C to 100 ° C for 1 hour to 24 hours.

Synthesis Route 8 The compound (VIII) can be synthesized according to the synthesis route 9. Specifically, the compound (XII) can be provided by the reaction of a corresponding boronic acid (X) - (a) (the compound which has a group benzyloxy in the 2-position) with a halide or triflate (XI) in a solvent such as DMF, ethanol, toluene, water and in the presence of a base such as cesium carbonate, sodium carbonate, tripotassium phosphate and a catalyst such as dichloride of bis (triphenylphosphine) palladium (II) or tetrakis (triphenylphosphine) palladium (0) from 50 ° C to 120 ° C for 12 hours to 2 days. The compound (XIII) can be supplied by treatment of the compound (XII) under an atmosphere of hydrogen in an organic solvent such as methanol, ethanol, 1,4-dioxane, TF in the presence of a catalyst such as carbon and palladium, Platinum dioxide at room temperature for 2 hours to 2 days. The compound (VIII) can be supplied by treatment of the compound (XIII) in acetone in the presence of iodine at 80 ° C to 130 ° C for 24 hours to 5 days.

Synthesis Route 9 (xm) (VID) The synthesis route 9 can also be synthesized according to the synthesis route 10. Specifically, the compound (XII) - (a) can be supplied by the treatment of the compound (XII) under an atmosphere of hydrogen in an organic solvent such as methanol, ethanol, 1,4-dioxane, TF in the presence of a catalyst such as carbon and palladium, platinum dioxide at room temperature for 2 hours to 2 days. The compound (XIII) can be provided by refluxing the compound (XII) - (a) in pyridine for 2 hours to 1 day.

Synthesis Route 10 The compound (VIII) can also be synthesized according to the synthesis route 11. Specifically, the compound (XIV) can be provided by the reaction of a corresponding boronic acid (X) - (b) (the compound which has a fluorine atom in the 2-position) with a halide or triflate (XI) in a solvent such as DMF, ethanol, toluene, water in the presence of a base such as cesium caate, sodium caate, tripotassium phosphate and a catalyst such as bis (triphenylphosphine) palladium dichloride) (II), tetrakis (triphenylphosphine) palladium (0) of 50 ° C at 120 ° C for 12 hours to 2 days. The compound (XV) can be provided by treating the compound (XIV) in a solvent such as water, methanol, ethanol in the presence of a base such as sodium hydroxide from 0 ° C to room temperature for 1 hour to 1 day . The compound (XVI) can be provided by the treatment of the compound (XV) in an organic solvent such as DMF, TF in the presence of a base such as sodium hydride a Room temperature up to 100 ° C for 1 hour to 2 days. The compound (XIII) can be provided by the treatment of the compound (XVI) under an atmosphere of hydrogen in an organic solvent such as methanol, ethanol, 1,4-dioxane, TF in the presence of a catalyst such as carbon and palladium, dioxide Platinum at room temperature for 2 hours to 2 days. The compound (VIII) can be supplied by treatment of the compound (XIII) in acetone in the presence of iodine from 80 ° C to 130 ° C for 24 hours to 5 days.

Synthesis Route 11 The compound (VIII) - (a) (the compound wherein the X ring is pyridine) can also be synthesized according to the synthesis route 12. Specifically, the compound (XVIII) can be provided by the reaction of a corresponding boronic acid (XVII) (the compound which has a methoxy group in the 2-position) with a halide (XI) in a solvent such as DMF, ethanol, toluene, water in the presence of a base such as cesium carbonate, sodium carbonate and a catalyst such as bis (triphenylphosphine) palladium (II) dichloride, tetrakis (triphenylphos-fine) palladium (0) from 50 ° C to 120 ° C for 12 hours. hours to 2 days. The compound (XIX) can be provided by the treatment of the compound (XVIII) in an organic solvent such as methylene dichloride, methanol, ethanol, in the presence of an acid such as boron tribromide, HCl from -78 ° C to 0 °. C for 1 hour to 12 hours. The compound (XX) can be provided by the treatment of the compound (XIX) in a solvent such as water, methanol, ethanol in the presence of a base such as sodium hydroxide from 0 ° C to room temperature for 1 hour to 1 day . The compound (XXI) can be provided by the treatment of the compound (XX) in an organic solvent such as DMF, methylene dichloride in the presence of a condensation reagent such as N, N '-diciohexylcarbodiimide, O- (7-) hexafluorophosphate azabenzotriazol-1-yl) -N, N, N, N-tetramethyluronium and a base such as DIEA from room temperature to 50 ° C for 1 hour to 3 days. The compound (XXII) can be supplied by the treatment of the compound (XXI) under an atmosphere of hydrogen in an organic solvent such as methanol, ethanol, 1,4-dioxane, TF in the presence of a catalyst such as carbon and palladium, platinum dioxide at room temperature for 2 hours to 2 days . The compound (VIII) can be supplied by treatment of the compound (XXII) in acetone in the presence of iodine at 80 ° C and 130 ° C for 24 hours to 5 days.

Synthesis Route 12 In order to find the utility of the present compound as a pharmaceutical substance by using a glucocorticoid receptor competitor analysis kit, a glucocorticoid receptor competitor analysis is carried out by a fluorescence polarization method. As a result, the present compound shows excellent glucocorticoid receptor binding activity.

Incidentally, the glucocorticoid receptor is related to the presentation of various diseases as described above, therefore, the present compound has an excellent glucocorticoid receptor binding activity and is useful as a glucocorticoid receptor modulator. A detailed explanation of this concept will be described in the section "pharmacological test" in the examples described in the following. The present compound can be administered orally or parenterally. Examples of the dosage form include a tablet, a capsule, a granule, a powder, an injection, eye drops and the like, said preparation can be prepared using a commonly used technique. For example, an oral preparation such as a tablet, a capsule, a granule or a powder can be prepared by optionally adding a necessary amount of an excipient such as lactose, mannitol, starch, crystalline cellulose, light silicic anhydride, calcium carbamate or calcium acid phosphate, a lubricant such as stearic acid, magnesium stearate or talc; a binder such as starch, hydroxypropylcellulose, hydroxypropylmethylcellulose or polyvinylpyrrolidone; a disintegrant such as carboxymethylcellulose or low substituted hydroxypropylmethylcellulose or calcium citrate; a coating agent such as hydroxypropylmethylcellulose, macrogol or a silicone resin; a stabilizer such as ethyl p-hydroxybenzoate or benzyl alcohol; a concealer such as a sweetener, an agent against bitter taste or a flavor or the like. A parenteral preparation such as an injection or eye drops can be prepared by optionally adding a necessary amount of a tonicity agent such as sodium chloride, concentrated glycerin, propylene glycol, polyethylene glycol, potassium chloride, sorbitol or mannitol; a buffer such as sodium phosphate, sodium acid phosphate, sodium acetate, citric acid, glacial acetic acid or trometamol; a surfactant such as polyoxyethylene sorbitan monooleate, polyoxy stearate 40 or polyoxyethylene hydrogenated castor oil; a stabilizer such as sodium citrate or sodium edetate; a preservative such as benzalkonium chloride, paraben, benzethonium chloride, p-hydroxybenzoate ester, sodium benzoate, chlorobutanol or sorbic acid; a pH adjusting agent such as hydrochloric acid, citric acid, phosphoric acid, glacial acetic acid, sodium hydroxide, sodium carbonate or sodium hydrogen carbonate; a subtle oil such as benzyl alcohol or similar. The dose of the present compound can be appropriately selected based on the symptoms, age, dosage form or the like. For example, in the case of an oral preparation, it may be administered in an amount generally of 0.01 to 1000 mg, preferably 1 to 100 mg per day in a single dose or in several divided doses. In addition, in the case of eye drops, a preparation containing the present compound can be administered in a concentration generally of 0.0001% to 10% (w / v), preferably from 0.01% to 5% (w / v) in a single dose or in several divided doses. Next, examples of production of the present compound, preparation examples and results of pharmacological tests will be described. However, these examples are described for the purpose of understanding the present invention in a better way and does not mean that they limit the scope of the present invention.

EXAMPLES [Production Examples] Reference Example 1 2,2, 4-trimethyl-1,2-dihydro-6-oxa-1-azacrisen-5-one (reference compound No. 1-1) 2- (2- benzyloxyphenyl) -5-nitrobenzoate (Reference compound No. 1-1- (1)) A mixture of 2-benzyloxyphenylboronic acid (20.2 g, 88.6 mmol), methyl 2-bromo-5-nitrobenzoate (25.4 g, 97.5 mmol), cesium carbonate (57.7 g, 177 mmol) and bis (triphenylphosphine) palladium (II) dichloride (1.16 g, 1.65 mmol) is suspended in 300 ml of anhydrous N, N-dimethylformamide and then stirred under an argon atmosphere at 80 ° C for 3 days. After cooling, 500 ml of ethyl acetate, 300 ml of diethyl ether and 500 ml of water are added thereto and then separated. The aqueous layer is extracted with a mixture of 200 ml of ethyl acetate and 200 ml of diethyl ether. The combined organic layer is washed with water (500 ml, twice) and 300 ml of saturated brine, successively, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to provide 21.0 g of the title reference compound as a light yellow oil (yield, 65%). - 8-aminobenzo [c] chromen-6-one (reference compound No. 1-1- (2)) Dissolve methyl 2- (2-benzyloxyphenyl) -5-nitrobenzoate (reference compound No. 11- (1) ), 21.0 g, 57.8 mmol) in a mixture of 135 ml of methanol and 90 ml of tetrahydrofuran, then 2.19 g of 5% palladium in charcoal are added thereto and then the reaction mixture is stirred under an atmosphere of hydrogen at room temperature overnight. After the insoluble materials are filtered, the filtrate is removed under reduced pressure. A mixture of ethyl acetate and hexane is added to the residue and then the mixture is filtered to provide 8.92 g of the title reference compound as a light yellow solid (yield, 73%).

NMR-H1 (400 MHz, DMSO-d6) d 5.94 (br s, 2H), 7.17 (dd, J = 8.7, 2.6 Hz, ÍH), 7.30-7.41 (m, 4H), 8.11 (d, J = 8.8 Hz, ÍH), 8.14 (d, J = 6.3 Hz, ÍH) 2,2, 4-trimethyl-1,2-dihydro-6-oxa-l-azacrisen-5-one (reference compound No. 1-1) In a pressure tube 8-aminobenzo [c] chromen- 6-one (reference compound No. 1-1- (2), 8.81 g, 41.7 mmoles) in 300 ml of acetone, then iodine (4.24 g, 16.7 mmoles) is added thereto and the pressure tube is subsequently sealed and subsequently the reaction mixture is stirred at 105 ° C for 2 days. After cooling, the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to give 4.83 g of the title reference compound as a yellow solid (yield, 40%). (^ y ° ^ y ° NMR-H1 (400 MHz, DMSO-d6) Kx Si d 1.23 (s, 6H), 1.96 (s, 3H), XXN ÍH), 6.96 (s, ÍH), 7.18 Hk 5.45 (s, (d, J = 8.9 Hz, ÍH), 7.28-7.32 (m, 2H), 7.39 (td, J = 7.7, 1.7 Hz, ÍH), 8.02 (d, J = 8.9 Hz, ÍH) , 8.11-8.13 (m, ÍH) - - 7, 8-difluoro-2, 2,4-trimethyl-1,2-dihydro-6-oxa-1-azacrisen-5-one (reference compound No. 1-2) 2- (2,3,4- methyl trifluorophenyl) -5-nitrobenzoate (reference compound No. 1-2- (1)) A mixture of 2,3,4-trifluorophenylboronic acid (4.70 g, 26.7 mmol), 2-bromo-5-nitrobenzoate methyl (9.02 g, 34.7 mmol), sodium carbonate (8.49 g, 80.1 mmol) and tetrakis (triphenylphosphine) palladium (0) (1.55 g, 1.34 mmol) is suspended in a mixture of 160 ml of toluene-40 ml of ethanol -80 ml of water and the mixture is stirred under a nitrogen atmosphere at 95 ° C overnight. After cooling, 200 ml of ethyl acetate and 200 ml of water are added thereto and subsequently separated. The organic layer is washed with 150 ml of saturated brine, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to provide 4.37 g of the reference compound as a brown oil (yield, 53%). 1 H-NMR (400 MHz, DMSO-d6) d 3.77 (s, 3H), 7.34 (tdd, J = 8.1, 5.8, 2.1 Hz, ÍH), 7.48 (dtd, J = 8.1, 5.8, 2.1 HZ, HH) ), 7.78 (d, J = 8.4 Hz, ÍH), 8.54 (dd, J = 8.4, 2.5 Hz, ÍH), 8.68 (d, J = 2.5 Hz, ÍH) 2- (2,3,4-trifluorophenyl) -5-nitrobenzoic acid (Reference compound No. 1-2- (2)) Dissolve methyl 2- (2,3,3-trifluorophenyl) -5-nitrobenzoate (reference compound No. 1-2- (1), 4.37 g, 14.1 mmoles) in a mixture of 10 ml of tetrahydrofuran and 30 ml of methanol, then 20 ml of an aqueous NaOH solution IN is added thereto and subsequently the reaction mixture is stirred at room temperature overnight. 150 ml of water and 30 ml of IN aqueous HCl solution are added to the reaction mixture to acidify and then 150 ml of ethyl acetate are added thereto and subsequently separated. The organic layer is washed with 150 ml of saturated brine, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure to provide 4.18 g of the title reference compound as a gray solid (yield, 100%) NMR-H1 (400 MHz, DMSO-d6) d 7.33 (tdd, J = 8.8, 5.6, 2.2 Hz, ÍH), 7.46 (dtd, J = 8.8, 5.6, 2. 2 HZ, ÍH), 7.74 (d, J = 8.5 Hz, ÍH), 8.50 (dd, J = 8.5, 2.5 Hz, ÍH), 8.66 (d, J = 2.5 Hz, ÍH), 13.67 (br s, ÍH ) 3,4-difluoro-8-nitrobenzo [c] chromen-6-one (reference compound No. 1-2- (3)) Suspend 60% sodium hydride (2.82 g, 70.5 mmol) in 60 ml N , Anhydrous N-dimethylformamide and then, under cooling, 40 ml of an anhydrous solution of N, N-dimethylformamide and 2- (2,3,4-trifluorophenyl) -5-nitrobenzoic acid (reference compound) are added dropwise thereto. No. 1-2- (2), 6.97 g, 23.5 mmol) and then the reaction mixture is stirred under a nitrogen atmosphere at 80 ° C for 24 hours. After cooling, 400 ml of ethyl acetate, 400 ml of water and 80 ml of an aqueous HCl solution IN are added and then separated. The organic layer is washed with 200 ml of saturated brine, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. Chloroform is added to the solid which is obtained and then filtered to obtain 3.85 g of the title reference compound as a brown solid (yield, 59%).

NMR-H1 (400 MHz, DMSO-d6) d 7.61 (td, J = 9.6, 5.4 Hz, ÍH), 8.38 (ddd, J = 9.6, 7.3, 2.3 HZ, ÍH), 8.71 (d, J = 1.5 Hz, 2H), 8.87 (t, J = 1.5, Hz, ÍH) 8-amino-3, 4-difluorobenzo. { c] chromen-6-one (reference compound No. 1-2- (4)) 3,4-difluoro-8-nitrobenzo [c] chromen-6-one is dissolved (reference compound No. 1-2- (3), 3.75 g, 13.5 mmol) in 300 ml of 1,4-dioxane, then 375 mg of palladium in charcoal 5% are added thereto and then the reaction mixture is stirred under a nitrogen atmosphere (3 kgf / cm2) at room temperature for 4 days. After the mixture is filtered, the filtrate is removed under reduced pressure. 1,4-dioxane is added to the resulting residue and then filtered to provide 2.44 g of the title reference compound as an orange solid. (yield, 73%). 7, 8-difluoro-2, 2,4-trimethyl-1,2-dihydro-6-oxa-1-azacrisen-5-one (reference compound No. 1-2) In a pressure tube, 8 - amino-3,4-difluorobenzo [c] chromen-6-one (reference compound No. 1-2- (4), 2.30 g, 9.26 mmoles) in 60 ml of acetone and then iodine (939 mg) is added thereto , 3.70 mmoles) and then the tube is sealed under pressure and then the reaction mixture is stirred at 110 ° C for 5 days. After cooling, the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (chloroform-methanol) to give 0.95 g of the title reference compound as a yellow solid (yield, 31%) NMR-H1 (500 MHz, DMSO-d6) d 1.23 (s, 6H), 1.97 (s, 3H), 5.48 (s, ÍH), 7.05 (s, ÍH), 7. 19 (d, J = 8.9 Hz, ÍH), 7.37 (td, J = 9.7, 7.6 Hz, ÍH), 7.95 (ddd, J = 9.7, 5.2, 1.8 Hz, HH), 7.98 (d, J = 8.9, Hz, ÍH) 2,2,4-trimethyl-1,2-dihydro-6-oxa-1,7-diazacrisen-5-one (reference compound No. 1-3) 2- (2-methoxypyridin-3-yl) -5 Methyl nitrobenzoate (reference compound No. 1-3- (1)) - A mixture of 2-methoxypyridin-3-ylboronic acid (1.00 g, 6.54 mmol), methyl 2-bromo-5-nitrobenzoate (2.21 g, 8.50 mmoles), cesium carbonate (6.39 g, 17.6 mmoles) and bis (triphenylphosphine) palladium dichloride (II) (230 mg, 0.33 mmol) is suspended in 15 ml of anhydrous N, N-dimethylformamide and then the mixture is stirred under a nitrogen atmosphere at 80 ° C overnight. After cooling, 100 ml of water are added thereto and then the whole is extracted with ethyl acetate (80 ml, twice). The combined organic layer is washed with 100 ml of saturated brine, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to provide 1.54 g of the title reference compound as a yellow solid (yield, 81%). NMR-H1 (500 MHz, DMSO-d6) d 3.71 (s, 3H), 3.77 (s, 3H), 7.16 (dd, J = 7.3, 5.2 Hz, HH), 7.71 (d, J = 8.6 Hz, HH ), 7.78 (dd, J = 7.3, 1.8 Hz, HH), 8.24 (dd, J = 5.2, 1.8 Hz, HH), 8.47 (d, J = 8.6, 2.4 Hz, HH), 8.53 (d, J = 2.4 Hz, ÍH) 2- (2-hydroxypyridin-3-yl) -5-nitrobenzoate - methyl (reference compound No. 1-3- (2)) Dissolve methyl 2- (2-methoxypyridin-3-yl) -5-nitrobenzoate (reference compound No. 1-3- (1), 200 mg, 0.694 mmol) in 2 ml of anhydrous dichloromethane, then boron tribromide (118 μl, 1.25 mmol) was added thereto at -78 ° C. The reaction mixture is stirred at 0 ° C for 3 hours and then poured into 30 ml of ice-water. 50 ml of ethyl acetate are added and then separated. The organic layer is washed with 50 ml of saturated brine, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to provide 102 mg of the title reference compound as a yellow solid (yield, 54%). NMR-H1 (400 MHz, DMSO-d6) d 3.78 (s, 3H), 7.13 (dd, J = 7.3, 5.1 Hz, HH), 7.66 (d, J = 8.5 Hz, HH), 7.73 (dd, J) = 7.3, 1. 9 Hz, ÍH), 8.22 (dd, J = 5.1, 1.9 Hz, ÍH), 8.43 (dd, J = 8.5, 2.5 Hz, ÍH), 8.54 (d, J = 2.5 Hz, ÍH), 13.29 (s, ÍH) 2- (2-hydroxypyridin-3-yl) -5-nitrobenzoic acid (reference compound No. 1-3- (3)) Dissolves 2- (2-hydroxypyridin-3-yl) -5- Methyl nitrobenzoate (reference compound No. 1-3- (2), 300 mg, 1.09 mmoles) in 2 ml of methanol, then 5 ml of concentrated HCl are added thereto and then the reaction mixture is refluxed overnight. The solvent is removed under reduced pressure to provide 263 mg of the title reference compound as a yellow solid (yield, 93%). NMR-H1 (400 MHz, DMSO-d6) d 6.32 (t, J = 6.7 Hz, HH), 7.44 (dd, J = 6.7, 2.1 Hz, ÍH), 7.57 (dd, J = 6.7, 2.1 Hz, ÍH), 7.61 (d, J = 8.8 Hz, ÍH), 8.38 (dd, J = 8.3, 2.6 Hz, ÍH), 8.46 (d, J = 2.6 Hz, ÍH) , 11.77 (br s, ÍH), 13.09 (br s, ÍH) 8-Nitro-4-azabenzo [c] chromene-6 -one (reference compound No. 1-3- (4)) 2- (2-Hydroxypyridin-3-yl) -5-nitrobenzoic acid (compound of reference No. 1-3- (3), 50 mg, 0.20 mmoles) in 5 ml of N, N-dimethylformamide and then N, -diisopropylethylamine (141 μl, 0.81 mmol) and O- (7-hexafluorophosphate) are added thereto. azabenzotriazol-1-yl) -N, N, N ', N' -tetramethyluronium (154 mg, 0.41 mmol) and then the reaction mixture is stirred at room temperature overnight. 30 ml of ethyl acetate are added to the reaction mixture, the whole is washed with 30 ml of water and 30 ml of saturated brine, successively. The organic layer is dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. Chloroform is added to the resulting residue and then filtered to provide 35 mg of the title reference compound as a light yellow solid (yield, 71%).

NMR-H1 (400 MHz, DMSO-d6) d 7.61 (dd, J = 7.9, 4.7 Hz, ÍH), 8.61 (dd, J = 4.7, 1.8 Hz, ÍH), 8.72 (dd, J = 8.7, 2.4 Hz, ÍH), 8.77 (d, J = 8.7 Hz, ÍH), 8.88 (d, J = 2.4 Hz, ÍH), 9.00 (dd, J = 7.9, 1.8 Hz, ÍH) 8-amino-4-azabenzo [c] chromen-6-one (reference compound No. 1-3- (5)) Dissolve 8-nitro-4-azabenzo [c] chromen-6-one (reference compound) No. l-3- (4), 368 mg, 1.52 mmoles) in 10 ml of methanol, then 37 mg of 5% palladium on charcoal is added thereto and then the reaction mixture is stirred under a hydrogen atmosphere at room temperature. room temperature for 4 days. After the mixture is filtered, the solvent is removed under reduced pressure. Chloroform is added to the residue that is obtained and then filtered to provide 298 mg of the compound of reference of the title as a yellow solid (yield, 92%). NMR-H1 (500 MHz, DMSO-de) d 6.05 (br s, 2H), 7.17 (dd, J = 8.6, 2.4 Hz, ÍH), 7.39 (d, J = 2.4 Hz, ÍH), 7.42 (dd, J = 7.7, 4.6 Hz, ÍH), 8.15 (d, J = 8.6 Hz, ÍH), 8.31 (dd) , J = 4.6, 1.8 Hz, ÍH), 8.61 (dd, J = 7.7, 1.8 Hz, ÍH) 2,2,4-Trimethyl-1,2-dihydro-6-oxa-l, 7-diazacrisen-5-one (Reference Compound No. 1-3) In a pressurized tube, 8-amino-4 is dissolved azabenzo [c] chromen-6-one (Reference Compound No. 1-3 (5), 258 mg, 1.21 mmol) in 10 ml of acetone and then iodine (123 mg, 0.48 mmol) is added thereto subsequently. seal the tube under pressure and then the reaction mixture is stirred at 105 ° C for 1 day. After cooling the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to give 82.5 mg of the title reference compound as a yellow solid (yield, 23%).

NMR-H1 (400 MHz, DMSO-d6) d 1.24 (s, 6H), 1.98 (s, 3H), 5.49 (s, ÍH), 7.08 (s, ÍH), 7. 19 (d, J = 8.7 Hz, ÍH), 7.39 (dd, J = 8.0, 4.6 Hz, HH), 8.06 (d, J = 8.7 Hz, HH), 8.30 (dd, J = 4.6, 1.7 Hz, HH ), 8.59 (dd, J = 8.0, 1.7 Hz, ÍH) 8-Fluoro-2, 2,4, 11-tetramethyl-1,2-dihydro-6-oxa-1-azacrisen-5-one (Reference Compound No. 1-4) Methyl 2-hydroxy-3-methylbenzoate (Reference Compound No. 1-4- (1)) 2-Hydroxy-3-methylbenzoic acid (24.9 g) is dissolved, 0.164 moles) in 200 ml of methanol, then sulfuric acid (1.75 ml, 32.8 mmol) is added thereto and then the reaction mixture is refluxed for 7 days. Subsequently, the reaction mixture is poured into 300 ml of a saturated aqueous NaHC03 solution, the methanol is removed under reduced pressure. The aqueous layer is extracted with 500 ml of ethyl acetate, then the organic layer is washed with 200 ml of a saturated aqueous NaHCO 3 solution and 100 ml of saturated brine, successively, dried over anhydrous magnesium sulfate and then the solvent is separated. under reduced pressure to provide 23.0 g of the title reference compound as a brown oil clear (84% yield) O? H NMR-H1 (500 MHz, DMSO-d6) "° S d 2.20 (s, 3H), 3.91 (s, 3H), XJ 6.87 (t, J = 7.9 Hz, ÍH), 7.43- 7.45 (m, ÍH), 7.66 (dd, J = = 7.9, 1.7 Hz, ÍH), 10.87 (s, ÍH) 2 - . Methyl 2-hydroxy-3-methyl-5-nitrobenzoate (Reference Compound No. 1-4- (2)) Dissolves methyl 2-hydroxy-3-methylbenzoate (Reference Compound No. 1-4- (1), 22.9 g, 0.138 moles) in 190 ml of trifluoroacetic acid, then 90 ml of an aqueous solution of sodium nitrate (12.9 g, 152 g) are added thereto dropwise thereto. mmoles) for 1 hour at -10 ° C. The reaction mixture is then stirred at 0 ° C for 1.5 hours, then poured into 600 ml of ice water. The solid that appears is filtered and washed with 100 ml of methanol to provide 18.7 g of the title reference compound as a light red solid (64% yield) - 3 - . Methyl 3-methyl-5-nitro-2-trifluoromethylsulfonyloxybenzoate (Reference Compound No. 1-4- (3)) Methyl 2-hydroxy-3-methyl-5-nitrobenzoate is dissolved (Reference Compound No. 1-4- (2), 6.0 g, 28.4 mmoles) in 200 ml of tetrahydrofuran, then triethylamine (16.7 ml, 120 mmole) and trifluoromethanesulfonyl chloride (6.23 ml, 58.5 mmoles) are added thereto and subsequently the mixture of The reaction is stirred at room temperature overnight. 500 ml of water are added to the reaction mixture and then the whole is extracted with 500 ml of ethyl acetate. The organic layer is washed with a 0.2N aqueous NaOH solution (200 ml, twice) and 200 ml of saturated brine, successively, dried over anhydrous magnesium sulfate and subsequently the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to provide 9.32 g of the title reference compound as a light yellow oil (96% yield).

NMR-H1 (500 MHz, DMSO-ds) d 3. 32 (s, 3H), 3. 92 (s, 3H), 8 51 (d, J = 3. 1 Hz, ÍH), 8. 65 (d, J = 3. 1 Hz, ÍH) Methyl 2- (2-benzyloxy-4-fluorophenyl) -3-methyl-5-nitrobenzoate (Reference Compound No. 1-4- (4)) A mixture of 3-methyl-5-nitro-2-trifluoromethylsulfonyloxybenzoate methyl (Reference Compound No. 1-4- (3), 13.26 g, 38.6 mmol), 2-benzyloxy-4-fluoro-phenyl boronic acid (14.3 g, 58.1 mmol), potassium phosphate (21.3 g, 100 mmol) and tetrakis (triphenylphosphine) palladium (0) (3.23 g, 2.80 mmol) is suspended in 200 ml of anhydrous 1,4-dioxane and then the mixture is refluxed for 3 days. After cooling, 500 ml of ethyl acetate are added thereto and then the whole is washed with 500 ml of water and 50 ml of saturated brine, successively, it is dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. . The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to give 10.7 g of the title reference compound as a light brown solid (70% yield).

NMR-H1 (400 MHz, DMSO-d6) d 2.14 (s, 3H), 3.58 (s, 3H), 5. 06 (d, J = 12.5 Hz, ÍH), 5.12 (d, J = 12.5 Hz, ÍH), 6.87 (td, J = 8.4, 2.4 Hz, ÍH), 7.05-7.12 (m, 2H), 7.19-7.21 (m, 2H), 7.24-7.33 (m, 3H), 8.41 (dd, J = 9.5, 2.4 Hz, 2H) Methyl 5-amino-2- (4-fluoro-2-hydroxyphenyl) -3-methylbenzoate (Reference Compound No. 1-4- (5)) Dissolves 2- (2-benzyloxy-4-fluorophenyl) -3 methyl-methyl-5-nitrobenzoate (Reference Compound No. 1-4- (4), 10.7 g, 27.0 mmol) in a mixture of 50 ml of methanol and 50 ml of tetrahydrofuran, then 1.00 g are added thereto. of palladium 10% in charcoal and then the reaction mixture is stirred under a hydrogen atmosphere (3 kgf / cm2) at room temperature for 3 days. After the mixture is filtered, the solvent is removed under reduced pressure. Ethyl acetate is added to the resulting residue and then filtered to provide 4.79 g of the title reference compound as a light gray solid (64% yield) 8-amino-3-fluoro-10-methylbenzo [c] chromen-6-one (Reference Compound No. 1-4- (6)) Dissolve methyl 5-amino-2- (4-fluoro-2-hydroxyphenyl) -3-methylbenzoate (Reference Compound No. 1-4- (5) , 7.40 g, 26.9 mmol) in 250 ml of pyridine and then the reaction mixture is refluxed overnight. The reaction mixture is concentrated under reduced pressure, then ethyl acetate-hexane (1: 1) is added to the residue and subsequently filtered to provide 6.15 g of the title reference compound as a light yellow solid (yield 94). %).

NMR-H1 (400 MHz, DMSO-d6) d 2.72 (s, 3H), 5.85 (s, 2H), 6. 99 (d, J = 2.6 Hz, HH), 7.19 (ddd, J = 9.2, 8.3, 2.7 Hz, HH), 7.33 (d, J = 9.3, 2.7 Hz, HH), 7.37 (d, J = 2.6 Hz , ÍH), 8.24 (dd, J = 9.2, 6.3 Hz, ÍH) 8-fluoro-2, 2,4, 11-tetramethyl-1,2-dihydro-6-oxa-1-azacrisen-5-one (Reference Compound No. 1-4) In a pressure tube, it is dissolved -amino-3-fluoro-10-methylbenzo [c] chromen-6-one (Reference Compound No. 1-4- (6), 6.13 g, 25.2 mmol) in 175 ml of acetone and iodine is added thereto (2.56 g, 10.1 mmol) then the tube is sealed under pressure and subsequently the reaction mixture is stirred at 110 ° C for 2 days. After cooling, the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to provide 6.35 g of the title reference compound as a brown solid (78% yield).

F ^ OO NMR-H1 (500 MHz, DMSO-d6) / id 1.22 (s, 6H), 1.91 (s, 3H), Nk 2.68 (s, 3H), 5.44 (s, ÍH), 6.78 H (s, ÍH), 6.98 (s, ÍH), 7.16 (td, J = 8.9, 2.8 Hz, ÍH), 7.29 (dd, J = 9.2, 2.8 Hz, ÍH), 8.15 (dd, J = 8.9, 6.1 Hz, ÍH) ) Using the available compounds, the following reference compounds are obtained (Nos. 1- 5-1-20) by a method similar to those of the reference compound no. 1-1-1-4.

- Reference Example 2-methoxy-2,2,4-trimethyl-1,2-dihydro-6-oxa-1-azacrisen-5-one (Reference Compound No. 2-1) A mixture of 7-hydroxy- 2, 2, 4-trimethyl-l, 2-dihydro-6-oxa-1-azacrisen-5-one (Reference Compound No. 1-9, 430 mg, 1.40 mmol) methyl iodide 87.2 μl, 1.40 mmol) and potassium carbonate (387, 2.80 mmol) is suspended in 7 ml of anhydrous N, N-dimethylformamide and stirred at 50 ° C for 3 hours. After cooling, the reaction mixture is diluted with 150 ml of ethyl acetate. The whole is washed with 150 ml of water and 200 ml of saturated brine successively, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to provide 384 mg of the reference of the title as a yellow solid (yield 85%).

NMR-H1 (400 MHz, DMS0-d6) d 1.23 (s, 6H), 1.96 (s, 3H), 3.90 (s, 3H), 5.45 (s, ÍH), 6.96 (s, ÍH), 7.07 (d, J = 7.3 Hz, ÍH), 7.17 (d, J = 8.5 Hz, ÍH), 7.23 (t, J = 8.5 Hz, ÍH), 7.66 (d, J = 7.3 Hz, ÍH) , 7.97 (d, J = 8.5 Hz, ÍH) Using any of the compounds between the reference compounds Nos. 1-9, 1-18 and 1-19, the following reference compounds are obtained (Nos. 2-2-2-6) by a method similar to that of the compound of reference No. 2-1.

- Reference Example 3-Hydroxymethyl-6- (2-hydroxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Reference Compound No. 3-1) Under an argon atmosphere, lithium hydride is suspended and aluminum (1.48 g, 39.0 mmol) in 30 ml of anhydrous tetrahydrofuran. A solution of 2, 2, 4-trimethyl-1,2-hydro-6-oxa-1-azacrisen-5-one is added dropwise at 0 ° C (Reference Compound No. 1-1, 3.80 g, 13.0 mmoles) in 40 ml of anhydrous tetrahydrofuran and the reaction mixture is stirred at the same temperature for 1 hour. 15 ml of ethyl acetate and 5 ml of water are added dropwise, successively to the reaction mixture and then 350 ml of a 0.2 N aqueous HCl solution is added thereto. The whole is extracted with ethyl acetate (300 ml, 100 ml). The combined organic layer is washed with 300 ml of water and 100 ml of saturated brine, successively, dried over anhydrous magnesium sulfate. The solvent is removed under reduced pressure to provide 4.01 g of the title reference compound as a light brown solid (quantitative yield).

Using any of the compounds between the reference compounds Nos. 1-2-1-8, 1-10-1-17, 1-20 and 2-1-2-6, the following reference compounds are obtained (Nos. 3-2-3-23) by a method similar to that of reference compound No. 3-1.

Reference Example 4-Hydroxymethyl-6- (2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Reference Compound No. 4-1) 5-hydroxymethyl-6- (2-methoxyphenyl) -1,2,2,4-tetramethyl-1,2-dihydroquinoline (Reference Compound No. 4 -2) A mixture of 5-hydroxymethyl-6- (2-hydroxyphenyl) -2,2,4-trimethyl-1 , 2-dihydroquinoline (Reference Compound No. 3-1, 4.01 g, 13.6 mmol), methyl iodide (847 μl, 13.6 mmol) and potassium carbonate (3.76 g, 27.2 mmol) is suspended in 70 ml of anhydrous N, N-dimethylformamide and stirred at 50 ° C for 4 hours. After cooling the reaction mixture is diluted with 200 ml of ethyl acetate and 300 ml of diethyl ether. The whole is washed with water (500 ml, 300 ml) and 200 ml of saturated brine, successively, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-acetate ethyl) to provide the title reference compound No. 4-1 (3.01 g, 71% yield) and the title reference compound No. 4-2 (380 mg, yield, 9%) as a light yellow solid. , respectively.

Using any of the compounds between the reference compounds Nos. 3-1-3-10 and 3-12-3-23, the following reference compounds are obtained (No. 4- 3-4-32) by a similar method to that of reference compound No. 4-1 and No. 4-2. 1 H-NMR (400 MHz, DMSO-d 6) 6- (3-fluoro-2-methoxyphenyl) -d 1.15 (s, 3H), 1.21 (s, 3H), 5 - . 5 - . 5 - . 5-hydroxymethyl-2,2,4-2.25 (s, 3H), 3.52 (s, 3H), trimethyl-1, 2- 4.17-4.19 (m, ÍH), 4.46-4.50 dihydroquinoline (Compound (m, ÍH) , 4.48 (s, ÍH), 5.35 (s, ÍH), 5.93 (s, ÍH), 6.57 reference No.4 -19) (d, J = 8.2 Hz, ÍH), 6.71 (d, J = 8.2 Hz , ÍH), 7.03-7.05 (m, ÍH), 7.09 (td, J = 8.0, 5.0 Hz, HH), 7.20 (ddd, J = 11.4, 8.0, 1.8 Hz, HH) 1H-NMR (500 MHz, DMSO-d6) 6- (4,5-difluoro-2- d 1.14 (s, 3 H), 1.19 (s, 3 H), methoxyphenyl) -5- 2.23 (s, 3 H), 3.67 (s, 3 H), hydroxymethyl-2, 2 , 4- 4.05-4.08 (m, ÍH), 4.45-4.49 trimethyl-1, 2- (m, 2H), 5.34 (s, ÍH), 5.89 (s, ÍH), 6.53 (d, J = 8.2 Hz, dihydroquinoline (Compound HH), 6.65 (d, J = 8.2 Hz, HH), reference No.4-20) 7.14 (dd, J = 13.1, 7.3 Hz, HH), 7.22 (dd, J = 11.3, 9.5 Hz , ÍH) 1 H-NMR (400 MHz, DMSO-d 6) 6- (4-fluoro-2-methoxyphenyl) -d 1.16 (s, 3H), 1.17 (s, 3H), 5-hydroxymethyl-7-methoxy-2.20 (s, 3H), 3.51 (s, 3H), 2, 2, 4-trimethyl-1, 2- 3.65 (s, 3H), 3.96 (dd, J = dihydroquinoline (Compound 11.5, 4.5 Hz, HH), 4.25 (t, J = 4.5 Hz, HH), 4.32 ( dd, J = reference No.4 -23) 11.5, 4.5 Hz, ÍH), 5.19 (s, ÍH), 5.87 (s, ÍH), 6.23 (s, ÍH), 6.72 (td, J = 8.4, 2.4 Hz, HH), 6.86 (dd, J = 11.5, 2.4 Hz, HH), 7.06 (dd, J = 8.4, 7.3 Hz, HH) 1H-NMR (400 MHz, DMSO-d6) 6- (2-ethoxy-4-fluorophenyl) -d 1.11 (s, 3H), 1.19 (t, J = 5-hydroxymethyl-2, 2.4-7.0 Hz, 3H), 1.23 (s, 3H), trimethyl-1, 2- 2.22 (s, 3H), 3.97 (q, J = 7.0 dihydroquinoline (Compound Hz, 2H) , 4.09 (dd, J = 12.6, 3.8 Hz, ÍH), 4.40-4.43 (m, reference No.4 -24) ÍH), 4.54 (dd, J = 12.6, 6.1 Hz, ÍH), 5.32 (s, ÍH), 5.84 (s, ÍH), 6.53 (d, J = 8.3 Hz, ÍH), 6.65 (d, J = 8.3 Hz, ÍH), 6.77 (td, J = 8.4, 2.5 Hz, ÍH), 6.88 (dd, J = 11.6, 2.5 Hz, ÍH), 7.18 (dd, J = 8.4 , 7.3 Hz, ÍH) Reference Example 5-chloromethyl-6- (2-methoxyphenyl) -2,2, 4-trimethyl-1,2-dihydroquinoline (Reference Compound No. 5.1) 5-Hydroxymethyl-6- (2-methoxyphenyl) is dissolved - 2, 2, 4-trimethyl-1,2-dihydroquiniline (Compound of - Reference No. 4-1, 2.00 g, 6.46 mmoles) in 32 ml of anhydrous dichloromethane and then triethylamine (1.35 ml, 9.69 mmoles) and methanesulfonyl chloride (55 μl, 7.11 mmoles) are added thereto at 0 ° C. The reaction mixture is stirred at room temperature overnight. 500 ml of ethyl acetate, 200 ml of water and 200 ml of saturated brine are added to the reaction mixture and separated. The aqueous layer is extracted with 150 ml of ethyl acetate and the organic layer is combined. The organic layer is washed with 200 ml of saturated brine, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to provide 1.07 g of the title reference compound as a light yellow solid (50% yield).

Using any of the compounds between the reference compounds 4-3, 4-4, 4-6, 4-11, 4-17, 4-18, 4-20-4-27 and 4-32, the following are obtained reference compounds (No. 5-2-5-16) by a method similar to that of reference compound No. 5-1.

- - - NMR-H1 (500 MHz, DMSO-d6) 6- (4-chloro-2- d 1.15 (s, 3H), 1.20 (s, 3H), methoxyphenyl) -5- 2.26 (s, 3H), 3.72 (s) , 3H), 4.35 chloromethyl-2, 2,4- (d, J = 12.1 Hz, ÍH), 4.78 (d, J trimethyl-1, 2- = 12.1 Hz, ÍH), 5.46 (s, ÍH), 6.09 (br s, ÍH), 6.62 (d, J = dihydroquinoline 8.1 Hz, ÍH), 6.67 (d, J = 8.1 (Reference compound Hz, ÍH), 7.05 (dd, J = 8.2, 1.9 Hz, ÍH), 7.13 (d, J = 1.9 Hz, ÍH), 7.14 (d, J = 8.2 Hz, ÍH) Reference Example 6 5-hydroxymethyl-6- (2-trifluoromethylsulfonyloxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Reference Compound No. 6-1) 5-hydroxymethyl-6- (2- hydroxyphenyl) -2, 2, 4-trimethyl-1,2-dihydroquinoline (Reference Compound No. 3-1, 293 mg, 0.992 mmol) in 5 ml of anhydrous dichloromethane and then added thereto, at 0 ° C triethylamine (167 μL, 1.20 mmol) and trifluoromethanesulfonyl chloride (106 μL, 0.996 mmol). After the reaction mixture is stirred at 0 ° C for 1 hour, it is diluted with 20 ml of chloroform. The whole is washed with 20 ml of a saturated aqueous NaHCO 3 solution and then the solvent is removed under reduced pressure. The residue that obtained is purified by silica gel column chromatography (hexane-ethyl acetate) to give 177 mg of the title reference compound as an orange solid (42% yield).

NMR-H1 (400 MHz, DMSO-d6) d 1.15 (s, 3H), 1.20 (s, 3H), 2. 23 (s, 3H), 3.98-4.08 (m, ÍH), 4.55 (d, J = 12.0 Hz, ÍH), 4.57-4.62 (m, ÍH), 5.38 (s, ÍH), 6.04 (s, ÍH) , 6.61 (d, J = 8.3 Hz, ÍH), 6.73 (d, J = 8.3 Hz, ÍH), 7.40-7.63 (m, 4H) Using reference compound No. 3-2, the following reference compound No. 6-2) is obtained by a method similar to that of reference compound No. 6-1.

Reference Example 7 5-hydroxymethyl-6-phenyl-2,2,4-trimethyl-1,2-dihydroquinoline (Reference Compound No. 7-1) 5-Hydroxymethyl-6- (2-trifluoromethylsulfonyloxyphenyl) -2 is dissolved , 2, 4-trimethyl-l, 2-dihydroquinoline (Reference Compound Number 6-1, 136 mg, 0.318 mmol) in 1.5 ml of anhydrous N, N-dimethylformamide, then the solvent is bubbled with argon for 2 minutes and subsequently tetrakis (triphenylphosphine) palladium (0) (35.6 mg, 0.0308 mmol), triethylamine (221 μL, 1.59 mmol) and formic acid are added thereto. (60 μl, 1.6 mmol). After the reaction mixture is stirred at 60 ° C for 10 hours it is diluted with 50 ml of ethyl acetate. The whole is washed with 30 ml of a saturated NaHCO 3 solution and 30 ml of saturated brine, successively, it is dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to provide 93.0 mg of the title reference compound as a yellow oil (quantitative).

Using the reference compound 6-2, the following reference compound (number 7-2) is obtained by a method similar to that of reference compound number 7-1.

- Reference Example 8 Methyl 5-amino-2-bromobenzoate (Reference Compound Number 8). Dissolve methyl 2-bromo-5-nitrobenzoate (25.3 g, 97.3 mmol) in 50 mL of anhydrous methanol and add tin chloride (II) (93.3 g, 487 mmol) thereto and then the reaction mixture is subjected to at reflux for 2 hours. After cooling, 500 ml of ethyl acetate and 100 ml of water are added thereto and the mixture is neutralized with an aqueous solution of 4N NaOH and then filtered over Celite. The filtrate is concentrated under reduced pressure and 200 ml of ethyl acetate are added thereto and then washed with a saturated solution of NaHCO 3 (200 ml, twice), 200 ml of water and 200 ml of brine. saturated, successively. The organic layer is dried over anhydrous magnesium sulfate and the solvent is removed under reduced pressure to provide 21.0 g of the title reference compound as a yellow oil (yield 94) NMR-H1 (400 MHz, DMSO-d6) d 3.80 (s, 3H), 5.55 (s, 2H), 6.63 (dd, J = 8.8, 2.8 Hz, ÍH), 6.94 (d, J = 2.8 Hz, ÍH), 7.29 (d, J = 8.8 Hz, ÍH) Reference Example 9 Methyl 3-amino-4-chlorobenzoate (Reference Compound Number 9) 3-amino-4-chlorobenzoic acid (20.9 g, 0.122 mol) and cesium carbonate (79.5 g, 0.244 mol) are suspended in 500 ml of N, N-dimethylformamide and methyl iodide (7.60 ml, 0.122 mmol) are added thereto and subsequently the reaction mixture is stirred under an argon atmosphere at room temperature for 2 hours. 250 ml of ethyl acetate and 500 ml of diethyl ether are added to the reaction mixture and the whole is then washed with 1 l of water. The aqueous layer is extracted with ethyl acetate / diethylether (2/1) (300 ml, three times). The layer The combined organic is washed with water (500 ml, 4 times) and 300 ml of saturated brine, successively. The organic layer is dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure to provide 21.82 g of the title reference compound as a light brown solid (yield, 97%).

Reference Example 10 Methyl 5-amino-2-bromo-4-chlorobenzoate (Reference Compound Number 10) Dissolve methyl 3-amino-4-chlorobenzoate (reference compound number 9, 12.0 g, 64.7 mmole) in 250 ml of N, N-dimethylformamide and after cooling to 0 ° C N-bromosuccinimide (11.5 g, 64.6 mmol) is added thereto and then the reaction mixture is stirred under an argon atmosphere at room temperature for 30 minutes. 200 ml of ethyl acetate and 200 ml of diethyl ether are added to the reaction mixture and then the whole is washed with 500 ml of sodium hyposulfite solution. - aqueous 1%. The aqueous layer is extracted with 200 ml of ethyl acetate / diethylether (1/1). The combined organic layer is washed with water (400 ml, 4 times) and 300 ml of successively saturated brine, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The resulting residue is filtered with 15 ml of hexane to give 15.74 g of the title reference compound as a light brown solid (yield, 92%) Reference Example 11 (2-hydroxyphenyl) -ethyl acetate (Reference Compound No. 11-1) 2-Hydroxyphenylacetic acid (302.7 mg, 1.99 mmol) is dissolved in 10 ml of anhydrous methanol and 0.2 ml of sulfuric acid are added thereto. and subsequently the reaction mixture is stirred at 90 ° C for 6 hours. The reaction mixture is concentrated under reduced pressure. 50 ml of ethyl acetate, 5 ml of an aqueous solution of IN NaOH and 30 ml of a saturated aqueous solution of NaHCO 3 are added to the reaction mixture and separated. The layer Organic is washed with 30 ml of saturated brine, dried over anhydrous magnesium sulfate. The solvent is removed under reduced pressure to provide 242.4 mg of the title reference compound as a yellow solid (yield, 73%).

Using the available compounds, the following reference compound (number 11-2) is obtained by a method similar to that of reference compound number 11-1 Example 1 5- (2-Fluorobenzoyloxymethyl) -6- (4-fluoro-2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Compound Number 1-1) 1- (2-fluorobenzoyl) - 5- (2-fluorobenzoyloxymethyl) -6- (4-fluoro-2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Compound Number 1-2) Dissolves 6- (4-fluoro-2) -methoxyphenyl) -5-hydroxymethyl-2,2,4-trimethyl-1,2-dihydroquinoline (reference compound 4-3, 60.0 mg, 0.183 mmol) in 1 ml of anhydrous tetrahydrofuran, then triethylamine (81.0 mg) is added thereto. μl, 0.581 mmol) and 2-fluorobenzoyl chloride (51.0 μl, 0.427 mmol). The reaction mixture is stirred at room temperature overnight. It is diluted with 100 ml of ethyl acetate. The whole is washed with 100 ml of water and 50 ml of saturated brine successively, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to give the title compound 1-1 (43.0 mg, yield, 52%) as a colorless solid and the title compound 1 -2 (18.3 mg, Yield, 17%) as a light yellow oil.

Using any of the compounds between the compounds of references numbers 3-11, 4-1-4-10, 4-12-4-16, 4-18, 4-19, 4-22, 7-1 and 7-2 , the following compounds are obtained (numbers 1-3-1-58) by a method similar to that of compounds numbers 1-1 and 1-2 NMR-H1 (400 MHz, DMSO-d6) 5-benzoyloxymethyl-6- (2- d 1.15 (s, 3H), 1.23 (s, 3H), methoxyphenyl) -2.2.4- 2.09 (s, 3H) , 3.66 (s, 3H), 5.00 trimethyl-1, 2- (d, J = 12.8 Hz, ÍH), 5.23 (d, J dihydroquinoline = 12.8 Hz, ÍH), 5.46 (s, ÍH), 6.09 (s, ÍH), 6.67 (d, J = 8.3 (Compound No.1-5) Hz, ÍH), 6.77 (d, J = 8.3 Hz, ÍH), 6.91 (t, J = 7.4 Hz, ÍH), 7.02 (d , J = 7.8 Hz, HH), 7.13 (dd, J = 7.4, 1.8 Hz, HH), 7.27-7.30 (m, HH), 7.47 (t, J = 7.4 Hz, 2H), 7.61 (t, J = 7.4 Hz, ÍH), 7.81 (d, J = 7.4 Hz, 2H) NMR-H1 (400 MHz, DMSO-d6) l-benzoyl-5- d 1.38 (s, 3H), 1.55 (s, 3H), benzoyloxymethyl-6- (2- 2.29 (s, 3H), 3.65 (s, 3H), 5.10 methoxyphenyl) -2.2.4- (d, J = 13.1 Hz, ), 5.33 (d, J trimethyl-1, 2- = 13.1 Hz, HH), 5.93 (s, HH), 6.52 (d, J = 8.3 Hz, HH), 6.74 dihydroquinoline (d, J = 8.3 Hz, HH ), 6.94 (t, J = 7.4 Hz, ÍH), 7.05 (d, J = 7.8 Hz, ÍH), 7.11 (dd, J = 7.6, 1.7 Hz, ÍH), 7.31-7.36 (m, ÍH), 7.38 (t, J = 7.3 Hz, 2H), 7.44-7.54 (m, 5H), 7.63 (t, J = 7.4 Hz, ÍH), 7.81 (d, J = 7.1 Hz, 2H) NMR-H1 (400 MHz, DMSO-d6) 5-benzoyloxymethyl-6-d 1.16 (s, 3H), 1.22 (s, 3H), (2,3-dimethoxyphenyl) -2.08 (s, 3H), 3.41 (s) , 3H), 3.81 2, 2, 4-trimethyl-l, 2- (s, 3H), 5.03 (d, J = 12.8 Hz, dihydroquinoline HH), 5.28 (d, J = 12.8 Hz, HH), 5.46 ( s, ÍH), 6.12 (s, ÍH), 6.69 (Compound No.1-29) (d, J = 8.2 Hz, ÍH), 6.76-6.78 (m, ÍH), 6.83 (d, J = 8.2 Hz, ÍH), 7.00-7.01 (m, 2H), 7.47 (t, J = 7.4 Hz, 2H), 7.61 (t, J = 7.4 Hz, ÍH), 7.82 (d, J = 7.4 Hz, 2H) NMR-H1 (400 MHz, DMSO-de) 5-benzoyloxymethyl-6- (3- d 1.16 (s, 3H), 1.22 (s, 3H), ethoxy-2-methylphenyl) - 1.36 (t, J = 7.0 Hz , 3H), 2.08 2, 2, 4-trimethyl-1, 2- (S, 3H), 3.44 (s, 3H), 4.01-4.09 dihydroquinoline (m, 2H), 5.03 (d, J = 12.8 Hz, ), 5.28 (d, J = 12.8 Hz, ÍH), (Compound No.1-30) 5.46 (s, ÍH), 6.11 (s, ÍH), 6.68 (d, J = 8.1 Hz, ÍH), 6.75- 6.77 (m, ÍH), 6.83 (d, J = 8.1 Hz, ÍH), 6.97-6.99 (m, 2H), 7.47 (t, J = 7.5 Hz, 2H), 7.61 (t, J = 7.5 Hz, ÍH), 7.82 (d, J = 7.5 Hz, 2H) Example 2 1-acryloyl-5-benzoyloxymethyl-6- (4-fluoro-2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Compound Number 2-1) 5-benzoyloxymethyl-6- (4) is dissolved -fluoro-2-methoxyphenyl) -2, 2,4-trimethyl-1,2-dihydroquinoline (compound 1-14, 35.7 g, 0.0827 mmol) in 1 ml of anhydrous tetrahydrofuran, then triethylamine (115 μl) is added thereto. , 0.825 mmoles) and acryloyl chloride (40.4 μl, 0.497 mmoles). The reaction mixture is stirred at room temperature overnight. It is diluted with 100 ml of ethyl acetate. The whole is washed with 50 ml of water and 50 ml of saturated brine, successively, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to give 3.0 mg of the title compound as a light yellow oil (yield, 7%) Using any of the compounds between compounds numbers 1-7, 1-8, 1-25, 3-4 and 10-1 the following compounds are obtained (Number 2-2-2-6) by a method similar to that of the compound number 2-1.

Example 3 6- (2-methoxyphenyl) -5-phenoxymethyl-2,2,4-trimethyl-1,2-dihydroquinoline (Compound Number 3-1) Suspending a mixture of 5-chloromethyl-6- (2-methoxyphenyl) -2,2, 4-trimethyl-1,2-dihydroquinoline (reference compound 5-1, 52 mg, 0.16 mmol), phenol (42 μl, 0.48 mmol) and potassium carbonate (88 mg, 0.64 mmol) in 2 ml of anhydrous N, N-dimethylformamide and stirred at 80 ° C for 5 hours. After cooling, the reaction mixture is diluted with 60 ml of ethyl acetate. The whole is washed with 50 ml of water and 30 ml of saturated brine, successively, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The residue that obtained is purified by silica gel column chromatography (hexane-ethyl acetate) to give 24 mg of the title compound as a colorless oil (yield, 39%).

NMR-H1 (500 MHz, DMSO-d6) d 1.11 (s, 3H), 1.17 (s, 3H), 2.08 (s, 3H), 3.70 (s, 3H), 4.55 (d, J = 11.5 Hz, ), 5.02 (d, J = 11.5 Hz, ÍH), 5.39 (s, ÍH), 5.95 (s, ÍH), 6.62 (d, J = 8.2 Hz, ÍH), 6.67 (d, J = 7.9 Hz, 2H), 6.75 (d, J = 8.2 Hz, ÍH), 6.82 (t, J = 7.3 Hz, ÍH), 6.89 (td, J = 7.4, 1.0 Hz, ÍH), 7.01 (d, J = 7.6 Hz, ÍH), 7.13-7.17 (m , 3H), 7.24-7.27 (m, ÍH) Using any of the compounds between the reference compounds number 5-2, 5-3, 5-7-5-9 and 5-14-5-16, the following compounds are obtained (Number 3_2 ~ 3-102) by a method similar to compound number 3-1 NMR-H1 (400 MHz, DMSO-d6) 6- (4-fluoro-2- d 1.12 (s, 3H), 1.17 (s, 3H), methoxyphenyl) -5- 2.08 (s, 3H), 3.71 (s) , 3H), 4.51 phenoxymethyl-2, 2,4- (d, J = 11.1 Hz, ÍH), 5.00 (d, J trimethyl-1, 2- = 11.1 Hz, ÍH), 5.39 (s, ÍH), 5.99 (s, ÍH), 6.62 (d, J = 8.3 dihydroquinoline Hz, ÍH), 6.67-6.71 (m, 3H), 6.73 (Compound No.3-2) (d, J = 8.3 Hz, ÍH), 6.84 ( t, J = 7.3 Hz, ÍH), 6.91 (dd, J = 11.3, 2.3 Hz, ÍH), 7.13-7.19 (m, 3H) NMR-H1 (400 MHz, DMSO-d6) 6- (4-fluoro-2- d 1.13 (s, 3H), 1.17 (s, 3H), methoxyphenyl) -5- (4- 2.09 (s, 3H), 3.64 (s, 3H), 3.70 methoxyphenoxymethyl) - (s, 3H), 4.43 (d, J = 11.1 Hz, 2.2, 4-trimethyl-1, 2H), 4.93 (d, J = 11.1 Hz, ÍH), 5.39 (s, ÍH), 5.98 (s, ÍH), 6.60 dihydroquinoline (d, J = 8.2 Hz, ÍH), 6.61 (d, J = (Compound No.3-3) 9.1 Hz, 2H), 6.67-6.73 (m, ÍH), 6.71 (d, J = 8.2 Hz, ÍH), 6.73 (d, J = 9.1 Hz, 2H), 6.91 (dd, J = 11.5, 2.4 Hz, ÍH), 7.13 (dd) , J = 8.4, 7.1 Hz, ÍH) NMR-H1 (400 MHz, DMSO-d6) 6- (4-fluoro-2- d 1.11 (s, 3H), 1.15 (s, 3H), methoxyphenyl) -5- (3- 2.08 (s, 3H), 3.71 (s, 3H), 4.52 fluorophenoxymethyl) - (d, J = 11.5 Hz, ÍH), 5.02 (d, J 2, 2, 4-trimethyl-1, 2 - = 11.5 Hz, ÍH), 5.40 (s, ÍH), 6.01 (s, ÍH), 6.52-6.57 (m, ÍH), dihydroquinoline 6.62 (d, J = 8.2 Hz, ÍH), 6.64- (Compound No.3-6) 6.71 (m, 3H), 6.73 (d, J = 8.2 Hz, ÍH), 6.91 (dd, J = 11.5, 2.4 Hz, ÍH), 7.14 (dd, J = 8.4, 7.2 Hz, ÍH), 7.16-7.22 (m, ÍH) NMR-H1 (400 MHz, DMSO-d6) 6- (4-fluoro-2-d 1.11 (s, 3H), 1.15 (s, 3H), methoxyphenyl) -5- (2- 2.11 (s, 3H), 3.70 (s, 3H), 4.57 fluorophenoxymethyl) - (d, J = 11.5 Hz, ÍH), 5.10 (d, J 2, 2, 4-trimethyl-l, 2- = 11.5 Hz, ÍH), 5.40 (s, ÍH), 6.02 (s, ÍH), 6.62 (d, J = 8.1 dihydroquinoline Hz, ÍH), 6.67-6.85 (m, 3H), 6.73 (Compound No.3-7) (d, J = 8.1 Hz, ÍH ), 6.90-6.97 (m, 2H), 7.07-7.15 (m, 2H) NMR-H1 (500 MHz, DMSO-d6) 6- (4-fluoro-2- d 1.10 (s, 3H), 1.18 (s, 3H), methoxyphenyl) -5- (2- 2.01 (s, 3H), 3.73 (s, 3H), 4.39 hydroxymethylphenoxymethyl) (dd, J = 15.1, 5.8 Hz, HH), 4.43-2.2, 4-trimethyl-1, 2- (dd, J = 15.1, 5.8 Hz, HH), 4.55 (d, J = 11.8 Hz, ÍH), 4.84 (t, J dihydroquinoline = 5.8 Hz, ÍH), 5.01 (d, J = 11.8 (Compound No.3-26) Hz, ÍH), 5.39 (s, ÍH) ), 6.01 (s, ÍH), 6.55 (d, J = 7.5 Hz, ÍH), 6.62 (d, J = 8.2 Hz, ÍH), 6.71- 6.75 (m, ÍH), 6.74 (d, J = 8.2 Hz , ÍH), 6.83 (t, J = 7.5 Hz, ÍH), 6.93 (dd, J = 11.6, 1.9 Hz, ÍH), 7.03 (td, J = 8.1, 1.9 Hz, ÍH), 7.18 (dd, J = 8.1, 7.0 Hz, ÍH), 7.30 (d, J = 7.5 Hz, ÍH) NMR-H1 (500 MHz, DMSO -d6) 6- (4-fluoro-2- d 1.12 (s, 3H), 1.16 (s, 3H), methoxyphenyl) -5- (4- 2.07 (s, 3H), 2.37 (s, 3H), 3.71 methylthiophenoxymethyl) (s, 3H), 4.49 (d, J = 11.5 Hz, 2, 2, 4-trimethyl-1, 2H), 4.97 (d, J = 11.5 Hz, 1H), 5.39 (s, 1H) , 5.98 (s, ÍH), 6.61 dihydroquinoline (d, J = 8.2 Hz, ÍH), 6.67 (d, J = (Compound No.3-27) 8.8 Hz, 2H), 6.66-6.73 (m, ÍH), 6.72 (d, J = 8.2 Hz, ÍH), 6.91 (dd, J = 11.6, 2.4 Hz, ÍH), 7.11 (d, J = 8.8 Hz, 2H), 7.14 (dd, J = 8.4, 7.2 Hz, ÍH) ) NMR-H1 (500 MHz, DMSO-d6) 5- (2-cyanophenoxymethyl) d 1.05 (s), 3H), 1.12 (s, 3H), 6- (4-fluoro-2- 2.10 (s, 3H), 3.73 (s, 3H), 4.66 methoxyphenyl) -2,2,4- (d, J = 11.9 Hz, ÍH), 5.20 (d, J trimethyl-1, 2- = 11.9 Hz, ÍH), 5.41 (s, ÍH), 6.04 (s, ÍH), 6.64 (d, J = 8.3 dihydroquinoline Hz, ÍH), 6.72 (td, J = 8.4, 2.4 (Compound No.3-32) Hz, ÍH), 6.76 (d, J = 8.3 Hz, ÍH), 6.80 (d, J = 8.6 Hz, ÍH), 6.93 (dd, J = 11.3, 2.4 Hz, ÍH), 6.98 (t, J = 7.6 Hz, ÍH), 7.20 (dd, J = 8.4, 7.2 Hz, ÍH), 7.45- 7.49 (m, ÍH), 7.63 (dd, J = 7.6, 1. 5 Hz, 1H) NMR-H1 (500 MHz, DMSO-dg) 5- (2-ethylphenoxymethyl) -6- d 1.02 (t, J = 7.4 Hz, 3H), 1.10 (4-fluoro-2- (s, 3H), 1.18 (s, 3H), 2.01 (s, methoxyphenyl) -2,2,4- 3H), 2.45-2.49 (m, 2H), 3.73 (s, trimethyl) -1, 2- 3H), 4.57 (d, J = 11.6 Hz, ÍH), 5.01 (d, J = 11.6 Hz, ÍH), 5.37 dihydroquinoline (s, ÍH), 6.02 (s, ÍH), 6.58 (d , J (Compound No.3-33) = 7.6 Hz, ÍH), 6.64 (d, J = 8.2 Hz, ÍH), 6.72-6.78 (m, 2H), 6.75 (d, J = 8.2 Hz, ÍH), 6.93 ( dd, J = 11.3, 2.4 Hz, ÍH), 7.00 (td, J = 7.6, 1.5 Hz, ÍH), 7.05 (dd, J = 7.6, 1.5 Hz, ÍH), 7.16 (dd, J = 8. 3, 7.3 Hz, ÍH) NMR-H1 (400 MHz, DMSO-dg) 5- (2-ethoxyphenoxymethyl) d 1.14 (s, 3H), 1.17 (s, 3H), 6- (4-fluoro-2-methoxy1.23 (t, J = 6.9 Hz, 3H), 2.11 phenyl) -2,2, 4 -trimethyl- (s, 3H), 3.71 (s, 3H), 3.90 (q, J 1, 2 -dihydroquinoline = 6.9 Hz, 2H), 4.47 ( d, J = 11.7 Hz, ÍH), 5.05 (d, J = 11.7 Hz, (Compound No.3-34) ÍH), 5.38 (s, ÍH), 5.98 (s, ÍH), 6.59 (dd, J = 7.8, 1.6 Hz, ÍH), 6.61 (d, J = 8.2 Hz, ÍH), 6.67 (td, J = 8.3, 2.5 Hz, ÍH), 6.71 (td, J = 7.8, 1.6 Hz, ÍH), 6.71 (d, J = 8.2 Hz, ÍH), 6.78 (td, J = 7.8, 1.6 Hz, ÍH), 6.85 (dd, J = 7.8, 1.6 Hz, ÍH), 6.91 (dd, J = 11.5, 2.5 Hz, ÍH), 7.13 (dd, J = 8.3, 7.3 Hz, ÍH) NMR-H1 (400 MHz, DMSO-dg) 5- (4-carbamoylphenoxid 1.11 (s, 3H), 1.15 (s, 3H), methyl) - 6- (4-fluoro-2- 2.07 (s, 3H), 3.71 (s, 3H), 4.57 methoxyphenyl) -2,2,4- (d, J = 11.5 Hz, ÍH), 5.05 (d, J trimethyl -1, 2-dihydro- = 11.5 Hz, ÍH), 5.40 (s, ÍH), 6.01 (s, ÍH), 6.62 (d, J = 8.2 quinoline (Compound Hz, ÍH), 6.70 (td, J = 8.5 , 2.6 No.3-35) Hz, ÍH), 6.73 (d, J = 8.8 Hz, 2H), 6.74 (d, J = 8.2 Hz, ÍH), 6.91 (dd, J = 11.5, 2.6 Hz, ÍH) , 7.12 (br s, ÍH), 7.16 (dd, J = 8.5, 7.2 Hz, ÍH), 7.71 (d, J = 8.8 Hz, 2H), 7.75 (br s, ÍH) NMR-H1 (500 MHz, DMSO-d6) 6- (4-fluoro-2-d 1.09 (s, 3H), 1.15 (s, 3H), methoxyphenyl) -5- (pyridine-2.10 (s, 3H), 3.71 (s, 3H), 4.59 3-yloxymethyl) -2,2,4- (d, J = 11.6 Hz, ÍH), 5.09 (d, J trimethyl-1, 2- = 11.6 Hz, ÍH), 5.41 ( s, ÍH), 6.01 (s, ÍH), 6.62 (d, J = 8.2 dihydroquinoline Hz, ÍH), 6.70 (td, J = 8.5, 2.6 (Compound No.3-52) Hz, ÍH), 6.74 (d , J = 8.2 Hz, ÍH), 6.91 (dd, J = 11.5, 2.6 Hz, ÍH), 7.07-7.09 (m, ÍH), 7.15 (dd, J = 8.5, 7.0 Hz, ÍH), 7.19 (dd, J = 8.6, 4.6 Hz, HH), 8.04 (d, J = 2.7 Hz, HH), 8.06 (dd, J = 4.6, 1. 2 Hz, 1H) NMR-H1 (400 MHz, DMSO-de) 6- (4-fluoro-2-d 1.02 (s, 3H), 1.17 (s, 3H), methoxyphenyl) -5- (3- 2.10 ( s, 3H), 3.72 (s, 3H), 3.81 methoxycarbonylphenoxymethi (s, 3H), 4.61 (d, J = 12.0 Hz, 1) -2.2, 4-trimethyl-1, 2H), 5.10 (d, J = 12.0 Hz, 1H), 5.40 (s, 1H), 6.00 (s, 1H), 6.60 dihydroquinoline (1H, J) = 8.1 Hz, ÍH), 6.73 (td, J (Compound No.3-53) = 8.4, 2.6 Hz, ÍH), 6.73 (d, J = 8.1 Hz, ÍH), 6.92 (dd, J = 11.5, 2.6 Hz, ÍH), 6.96 (ddd, J = 8.0 , 2.5, 1.2 Hz, ÍH), 7.15 (dd, J = 2.5, 1.2 Hz, ÍH), 7.18 (dd, J = 8.4, 7.2 Hz, ÍH), 7.30 (t, J = 8. 0 Hz, ÍH), 7.44 (dt, J = 8.0, 1.2 Hz, ÍH) NMR-H1 (400 MHz, DMS0-d6) 6- (4-fluoro-2- d 1.08 (s, 3H), 1.16 (s, 3H), methoxyphenyl) -5- (3- 2.13 (s, 3H), 3.71 (s, 3H), 4.59 phenylphenoxymethyl) -2,2,4- (d, J = 11.6 Hz, ÍH), 5.12 (d, J trimethyl-1, 2- = 11.6 Hz, ÍH), 5.40 (s, ÍH), 6.00 (s, ÍH), 6.68-6.75 (m, 2H), dihydroquinoline 6.62 (d, J = 8.3 Hz, ÍH), 6.74 (Compound No.3-64) (d, J = 8.3 Hz, ÍH ), 6.89-6.93 (m, 2H), 7.12-7.17 (m, 2H), 7.25 (t, J = 7.9 Hz, ÍH), 7.35-7.37 (m, ÍH), 7.43 (t, J = 7.9 Hz, 2H), 7.55 (d, J = 7.9 Hz, 2H) NMR-H1 (500 MHz, DMSO-de) 5- (3.5-d 1.12 (s, 3H), 1.14 (s, 3H), difluorophenoxymethyl) -6- 2.07 (s, 3H), 3.71 (s, 3H) ), 4.54 (4-fluoro-2- (d, J = 11.6 Hz, ÍH), 5.04 (d, J methoxyphenyl) -2,2,4- = 11.6 Hz, ÍH), 5.41 (s, ÍH), 6.03 (s, ÍH), 6.45 (dd, J = 9.4, trimethyl-1, 2- 2.2 Hz, 2H), 6.62 (d, J = 8.2 Hz, dihydroquinoline IH), 6.68 (tt, J = 9.4, 2.2 Hz, (Compound No.3-65) ÍH), 6.71 (td, J = 8.3, 2.6 Hz, ÍH), 6.74 (d, J = 8.2 Hz, ÍH), 6.92 (dd, J = 11.5, 2.6 Hz, ÍH) , 7.13 (dd, J = 8.3, 7.0 Hz, ÍH)t.

NMR-H1 (400 MHz, DMS0-d6) 6- (4-fluoro-2- d 0.91 (s, 3H), 1.18 (s, 3H), methoxyphenyl) -5- (2-methyl-2.12 (s, 3H ), 2.18 (s, 3H), 3.75 5-nitrophenoxymethyl) - (s, 3H), 4.75 (d, J = 12.7 Hz, 2, 2, 4-trimethyl-1, 2H), 5.28 (d, J) = 12.7 Hz, ÍH), 5.40 (S, ÍH), 6.04 (s, ÍH), 6.61 dihydroquinoline (d, J = 8.2 Hz, ÍH), 6.76 (d, J = (Compound No.3-72) 8.2 Hz , ÍH), 6.80 (td, J = 8.5, 2.8 Hz, ÍH), 6.96 (dd, J = 11.5, 2.8 Hz, ÍH), 7.14 (d, J = 2.2 Hz, ÍH), 7.25 (dd, J = 8.5, 7.1 Hz, ÍH), 7.33 (d, J = 8.3 Hz, ÍH), 7.63 (dd, J = 8.3, 2.2 Hz, ÍH) NMR-H1 (400 MHz, DMSO-dg) 6- (4-fluoro-2- d 0.81 (t, J = 7.4 Hz, 3H), 1.11 methoxyphenyl) -5- (2- (s, 3H), 1.19 ( s, 3H), 1.45 propylphenoxymethyl) - (sextete, J = 7.4 Hz, 2H), 2.02 2.2, 4-trimethyl-l, 2- (s, 3H), 2.38-2.46 (m, 2H), 3.72 ( s, 3H), 4.57 (d, J = 11.9 Hz, dihydroquinoline HH), 5.00 (d, J = 11.9 Hz, HH), (Compound No.3-73) 5.37 (s, HH), 6.02 (s, ÍH) ), 6.56 (d, J = 8.1 Hz, ÍH), 6.63 (d, J = 8.1 Hz, ÍH), 6.75 (d, J = 8.1 Hz, ÍH), 6.72-6.77 (m, 2H), 6.94 (dd) , J = 11.5, 2.2 Hz, HH), 7.00 (td, J = 8.1, 2.2 Hz, HH), 7.03 (dd, J = 7.3, 1.7 Hz, ÍH), 7.16 (dd, J = 8.1, 7.1 Hz, ÍH) Example 4 5-Benzoyloxymethyl-6- (2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Compound Number 4-1) Sodium hydride 60% (30 mg, 0.75 mmol) is suspended in 1 ml of anhydrous tetrahydrofuran and benzyl alcohol (78 μl, 0.75 mmol) is added thereto under an argon atmosphere at 0 ° C. After the reaction mixture is stirred at room temperature for 30 minutes, a solution of 5-chloromethyl-6- (2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline ( reference 5-1, 50 mg, 0.15 mmol) in 1.5 ml of solution of anhydrous tetrahydrofuran. The reaction mixture is stirred at 50 ° C for 7 hours. After cooling, 50 ml of ethyl acetate are added thereto. The whole is washed with 50 ml of water and 30 ml of saturated brine, successively, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to give 4.0 mg of the title compound as a colorless solid (yield, 7%).

Using compound number 5-2, we obtain the following compounds (number 4-2-4-6) by a method similar to that of compound number 4-1.

NMR-H1 (400 MHz, DMSO-dg) 6- (4-fluoro-2- d 1.16 (s, 3H), 1.18 (s, 3H), methoxyphenyl) -5- (thiophen-2- 2.16 (s, 3H ), 3.68 (s, 3H), 4.05 ylmethoxymethyl) -2,2,4- (d, J = 11.7 Hz, ÍH), 4.19 (d, J trimethyl-1, 2- = 12.3 Hz, ÍH), 4.24 ( d, J = 12.3 Hz, HH), 4.52 (d, J = 11.7 dihydroquinoline Hz, HH), 5.37 (s, HH), 5.9-3l (S, (Compound No.4 -3) HH, 6.58 (d , J = 8.1 Hz, ÍH), 6.68 (d, J = 8.1 Hz, ÍH), 6.75 (td, J = 8.4, 2.4 Hz, ÍH), 6.82 (dd, J = 3.5, 1.2 Hz, ÍH), 6.90 (dd, J = 4.9, 3.5 Hz, ÍH), 6.90 (dd, J = 11.7, 2.4 Hz, HH), 7.12 (dd, J = 8.4, 7.1 Hz, HH), 7.41 (dd, J = 4.9, 1.2 Hz, HH) NMR-H1 (400 MHz, DMSO-d6) ) 6- (4-fluoro-2- d 1.15 (s, 3H), 1.18 (s, 3H), methoxyphenyl) -5- (4- 2.17 (s, 3H), 2.25 (s, 3H), 3.67 methylbenzyloxymethyl) - (s, 3H), 3.99 (d, J = 11.4 Hz, 2, 2, 4-trimethyl-1, 2-HH), 4.03 (d, J = 11.7 Hz, HH), 4.04 (d, J = 11.4 Hz, HH), 4.49 dihydroquinoline (d, J = 11.7 Hz, HH ), 5.38 (s, (Compound No.4-4) ÍH), 5.93 (S, ÍH), 6.58 (d, J = 8.1 Hz, ÍH), 6.67 (d, J = 8.1 Hz, ÍH), 6.75 ( td, J = 8.4, 2.4 Hz, ÍH), 6.89 (dd, J = 11.5 2.4 Hz, ÍH), 6.98 (d, J = 7.9 Hz, 2H), 7.04 (d, J = 7.9 Hz, 2H), 7. 10 (dd, J = 8.4, 7.2 Hz, ÍH) Example 5 5-Benzoyloxymethyl-6- (3-hydroxy-2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Compound Number 5-1) Dissolve 5-benzoyloxymethyl-6- (2-methoxy-3-methoxymethoxyphenyl) -22, 4-trimethyl-1,2-dihydroquinoline (compound 1-28, 228 mg, 0.481 mmol) in 4 ml of 1,4-dioxane and 1 ml of 4N HCl / 1,4-dioxane is added thereto. and then the reaction mixture is stirred at room temperature for 45 minutes. The solvent is removed under reduced pressure and the resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to provide 14.0 mg of the title compound as a colorless solid (yield, 7%).

Using any of the compounds between reference compound number 2-6, compounds 1-38, 13-4 and 13-49-13-50, the following compounds are obtained (number 5-2-5-5) by a method similar to that of the compounds number 5-1.

Example 6 6- (2-methoxyphenyl) -5- [(pyrrolidin-1-yl) methyl] -2,2,4-trimethyl-1,2-dihydroquinoline (Compound Number 6-1) A mixture of 5-chloromethyl-6- (2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline (reference compound number 5-1, 41.2 mg, 0.126 mmol), pyrrolidine (52.6 μl, 0.630) mmoles) and potassium carbonate (34.8 mg, 0.252 mmol) is suspended in 1 ml of anhydrous N, N-dimethylformamide and the reaction mixture is stirred at 50 ° C for 1 hour. After cooling, it is diluted with 50 ml of ethyl acetate. The whole is washed with 50 ml of water and 50 ml of saturated brine, successively, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to provide 36.1 mg of the title compound as a colorless solid (yield, 79%).

Using any of the compounds between the reference compound 5-1-5-10 and number 5-14-5-16, the following compounds are obtained (numbers 6-2-6-86) by a method similar to that of the compound number 6-1.

NMR-H1 (400 MHz, DMSO-dg) 6- (2-methoxyphenyl) -5- [(N- d 1.15 (s, 3H), 1.20 (s, 3H), methyl-N-phenylamino) methyl] - 1.92 (s, 3H), 2.38 (s, 3H), 3.70 2,2, 4-trimethyl-1, 2- (s, 3H), 4.04 (d, J = 13.4 Hz, dihydroquinoline (Compound ΔH), 4.31 (d , J = 13.4 Hz, ÍH), 5.34 (s, ÍH), 5.95 (s, ÍH), No .6 - 6) 6.57-6.62 (m, 3H), 6.63 (d, J = 8.3 Hz, ÍH), 6.72 (d, J = 8.3 Hz, ÍH), 6.93 (t, J = 7.3 Hz, ÍH), 6.99 (d, J = 8.1 Hz, ÍH), 7.04 (dd, J = 7.4, 1.8 Hz, ÍH), 7. 09 (t, J = 7.9 Hz, 2H), 7.23- 7.27 (m, HH) NMR-H1 (400 MHz, DMSO-d6) 5- (4-chlorophenylaminomethyl) -d 1.16 (s, 3H), 1.19 (s) , 3H), 6- (2-methoxyphenyl) -2,2,4- 2.08 (S, 3H), 3.68 (s, 3H), trimethyl-1, 2- 3.68-3.73 (m, ÍH), 3.97 (dd , J = dihydroquinoline (Compound 12.2, 4.5 Hz, ÍH), 5.35 (s, ÍH), 5.44 (t, J = 4.5 Hz, ÍH), 5.91 No .6 - 7) (s, ÍH), 6.43 (d, J = 8.8 Hz, 2H), 6.58 (d, J = 8.3 Hz, HH), 6.69 (d, J = 8.3 Hz, HH), 6.87 (t, J = 7.4 Hz, HH), 6.95-6.98 (m, ÍH), 6.97 (d, J = 8.8 Hz, 2H), 7.17 (dd, J = 7.3, 1.7 Hz, ÍH), 7.20-7.24 (m, ÍH) NMR-H1 (400 MHz, DMSO-d6) 6- (2-methoxy-5-methylphenyl) -d 1.17 (s, 3H), 1.20 (s, 3H), 5-phenylaminomethyl-2, 2.4-2.21 ( s, 3H), 2.15 (s, 3H), 3.65 trimethyl-1, 2- (s, 3H), 3.78 (d, J = 11.8 Hz, dihydroquinoline (Compound ÍH), 3.96 (d, J = 11.8 Hz, ÍH ), 5.02 (s, ÍH), 5.36 (s, ÍH), 5.90 No.6-12) (br s, ÍH), 6.44-6.48 (m, 3H), 6.58 (d, J = 8.0 Hz, ÍH) , 6.69 (d, J = 8.0 Hz, ÍH), 6.85 (d, J = 8.3 Hz, ÍH), 6.95-7.01 (m, 4H) NMR-H1 (400 MHz, DMSO-d6) 6- (4-fluoro-2-methoxyphenyl) -d 1.17 (s, 3H), 1.20 (s, 3H), 5-phenylaminomethyl-2, 2.4- 2.10 ( s, 3H), 3.67-3.72 (m, ÍH), trimethyl-1, 2- 3.70 (s, 3H), 3.98 (dd, J = dihydroquinoline (Compound 12.1, 4.5 Hz, ÍH), 5.12 (t, J = 4.5 Hz, ÍH), 5.36 (s, ÍH), 5.92 No.6-13) (s, ÍH), 6.43 (d, J = 7.4 Hz, 2H), 6.46 (t, J = 7.4 Hz, ÍH), 6.57 (d, J = 8.0 Hz, ÍH), 6.65- 6.69 (m, ÍH), 6.67 (d, J = 8.0 Hz, ÍH), 6.86 (dd, J = 11.5, 2.7 Hz, ÍH), 6.97 (t, J = 7.4 Hz, 2H), 7.19 (dd, J = 8.3, 7.1 Hz, ÍH) NMR-H1 (400 MHz, DMSO-dg) 6- (4-fluoro-2-methoxyphenyl) -d 1.16 (s, 3H), 1.20 (s, 3H), 5- (2- 2.03 (S, 3H), 2.20 (s, 3H), 3.67 methylthiophenylaminomethyl) - (s, 3H), 3.70 (d, J = 4.1 Hz, 2, 2, 4 -trimethyl-1, 2- HH), 4.00 (d, J = 4.1 Hz, HH), 4.74 (t, J = 4.1 Hz, HH), 5.40 dihydroquinoline (Compound (s, HH), 6.07 (s, ÍH), 6.39 (d, No.6-22) J = 7.6 Hz, ÍH), 6.55 (td, J = 7.5, 1.1 Hz, ÍH), 6.63 (d, J = 8.3 Hz, ÍH), 6.72 (d, J = 8.3 Hz, ÍH) ), 6.74 (td, J = 9.5, 2.4 Hz, ÍH), 6.90 (dd, J = 11.5, 2.4 Hz, ÍH), 7.04-7.08 (m, ÍH), 7.14 (dd, J = 8.2, 7.2 Hz, HH), 7.26 (dd, J = 7.6, 1.5 Hz, HH) NMR-H1 (500 MHz, DMSO-dg) 5- (2- d 1.17 (s, 3H), 1.22 (s, 3H), acetylaminophenylaminomethyl) 1.95 (s, 3H), 2.01 (s, 3H), 3.70 -6- (4-fluoro-2- (s, 3H), 3.76 (dd, J = 12.7, 4.1 methoxyphenyl) -2.2.4-Hz, ÍH), 4.06 (dd, J = 12.7, 4.1 Hz, ÍH), 4.46 (t, J = 4.1 Hz, trimethyl-1, 2- ÍH), 5.36 (s, ÍH), 5.99 (s, ÍH), dihydroquinoline (Compound 6.39 (d, J = 7.3 Hz, ÍH), 6.53 No.6-23) (t, J = 7.3 Hz, ÍH), 6.60 (d, J = 8.2 Hz, ÍH), 6.70 (d, J = 8.2 Hz, ÍH), 6.66-6.73 (m, ÍH), 6.89 (dd, J = 11.3, 2.4 Hz, ÍH), 6.93 (t, J = 7.3 Hz, ÍH), 7.08 (d, J = 7.3 Hz, ÍH), 7.15 (dd, J = 8. 2, 7.0 Hz, ÍH), 9.16 (s, ÍH) NMR-H1 (400 MHz, DMSO-dg) 6- (4-fluoro-2-methoxyphenyl) -d 1.14 (s, 3H), 1.20 (s, 3H), 5- (2-1.71 (s, 3H), 2.06 (s, 3H), 3.65 methoxyphenylaminomethyl) - (dd, J = 11.7, 2.9 Hz, ÍH), 3.67 2,2,4,7-tetramethyl-1, 2- (s, 3H), 3.73 (s, 3H), 3.96 (dd, J = 11.7, 6.7 Hz, ÍH), 4.14 (dd, dihydroquinoline (Compound J = 6.7, 2.9 Hz, ÍH), 5.33 (s, No.6-28) ÍH), 5.86 (s, ÍH), 6.33 (d, J = 7.8 Hz, ÍH), 6.47-6.51 (m, ÍH), 6.49 (s, ÍH), 6.64-6.73 (m, 3H), 6.86 (dd, J = 11.5, 2.4 Hz, ÍH), 6.99 (dd, J = 8.3, 7.1 Hz, ÍH) NMR-H1 (400 MHz, DMSO-dg) 6- (4-fluoro-2-methoxyphenyl) -d 1.15 (S, 3H), 1.20 (s, 3H), 7-methoxy-5- (2- 2.04 (s, 3H), 3.53 (s, 3H), methoxyphenylaminomethyl) - 3.60-3.65 (m, ÍH), 3.64 (s, 3H), 2, 2, 4-trimethyl-1, 2- 3.72 (s, 3H), 3.92-3.97 (m, HH), 4.13-4.15 (m, HH), 5.23 (s, HH), dihydroquinoline (Compound 6.03 (s) , ÍH), 6.30 (s, ÍH), 6.32 No.6-29) (d, J = 7.8 Hz, ÍH), 6.49 (td, J = 7.8, 1.4 Hz, ÍH), 6.64-6.69 (m, 2H), 6.73 (dd, J = 7.8, 1.2 Hz , ÍH), 6.81 (dd, J = 11.5, 2.4 Hz, ÍH), 6.98 (dd, J = 8.3, 7.1 Hz, ÍH) NMR-H1 (500 MHz, DMSO-d6) 6- (4-fluoro-2-methoxyphenyl) -d 1.17 (s, 3H), 1.20 (s, 3H), 5- (3- 2.09 (s, 3H), 3.67-3.70 (m, ÍH), hydroxymethylphenylaminomethyl 3.70 (s, 3H), 3.97 (dd, J = ) -2,2, 4-trimethyl-1, 2- 12.2, 4.6 Hz, HH), 4.30 (d, J = 5.8 Hz, 2H), 4.93 (t, J = 5.8 dihydroquinoline (Compound Hz, HH), 5.08 (br s, ÍH), 5.35 No.6-34) (s, ÍH), 5.91 (s, ÍH), 6.31 (d, J = 7.7 Hz, ÍH), 6.41 (s, ÍH), 6.44 (d, J = 7.7 Hz, ÍH), 6.57 (d, J = 8.2 Hz, ÍH), 6.66 (d, J = 8.2 Hz, ÍH), 6.68 (td, J = 8.3, 2.6 Hz, ÍH), 6.87 (dd, J = 11. 5, 2.6 Hz, HH), 6.92 (t, J = 7.7 Hz, HH), 7.20 (dd, J = 8.3, 7.3 Hz, HH) NMR-H1 (400 MHz, DMSO-dg) 6- (4-fluoro) - 2-methoxyphenyl) - d 1.17 (s, 3H), 1.19 (s, 3H), 5- (4-methylphenylaminomethyl) -2.10 (s, 6H), 3.65-3.70 (m, 1H), 2.2, 4 -trimethyl-l, 2- 3.70 (s, 3H), 3.92 (dd, J = dihydroquinoline (Compound 12.0, 4.5 Hz, ÍH), 4.87 (t, J = 4.5 Hz, ÍH), 5.35 (s, ÍH), 5.92 No.6-35) (s, ÍH), 6.35 (d, J = 8.2 Hz, 2H), 6.56 (d, J = 8.3 Hz, ÍH), 6.66 (d, J = 8.3 Hz, ÍH), 6.67 (td, J = 8.5, 2.6 Hz, ÍH), 6.79 (d, J = 8.2 Hz, 2H), 6.86 (dd, J = 11.5, 2.6 Hz, ÍH), 7.18 (dd, J = 8.5, 7.1 Hz, ÍH) NMR-H1 (400 MHz, DMSO-dg) 5- (4- d 1.16 (s, 3H), 1.17 (s, 9H), tert-butylphenylaminomethyl) -6- 1.19 (s, 3H), 2.10 (s, 3H), 3.71 (4-fluoro-2-methoxyphenyl) - (s, 3H), 3.67-3.71 (m, ÍH), 3.95 2, 2, 4-trimethyl-1, 2- (dd, J = 12.0, 4.6 Hz, ), 4.88 (t, J = 4.6 Hz, ÍH), 5.35 (s, dihydroquinoline (Compound ÍH), 5.91 (s, ÍH), 6.38 (d, J = No .6 - 38) 8.7 Hz, 2H), 6.56 (d, J = 8.3 Hz, ÍH), 6.65 (d, J = 8.3 Hz, ÍH), 6.68 (td, J = 8.4, 2.6 Hz, ÍH), 6.87 (dd, J = 11.5, 2.6 Hz, ÍH) , 7.00 (d, J = 8.7 Hz, 2H), 7.19 (dd, J = 8.4, 7.1 Hz, ÍH) NMR-H1 (500 MHz, DMSO-d6) 6- (4-fluoro-2-methoxyphenyl) -d 1.10 (d, J = 6.8 Hz, 6H), 1.15 5- (3- (s, 3H), 1.20 (s, 3H), 2.11 (s, isopropylphenylaminomethyl) - 3H), 2.65 (sextete, J = 6.8 Hz, 2, 2, 4-trimethyl-1, 2-HH), 3.70 (s, 3H), 3.74 (dd, J = 12.2, 4.7 Hz, HH), 3.98 (dd, J = dihydroquinoline (Compound 12.2, 4.7 Hz, ÍH), 4.95 (t, J = No.6-39) 4.7 Hz, ÍH), 5.36 (s, ÍH), 5.90 (s, ÍH), 6.22 (d, J = 7.7 Hz, ÍH), 6.31 (s, ÍH), 6.36 (d, J = 7.7 Hz, ÍH), 6.57 (d, J = 8.1 Hz, ÍH), 6.66 (d, J = 8.1 Hz, ÍH), 6.68 (td, J = 8.3, 2.6 Hz, ÍH), 6.86 (dd, J = 11.5, 2.6 Hz, ÍH), 6.88 (t, J = 7.7 Hz, ÍH), 7.18 (dd, J = 8.3, 7.0 Hz, ÍH) NMR-H1 (400 MHz, DMSO-d6) 5- (2,3- d 1.14 (s, 3H), 1.21 (s, 3H), dimethylphenylaminomethyl) -6- 1.83 (s, 3H), 2.01 (s, 3H) ), 2.14 (4-fluoro-2-methoxyphenyl) - (s, 3H), 3.71 (s, 3H), 3.78 (t, 2,2, 4-trimethyl-1, 2- J = 4.9 Hz, ÍH), 3.88 (dd, J = 12.3, 4.9 Hz, ÍH), 3.99 (dd, J = dihydroquinoline (Compound 12.3, 4.9 Hz, ÍH), 5.39 (s, ÍH), No.6-52) 6.02 (s, ÍH) , 6.20 (d, J = 7.8 Hz, ÍH), 6.40 (d, J = 7.8 Hz, ÍH), 6.60 (d, J = 8.1 Hz, ÍH), 6.70 (d, J = 8.1 Hz, ÍH), 6.74 (td, J = 8.3, 2.5 Hz, ÍH), 6.81 (t, J = 7.8 Hz, ÍH), 6.91 (dd, J = 11.4, 2.5 Hz, ÍH), 7.18 (dd, J = 8.3, 7.1 Hz, HH) NMR-H1 (500 MHz, DMSO-d6) 5- (2.5-d 1.12 (s, 3H), 1.21 ( s, 3H), dimethylphenylaminomethyl) -6- 1.88 (s, 3H), 2.03 (s, 3H), 2.12 (4-fluoro-2-methoxyphenyl) - (s, 3H), 3.72 (s, 3H), 3.75 ( t, 2,2, 4-trimethyl-l, 2- J = 4.7 Hz, HH), 3.90 (dd, J = 12.5, 4.7 Hz, HH), 4.03 (dd, J = dihydroquinoline (Compound 12.5, 4.7 Hz, ÍH), 5.40 (s, ÍH), No.6-53) 6.01 (s, ÍH), 6.10 (s, ÍH), 6.28 (d, J = 7.6 Hz, ÍH), 6.60 (d, J = 8.2 Hz , ÍH), 6.70 (d, J = 8.2 Hz, ÍH), 6.73-6.79 (m, ÍH), 6.77 (d, J = 7.6 Hz, ÍH), 6.93 (dd, J = 11.6, 2.4 Hz, ÍH) , 7.19 (dd, J = 8.2, 7.0 Hz, ÍH) XH-NMR (400 MHz, DMSO-d6) 6- (4-fluoro-2-methoxyphenyl) -d 1.13 (s, 3H), 1.21 (s, 3H), 5- (5-methoxy-2- 1.86 (s, 3H), 2.03 (s, 3H), 3.60 methylphenylaminomethyl) - (s, 3H), 3.71 (s, 3H), 3.81-3.91 2, 2, 4 -trimethyl-1, 2- (m, 2H), 3.97-4.05 (m, HH), 5.40 (s, HH), 5.84 (d, J = 2.4 Hz, dihydroquinoline (Compound HH), 6.02 (s, ÍH), 6.05 (dd, J = 8.1, 2.4 Hz, ÍH), 6.60 (d, J = 8.3 Hz, ÍH), 6.70 (d, J = 8.3 Hz, ÍH), 6.74 (td, J = 8.4, 2.6 Hz, ÍH), 6.79 (d, J = 8.1 Hz, ÍH), 6.92 (dd, J = 11.4, 2.6 Hz, ÍH), 7.19 (dd, J = 8.4, 7.1 Hz, HH) NMR-H1 (400 MHz, DMSO-d6) 6- (4-fluoro-2-methoxyphenyl) -d 1.17 (s, 3H), 1.19 (s, 3H), 5- [4- (l- 1.22 (d, J = 6.3 Hz, 3H), 2.10 hydroxyethyl) phenylaminomethyl (s, 3H), 3.67-3.70 (m, ÍH), 3.70 ] -2, 2, 4-trimethyl-1, 2- (s, 3H), 3.95 (dd, J = 11.8, 4.6 Hz, HH), 4.47-4.53 (m, HH), 4.74 dihydroquinoline (Compound (d, J = 3.9 Hz, ÍH), 4.99 (t, J No.6-55) = 4.6 Hz, ÍH), 5.35 (s, ÍH), 5.91 (s, ÍH), 6.39 (d, J = 8.5 Hz, 2H), 6.57 (d, J = 8.2 Hz, ÍH) , 6.66 (d, J = 8.2 Hz, ÍH), 6.68 (td, J = 8.4, 2.5 Hz, ÍH), 6.87 (d, J = 11.5, 2.5 Hz, ÍH), 6.95 (d, J = 8.5 Hz, 2H), 7.19 (dd, J = 8.4, 7.3 Hz, ÍH) NMR-H1 (400 MHz, DMSO-d6) 6- (4-fluoro-2-methoxyphenyl) -d 1.18 (s, 3H), 1.22 (s, 3H), 5- (2-methyl-1--97 (s) , 3H), 2.05 (s 3H), 3.54-naphthylaminomethyl) -2.2.4- 3.58 (m, ÍH), 3.58 (s, 3H), 4.14 trimethyl-1, 2- (dd, J = 13.4, 6.8 Hz, ÍH), 4.37 (dd, J = 13.4, 3.8 Hz, ÍH), 5.39 dihydroquinoline (Compound (s, ÍH), 5.99 (s, ÍH), 6.46 (td, No.6-60) J = 8.3, 2.4 Hz, ÍH), 6.57 (d, J = 8.1 Hz, ÍH), 6.62 (d, J = 8.1 Hz, ÍH), 6.66 (dd, J = 8.3, 7.1 Hz, ÍH), 6.76 (dd, J = 11.5, 2.4 Hz, ÍH), 7.12 (d, J = 8.3 Hz, ÍH), 7.20-7.24 (m, ÍH), 7.29- 7. 34 (m, HH), 7.32 (d, J = 8.1 Hz, HH), 7.63 (d, J = 8.5 Hz, HH), 7.71 (d, J = 7.6 Hz, HH) NMR-H1 (400 MHz, DMSO -dg) 5- (2-Ethyl-6- d 0.87 (t, J = 7.6 Hz, 3H), 1.16 methylphenylaminomethyl) -6- (4- (s, 3H), 1.25 (s, 3H), 1.89 (s) , fluoro-2-methoxyphenyl) - 3H), 2.15 (s, 3H), 2.23 (q, J = 2, 2, 4-trimethyl-1, 2-7.6 Hz, 2H), 3.02-3.04 (m, HH), 3.63 (s, 3H), 3.90 (dd, J = dihydroquinoline (Compound 13.1, 6.3 Hz, HH) , 4.15 (dd, J = No.6-61) 13.1, 3.9 Hz, ÍH), 5.45 (s, ÍH), 6.03 (s, ÍH), 6.58 (d, J = 8.1 Hz, ÍH), 6.58-6.67 (m, 2H), 6.66 (d, J = 8.1 Hz, ÍH), 6.78-7.86 (m, 4H) NMR-H1 (400 MHz, DMSO-d6) 5- (2-ethoxyphenylaminomethyl) -d 1.16 (s, 3H), 1.21 (s, 3H), 6- (2-methoxy-5- 1.26 (t, J = 7.0 Hz, 3H), 2.06 trifluoromethylphenyl) -2,2,4- (s, 3H), 3.74 (s, 3H), 3.87-3.98 trimethyl-1, 2- (m, 4H), 4.13-4.14 (m, HI ), 5.42 (s, ÍH), 6.10 (s, ÍH), 6.29 (d, dihydroquinoline (Compound J = 7.8 Hz, ÍH), 6.49 (t, J = No.6-70) 7.8 Hz, ÍH), 6.63 (d, J = 8.2 Hz, HH), 6.65 (t, J = 7.8 Hz, ÍH), 6.72 (d, J = 7.8 Hz, HH), 6.75 (d, J = 8.2 Hz, HH), 7.18 (d , J = 8.7 Hz, ÍH), 7.40 (d, J = 2.0 Hz, ÍH), 7.63 (dd, J = 8. 7, 2.0 Hz, 1H) NMR-H1 (500 MHz, DMSO-d6) 5- (3-ethylphenylaminomethyl) -d 1.07 (t, J = 7.6 Hz, 3H), 1.17 6- (2-methoxy-5 - ( s, 3H), 1.20 (s, 3H), 2.12 (s, trifluoromethylphenyl) -2,2,4- 3H), 2.38 (q, J = 7.6 Hz, 2H), trimethyl-1, 2- 3.63 (dd, J = 12.3, 3.6 Hz, ÍH), 3.77 (s, 3H), 4.03 (dd, J = dihydroquinoline (Compound 12.3, 5.0 Hz, ÍH), 5.09-5.11 (m, No.6-71) ÍH), 5.37 (s, ÍH), 5.97 (s, ÍH), 6.21 (d, J = 7.7 Hz, ÍH), 6.25 (S, ÍH), 6.30 (d, J = 7.7 Hz, ÍH), 6.59 (d, J = 8.3 Hz, ÍH), 6.71 (d, J = 8.3 Hz, ÍH), 6.84 (t, J = 7.7 Hz, ÍH), 7.15 (d, J = 8.6 Hz, HH), 7.53 (d, J = 2.4 Hz, HH), 7.56 (d, J = 8.6 Hz, HH) Example 7 5-acryloyloxymethyl-1-allyl-6- (2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Compound Number 7-1) A mixture of 5-acryloyloxymethyl-6- (2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline (compound number 1-7, 50 mg, 0.14 mmol), allyl bromide (111 μl, 1.28 mmoles) and potassium carbonate (78 mg, 0.56 mmol) is suspended in 2 ml of anhydrous N, N-dimethylformamide and the reaction mixture is stirred at 60 ° C for 4 days. After cooling, it is diluted with 25 ml of ethyl acetate. The whole is washed with water (30 ml, twice) and 30 ml of saturated brine successively, dried over sodium sulfate.

Anhydrous magnesium and then the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to provide 23 mg of the title compound as a light yellow oil (yield, 41%).

NMR-H1 (400 MHz, DMSO-dg) d 1.17 (s, 3H), 1.27 (s, 3H), 2.07 (s, 3H), 3.69 (s, 3H), 3.95-3.97 (m, 2H), 4.85 (d, J = 12.8 Hz, ÍH), 5.10 (d, J = 12.8 Hz, ÍH), 5. 13 (dd, J = 10.1, 1.9 Hz, HH), 5.26 (dd, J = 17.1, 1.9 Hz, HH), 5.50 (s, HH), 5.86 (dd, J = 10.3, 1.8 Hz, HH ), 5.89-5.96 (m, HH), 6.00 (dd, J = 17.3, 10.3 Hz, HH), 6.16 (d, J = 17.3, 1.8 Hz, HH), 6.62 (d, J = 8.5 Hz, HH) , 6.85 (d, J = 8.5 Hz, ÍH), 6.95 (td, J = 7.6, 1.1 Hz, ÍH), 7.03 (dd, J = 8.3, 1.1 Hz, ÍH), 7.12 (dd, J = 7.6, 1.8 Hz, ÍH), 7.31 (ddd, J = 8.3, 7.6, 1.8 Hz, ÍH) Using compound number 1-7 or 9-5, the following compounds are obtained (number 7-2 and 7-3) by a method similar to that of compound number 7-1.

EXAMPLE 8 6- (2-Hydroxyphenyl) -5- [(pyrrolidin-1-yl) carbonyl] -2,2,4-trimethyl-1,2-dihydroquinoline (Compound Number 8-1) Pyrrolidine (135 μl, 1.62 mmoles) is dissolved in 1 ml of anhydrous tetrahydrofuran and a solution of 1.6 M hexane in n-butyl lithium is added dropwise thereto at 0 ° C. Then, the reaction mixture is stirred at the same temperature for 30 minutes, dripped in 3 ml of an anhydrous solution of tetrahydrofuran 2,2,4-trimethyl-1,2-dihydro-6-oxa-azacrisen-5-one (reference compound number 1-1, 80 mg, 0.27 mmol) and then the reaction mixture is stirred for an additional 30 minutes. After 5 ml of a saturated aqueous solution of NH 4 Cl are added to the reaction mixture, the reaction mixture is diluted with 100 ml of ethyl acetate. The whole is washed with 100 ml of water and 50 ml of saturated brine, successively, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to give 80.2 mg of the title compound as a light yellow solid (yield, 82%).

NMR-H1 (400 MHz, DMSO-dg) d 1.17 (s, 3H), 1.21-1.30 (m, HH), 1.22 (s, 3H), 1.37-1.45 (m, HH), 1.58-1.65 (m, 2H), 1. 83 (s, 3H), 2.81-2.93 (m, 2H), 3.07-3.15 (m, 2H), 5.33 (s, ÍH), 6.02 (s, ÍH), 6.56 (d, J = 8.2 Hz, ÍH) , 6.70 (t, J = 7.4 Hz, ÍH), 6.84 (d, J = 7.1 Hz, ÍH), 6.85 (d, J = 8.2 Hz, ÍH), 7.00 (d, J = 7.6 Hz, ÍH), 7.02 - 7.07 (m, ÍH), 9.05 (s, ÍH) Using the reference compound number 1-1, the following compounds are obtained (number 8-2-8-8) by a method similar to that of compound number 8-1 Example 9 6- (2-methoxyphenyl) -5- [(pyrrolidin-1-yl) carbonyl] -2,2,4-trimethyl-1,2-dihydroquinoline (Compound Number 9-1) A mixture of 6- (2-hydroxyphenyl) -5- [(pyrrolidin-1-yl) carbonyl] -2,2,4-trimethyl-1,2-dihydroquinoline (compound number 8-1, 65.0 mg, 0.179 mmol) , methyl iodide (11.1 μl, 0.178 mmol) and potassium carbonate (49.5 mg, 0.358 mmol) is suspended in 1.5 ml of anhydrous N, N-dimethylformamide and the reaction mixture is stirred at 50 ° C overnight. After cooling, it is diluted with 100 ml of ethyl acetate. The whole is washed with 100 ml of water and 50 ml of saturated brine, successively, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to provide 42.5 mg of the title compound as a colorless solid (yield, 63%).

Using any of the compounds between compounds numbers 8-2-8-8, the following compounds are obtained (number 9-2-9-8) by a method similar to that of compound number 9-1.

Example 10 6- (2-methoxyphenyl) -5-phenylthiomethyl-2,2,4-trimethyl-1,2-dihydroquinoline (Compound No. 10-1) A mixture of 5-chloromethyl-6- (2-methoxyphenyl) - 2, 2, 4-trimethyl-1,2-dihydroquinoline (Reference Compound No. 5-1, 80 mg, 0.24 mmol), thiophenol (148 μl, 1.44 mmol) and potassium carbonate (266 mg, 1.92 mmol) are They are suspended in 2 ml of anhydrous N, N-dimethylformamide and the reaction mixture is stirred at 50 ° C overnight. After cooling, it is diluted with 50 ml of ethyl acetate. The whole is washed with 50 ml of water and 30 ml of saturated brine, successively, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The residue that is obtained is purified by column chromatography on silica gel (hexane-ethyl acetate) to provide 53 mg of the title compound as a yellow solid (yield, 55%).

Using the reference compound No. 5-2, the following compounds are obtained (No. 10-2-10-5) by a method similar to that of compound No. 10-1.

NMR-H1 (500 MHz, DMSO-d6) 5- (2.5-d 1.15 (s, 3H), 1.23 (s, 3H), dimethylphenylthiomethyl) -6- (4- 2.03 (s, 3H), 2.14 ( s, 3H), fluoro-2-methoxyphenyl) - 2.26 (s, 3H), 3.68 (s, 3H), 2, 2, 4-trimethyl-l, 2- 3.75 (d, J = 12.4 Hz, ÍH), 4.20 (d, J = 12.4 Hz, ÍH), dihydroquinoline (Compound 5.42 (s, ÍH), 5.95 (s, ÍH), No.10-4) 6.55 (d, J = 7.9 Hz, ÍH), 6.62 (d , J = 7.9 Hz, ÍH), 6.69 (dd, J = 8.3, 2.4 Hz, ÍH), 6.70 (s, ÍH), 6.85 (d, J = 7.8 Hz, ÍH), 6.89 (dd, J = 11.6, 2.4 Hz, ÍH), 6.95 (dd, J = 8.3, 7.0 Hz, HH), 6.98 (d, J = 7.8 Hz, HH) NMR-H1 (500 MHz, DMSO-d6) 6- (4-fluoro-2-methoxyphenyl) -d 1.13 (s, 3H), 1.22 (s) , 3H), 5- (2-methoxyphenylthiomethyl) -2.23 (s, 3H), 3.67 (s, 3H), 2, 2, 4-trimethyl-1, 2- 3.69 (s, 3H), 3.73 (d, J = dihydroquinoline (Compound 12.1 Hz, ÍH), 4.15 (d, J = 12.1 Hz, ÍH), 5.40 (s, ÍH), No.10-5) 5.95 (s, ÍH), 6.54 (d, J = 7.9 Hz , ÍH), 6.62 (d, J = 7.9 Hz, ÍH), 6.70 (td, J = 8.4, 2.4 Hz, ÍH), 6.80 (t, J = 7.7 Hz, ÍH), 6.86-6.94 (m, 2H) 6.89 (dd, J = 11.6, 2.4 Hz, ÍH), 7.03 (t, J = 7.7 Hz, ÍH), 7.11 (t, J = 7.7 Hz, ÍH) Example 11 5-Benzylthiomethyl-6- (2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Compound No. 11-1) 5-Chloromethyl-6- (2-methoxyphenyl) -2 is dissolved , 2,4-trimethyl-1,2-dihydroquinoline (Compound of Reference No. 5-1, 80 mg, 0.24 mmol) and benzylmercaptan (85 μl, 0.72 mmol) in 2 ml of anhydrous tetrahydrofuran and 60% sodium hydride (38 mg, 0.95 mmol) is added thereto under an argon atmosphere at 0 ° C. 0.5 ml of anhydrous N, N-dimethylformamide are added thereto at room temperature and then the reaction mixture is stirred for 4 hours. The reaction mixture is diluted with 50 ml of ethyl acetate. The whole is washed with 50 ml of water and 50 ml of saturated brine, successively, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to give 65 mg of the title compound as a colorless solid (yield, 65%).

Using the reference compound No. 5-2, the following compounds are obtained (Nos. 11-2-11-3) by a method similar to that of compound No. 11-1.

NMR-H1 (400 MHz, DMS0-d6) 6- (4-fluoro-2-methoxyphenyl) -d 1.11 (s, 3H), 1.19 (s, 3H), 5-benzylthiomethyl-2, 2.4-2.23 ( s, 3H), 3.33 (d, J = 12.7 trimethyl-1, 2- Hz, ÍH), 3.36 (d, J = 13.2 Hz, dihydroquinoline (Compound ÍH), 3.41 (d, J = 13.2 Hz, ÍH), 3.64 (s, 3H), 3.72 (d, J = 12.7 No.11-2) Hz, ÍH), 5.36 (s, ÍH), 5.91 (s, ÍH), 6.51 (d, J = 8.3 Hz, ÍH) , 6.61 (d, J = 8.3 Hz, ÍH), 6.73 (td, J = 8.4, 2.4 Hz, ÍH), 6.86 (dd, J = 11.5, 2.4 Hz, ÍH), 6. 99-7.01 (m, 2H), 7.08 (dd, J = 8.4, 7.1 Hz, ÍH), 7.15-7.21 (m, 3H) NMR-H1 (500 MHz, DMSO-d6) 6- (4-fluoro-2) -methoxyphenyl) - d 1.10 (s, 3H), 1.20 (s, 3H), 5- (2-phenylethylthiomethyl) -2.22 (s, 3H), 2.32-2.53 (m, 4H), 2, 2, 4-trimethyl. -l, 2- 3.46 (d, J = 13.3 Hz, ÍH), 3.67 dihydroquinoline (Compound (s, 3H), 3.86 (d, J = 13.3 Hz, ÍH), 5.38 (s, ÍH), 5.91 (s, ÍH), No.11-3) 6.52 (d, J = 8.2 Hz, ÍH), 6.64 (d, J = 8.2 Hz, ÍH), 6.79 (td, J = 8.3, 2.4 Hz, ÍH), 6.94 (dd , J = 11.6, 2.4 Hz, ÍH), 7.00 (d, J = 7.2 Hz, 2H), 7.12 (dd, J = 8.3, 7.3 Hz, ÍH), 7.15 (t, J = 7.2 Hz, ÍH), 7.23 (t, J = 7.2 Hz, 2H) Example 12 6- (4-Fluoro-2-methoxyphenyl) -5- (4-methylthiobenzoyloxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Compound No. 12-1) 5 Suspended 5- chloromethyl-6- (4-fluoro-2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Reference Compound No. 5-2, 50.0 mg, 0.145 mmol) 4-methylthiobenzoic acid (73.2 mg , 0.435 mmol) and potassium carbonate (80.2 mg, 0.580 mmol) in 1 ml of N, N-Q-dimethylformamide anhydrous and the reaction mixture is stirred at 80 ° C for 2.5 hours. 100 ml of ethyl acetate are added to the reaction mixture and the whole is washed with 100 ml of water and 100 ml of saturated brine, successively, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to provide 32.4 mg of the title compound as a colorless amorphous product (yield, 47%). 0 5 Using any of the compounds between the reference compounds No. 5-2-5-3 and 5-5-5-16, the following compounds (No. 12-2-12-80) are obtained by a method similar to that of compound No. 12-1.

NMR-H1 (400 MHz, DMS0-d6) 6- (4-f luoro-2- d 1.13 (s, 3H), 1.21 (s, 3H), methoxyphenyl) -5- (4- 2.09 (s, 3H) , 3.66 (s, 3H), f-enoxybenzoyloxymethyl) - 4.94 (d, J = 12.7 Hz, ÍH), 2,2, 4-trimethyl-1, 2- 5.18 (d, J = 12.7 Hz, HH), 5.45 (s, HH), 6.09 (s, HH), dihydroquinoline 6.65 (d, J = 8.3 Hz, HH) , 6.72 (Compound No.12-6) (td, J = 8.5, 2.8 Hz, ÍH), 0 j ° O 6.74 (d, J = 8.3 Hz, ÍH), 6.92 FV (dd, J = 11.5, 2.8 Hz, ÍH), 7.00 (dt, J = 8.9, 2.4 Hz, .o XNX 2H), 7.11 (dd, J = 8.6, 1.1 Hz, 2H), 7.13 (dd, J = 8.5, H 7.1 Hz, ÍH), 7.24 (t, J = = 7.0 Hz, ÍH), 7.45 ( dd, J = 8.6, 7.6 Hz, 2H), 7.81 (dt, J = 8.9, 2.4 Hz, 2H) NMR-H1 (500 MHz, DMS0-d6) 6- (4-f luoro-2- dl.12! (S, 3H), 1.21 (s, 3H), methoxyphenyl) -5- [(thiazole-5- 2.10 (s, 3H), 3.69 (s, 3H), il) carbonyloxymethyl] - 4.99 (d, J = 12.7 Hz, ÍH), 2,2, 4-trimethyl-1, 2-5.22 (d, J = 12.7 Hz, HH), 5.46 (s, HH), 6.11 (s, HH), dihydroquinol ina 6.66 (d, J = 8.3 Hz, HH ), 6.73 (Compound No. 12-39) (td, J = 8.4, 2.6 Hz, ÍH), 0? X r - sN > 6.74 (d, J = 8.3 Hz, ÍH), 6.92 (dd, J = 11.5, 2.6 Hz, ÍH), F? P ° I 7.13 (dd, J = 8.4, 7.2 Hz, ^ A '^ A ^ -AA ^ / O 1 X [NX z' ÍH), 8.37 (d, J = 0.6 Hz, ÍH), H 9.33 (d, J = 0.6 Hz, ÍH) RMN-P I1 (400 MHz, DMSO-dg) 6- (4-f luoro- 2- d i .: L4 (s, 3H), 1.20 (s, 3H), methoxyphenyl) -5- [(thiazole-4- 2.11 (s, 3H ), 3.65 (S, 3H), il) carbonyloxymethyl] - 4.91 (d, J = 12.5 Hz, ÍH), 2,2,4-trimethyl-1, 2-5-20 (d, J = 12.5 Hz, HH), 5.44 (s, HH), 6.08 (s, HH), dihydroquinoline 6.65 (d, J = 8.2 Hz, HH) , 6.68 (Compound No.12-40) (td, J = 8.5, 2.5 Hz, ÍH), N == \ o ^ AJ 6.73 (d, J = 8.2 Hz, ÍH), 6.91 (dd, J = 11.5, 2.5 Hz , ÍH), F? "I? R °? 7.13 (dd, J = 8.5, 7.2 Hz, ^ A ^ A ^ A ^ / O K 1XN / ÍH), 8.37 (d, J = 1.8 Hz, ÍH), H 9.13 (d, J = 1.8 Hz, ÍH) NMR-H1 (400 MHz, DMSO-dg) 5-cinnamoyloxymethyl-6- (4- d 1.18 (s, 3 H), 1.22 (s, 3 H), f luoro-2-methoxyphenyl) - 2.09 (s, 3 H), 3.70 (s, 3H), 2, 2, 4-trimethyl-1, 2- 4.81 (d, J = 12.7 Hz, HH), dihydroquinoline 5.08 (d, J = 12.7 Hz, HH), 5.45 (s, HH), 6.07 (s, HH) , (Compound No.12-47) 6.51 (d, J = 16.0 Hz, ÍH), X]] O XX 6.64 (d, J = 8.2 Hz, HH), 6.73 (d, J = 8.2 Hz, HH), 6.74 (td, J = 8.4, 2.5 Hz, ÍH), 6.92 (dd, J = 11.4, 2.5 Hz, ÍH), H 7.13 (dd, J = 8.4, 7.3 Hz, ÍH), 7.40-7.42 (m, 3H) , 7.50 (d, J = 16.0 Hz, ÍH), 7.64-7.67 (m, 2H) NMR-H1 (500 MHz, DMSO-dg) 5- [(benzothiophen-2-d 1.16 (s, 3H), 1.22 ( s, 3H), il) carbonyloxymethyl] -6- (4- 2.15 (s, 3H), 3.67 (s, 3H), f luoro-2-methoxyf enyl) - 5.00 (d, J = 12.5 Hz, ÍH), 2, 2, 4-trimethyl-1, 2-5.25 (d, J = 12.5 Hz, HH), 5.47 (s, HH), 6.11 (s, HH), dihydroquinoline 6.67 (d, J = 8.2 Hz, HH) , 6.72 (Compound No.12-48) (td, J = 8.5, 2.5 Hz, ÍH), XX) 6.75 (d, J = 8.2 Hz, ÍH), 6.92 oys (dd, J = 11.6, 2.5 Hz, ÍH ), 7.15 (dd, J = 8.5, 7.2 Hz, FOujk ÍH), 7.46 (ddd, J = 8.0, 7.0, / Ny 1.2 Hz, HH), 7.52 (ddd, J = H 8.0, 7.0, 1.2 Hz, ÍH), 7.99 (d, J = 8.0 Hz, HH), 8.04 (d, J = 8.0 Hz, HH), 8.06 (Yes H) Example 13 5- (3-aminobenzoyloxymethyl) -6- (4-fluoro-2- methoxyphenyl) -2,2, 4-trimethyl-1,2-dihydroquinoline (Compound No. 13-1) 6- (4-Fluoro-2-methoxyphenyl) -5-hydroxymethyl-2,2,4-trimethyl- 1, 2-dihydroquinoline (Reference Compound No. 4-3, 49.7 mg, 0.15 mmol), 3-aminobenzoic acid (49.0 mg, 0.35 mmol), tri-n-butylphosphine (87.0 μl, 0.35 mmol) and 1.1 '- (azodicarbonyl) dipiperidine (89.4 mg, 0.35 mmol) in 2 ml of anhydrous benzene and then the mixture is stirred under an argon atmosphere at room temperature overnight. 3 ml of hexane-3 ml of ethyl acetate are added to the reaction mixture and the insoluble materials are filtered. The filtrate is concentrated under reduced pressure and the residue is purified by silica gel column chromatography (hexane-ethyl acetate) to provide 28.0 mg of the title compound as a colorless amorphous product (yield, 42%).

Using any of the compounds between reference compounds No. 4-1, 4-3 and 4-31, the following compounds (No. 13-2-13-4) are obtained by a method similar to that of compound No. 13 -1.

Example 14 6- (4-Fluoro-2-methoxyphenyl) -5- (2-methoxycarbonylmethylphenoxymethyl) -2,2,4-trimethyl-l, 2-dihydroquinoline (Compound No. 14-1) Dissolves 6- (4- fluoro-2-methoxyphenyl) -5-hydroxymethyl-2,2,4-trimethyl-1,2-dihydroquinoline (Reference Compound No. 4-3, 100.1 mg, 0.31 mmol), methyl 2-hydroxyphenylacetate (76.1 mg, 0.46 mmol), trin-butylphosphine (114 μl, 0.46 mmol) and 1,1'- (azodicarbonyl) dipepyridine (117 mg, 0.46 mmol) in 2 ml of anhydrous benzene and the mixture is stirred under an argon atmosphere. room temperature under 1 hour. 5 are added ml of hexane to the reaction mixture and the insoluble materials are filtered. The filtrate is concentrated under reduced pressure and the residue is purified by silica gel column chromatography (hexane-ethyl acetate) to provide 107.1 mg of the title compound as a colorless amorphous product (yield, 74%).

Using any of the compounds between the reference compounds No. 4-3-4-4, 4-6, 4-17, 4-27 and 4- 29-4-32, the following compounds are obtained (No. 14- 2-14-56) by a method similar to that of compound No. 14-1.

NMR-H1 (500 MHz, DMS0-d6) 5- (2- d 1.09 (s, 3H), 1.17 (s, 3H), acetylaminophenoxymethyl) -6- 2.03 (s, 3H), 2.09 (s, 3H), 3.74 (4-fluoro-2-methoxyphenyl) - (s, 3H), 4.59 (d, J = 11.8 Hz, 2, 2, 4-trimethyl-1, 2-H), 5.11 (d, J = 11.8 Hz, ÍH), 5.42 (s, ÍH), 6.02 (s, ÍH), 6.60 dihydroquinoline (Compound (d, J = 7.5 Hz, ÍH), 6.62 (d, J No.14-6) = 8.1 Hz, ÍH), 6.72 (dt, J = 8.5, 2.6 Hz, ÍH), 6.75 (d, J = 8.1 Hz, ÍH), 6.79 (t, J = 7.5 Hz, ÍH), 6.87 (t, J = 7.5 Hz, ÍH), 6.94 (dd, J = 11.3, 2.6 Hz, ÍH), 7.22 (dd, J = 8.5, 7.2 Hz, ÍH), 7.85 (d, J = 7.5 Hz, ÍH), 8.47 (s, ÍH) NMR-H1 (400 MHz, DMSO-d6) 5- (5-amino-2- d 1.13 (s, 3H), 1.20 (s, 3H), methylphenoxymethyl) -6- (4- 1.87 (s, 3H), 1.96 (s, 3H), 3.75 fluoro-2-methoxyphenyl) - (s, 3H), 4.42 (d, J = 11.2 Hz , 2,2, 4-trimethyl-1, 2H), 4.71 (br s, 2H), 4.85 (d, J = 11.2 Hz, ÍH), 5.37 (s, ÍH), dihydroquinoline (Compound 5.89 (s, ÍH), 5.97 (dd, J = 8.1, No.14-7) 2.0 Hz, ÍH), 6.01 (s, ÍH), 6.63 (d, J = 8.1 Hz, ÍH), 6.66 (d, J = 8.1 Hz , ÍH), 6.73-6.77 (m, ÍH), 6.74 (d, J = 8.1 Hz, ÍH), 6.95 (dd, J = 11.6, 2.6 Hz, ÍH), 7.19 (dd, J = 8.3, 7.1 Hz, ÍH) Example 15 6- (4-Benzyloxy-2-methoxyphenyl) -5- (5-fluoro-2-methylphenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Compound No. 15-1) Dissolves - (5-fluoro-2-methylphenoxymethyl) -6- (4-hydroxy-2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Reference Compound No. 5-3, 20.1 mg, 0.046 mmoles), potassium carbonate (16.7 mg, 0.12 mmol) and benzyl bromide (6.6 μl, 0.055 mmol) in 0.5 ml of anhydrous N, N-dimethylformamide and the mixture is stirred at 60 ° C for 40 minutes. 50 ml of ethyl acetate are added to the reaction mixture and the whole is washed with 50 ml of water and 30 ml of saturated brine, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The residue is purified by silica gel column chromatography (hexane-ethyl acetate) to give 5.1 mg of the title compound as a colorless oil, (yield, 19%).

Using a reference compound No. 5-3 or 5-4, the following compounds are obtained (No. 15-2-15-18) or a method similar to that of compound No. 15-1.

Example 16 6- (4-Fluoro-2-methoxyphenyl) -5- (4-hydroxybenzoyloxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Compound No. 16) 5- (4-acetoxybenzoyloxymethyl) is suspended -6- (4-fluoro-2-methoxyphenyl) -2,2, 4-trimethyl-1,2-dihydroquinoline (compound No. 12-5, 40.9 mg, 0.0835 mmol) and potassium carbonate (24.0 mg, 0.174 mmol) ) in 1 ml of anhydrous methanol and the mixture is stirred at room temperature for 1.5 hours. After the insoluble materials are filtered, the filtrate is concentrated under reduced pressure and 50 ml of ethyl acetate and 50 ml of water are added thereto. then it separates. The organic layer is washed with 30 ml of water and 30 ml of saturated brine, successively, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The resulting residue is filtered with hexane to provide 28.8 mg of the title compound as a colorless solid, (yield, 78%).

Example 17 5-Benzoylaminomethyl-6- (4-fluoro-2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Compound No. 17-1) Sodium hydride 60% (23.2 mg, 0.580 mmoles) in 3 ml of anhydrous N, N-dimethylformamide and added to the same benzamide (70.3 mg, 0.580 mmol) at 0 ° C. After the reaction mixture is stirred at room temperature for 25 minutes, 5-chloromethyl-6- (4-fluoro-2-methoxyphenyl) -2,2, 4-trimethyl-1 is added thereto., 2-dihydroquinoline (Reference Compound No. 5-2, 50.0 mg, 0.145 mmol) and the reaction mixture is stirred at 50 ° C for 1 hour. 100 ml of ethyl acetate are added to the reaction mixture, then the whole is washed with 100 ml of water and 50 ml of saturated brine, successively, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to provide 34.1 mg of the title compound as a light yellow amorphous product. (yield, 55%).

Using the reference compound No. 5-2, the following compounds are obtained (No. 17-2-17-4) by a method similar to that of compound No. 17-1.

EXAMPLE 18 6- (4-Fluoro-2-methoxyphenyl) -5- phenylaminocarbonyloxymethyl-2,4,4-trimethyl-l, 2-dihydroquinoline (Compound No. 18) Dissolves 6- (4-fluoro-2-methoxyphenyl) -5-hydroxymethyl-2,2,4-trimethyl-1,2-dihydroquinoline (Reference Compound No. 4-3, 50.0 mg, '0.153 mmol) and 4-dimethylaminopyridine (1.87 mg, 0.0153 mmol) in 1 ml of anhydrous tetrahydrofuran, then 1,1'-carbonyldiimidazole (32.3 mg, 0.199 mmol) is added thereto and subsequently the mixture is stirred at room temperature overnight.

[Solution 1] A solution of n-butyl-lithium 1.6M in hexane (430 μl, 0.688 mmol) is added to an aniline solution (69.7 μl, 0.765 mmoles) in 2 ml of tetrahydrofuran 5 anhydrous, dropwise, and the mixture is stirred at 0 ° C for 30 minutes [Solution 2]. Then, solution 2 is cooled to -78 ° C, solution 1 is added dropwise thereto and the reaction mixture is stirred at -78 ° C for 30 minutes. - Subsequently, 5 ml of a saturated aqueous solution of NH 4 Cl is added to the reaction mixture, the mixture is diluted with 100 ml of ethyl acetate. The whole is washed with 100 ml of water, 100 ml of a 0.02N aqueous HCl solution, 50 ml of water and 50 ml of saturated brine, successively, dried over anhydrous magnesium sulfate and then the solvent is removed under pressure. reduced. The resulting residue is purified by silica gel column chromatography (toluene-ethyl acetate) to give 66.0 mg of the title compound as a pale yellow amorphous product (yield, 97%). 25 Example No. 19 5- (2-carboxymethylphenoxymethyl) -6- (4-fluoro-2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Compound No. 19-1) Dissolves 6 - (4-fluoro-2-methoxyphenyl) -5- (2-methoxycarbonylmethylphenoxymethyl) -2,2,4-trimethyl-l, 2-dihydroquinoline (Compound No. 14-1, 84.0 mg, 0.18 mmol) in 2 ml of methanol - 1 ml of tetrahydrofuran and 0.56 ml of an aqueous NaOH solution IN is added thereto and the mixture is stirred at room temperature overnight. After of which 100 ml of ethyl acetate have been added to the reaction mixture, the whole is washed with 100 ml of a 0.01N aqueous HCl solution and 50 ml of successively saturated brine, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to provide 74.1 mg of the title compound as a colorless solid, (yield, 89%).

Using any of the compounds between compounds No. 3-5, 3-53 and 14-3, the following compounds are obtained (No. 19-2-19-4) by a method similar to that of compound No. 19-1 .

Example 20 5- (2-aminophenoxymethyl) -6- (4-fluoro-2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Compound No. 20-1). 1 ml of a solution of 4N HCl / 1,4-dioxane is added to 5- (2-t-butoxycarbonylamino-phenoxymethyl) -6- (4-fluoro-2-methoxyphenyl) -2,2,4-trimethyl-2. -dihydroquinoline (Compound No. 3-79, 9.6 mg, 0.019 mmol), then the reaction mixture is stirred at room temperature for 1 hour. The reaction mixture is concentrated under reduced pressure. 10 ml of ethyl acetate and 10 ml of a saturated aqueous solution of NaHCO 3 are added to the residue and separated. The organic layer is dried over anhydrous magnesium sulfate. The solvent is removed under reduced pressure to provide 5.4 mg of the title compound as a yellow oil, (yield, 70%).

Using compound No. 6-86, the following compound No. 20-2 is obtained by a method similar to that of compound No. 20-1.

Example 21 6- (5-amino-2-methoxyphenyl) -5- (5-fluoro-2-methylphenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Compound No. 21-1) Dissolves - (5-fluoro-2-methylphenoxymethyl) -6- (2-methoxy-5-nitrophenyl) -2, 2, 4-trimethyl-1,2-dihydroquinoline (Compound No. 14-48, 100.4 mg, 0.271 mmol) in a solution of 4N aqueous NaOH (405 μL, 1.62 mmol) - 5 mL of ethanol (292.9 mg, 4.48 mmoles) and zinc is added thereto and then the reaction mixture is stirred at 110 ° C overnight. 20 ml of ethyl acetate are added to the reaction mixture and the insoluble materials are filtered. After 50 ml of ethyl acetate have been added to the filtrate, the whole is washed with 100 ml of water and 50 ml of saturated brine, successively, it is dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The resulting residue is purified by silica gel column chromatography (hexane-ethyl acetate) to give the title compound (12.1 mg) as a yellow amorphous product, (yield, 13%).

Example 22 6- (2-methoxy-5-phenylacetylphenyl) -5- (4-methylbenzoyloxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Compound No. 22) Aluminum chloride (97.0 mg, 0.73 mmole) to 0.5 ml of anhydrous dichloroethane and the solution is cooled to 0 ° C. Phenylacetyl chloride (97 μl, 0.73 mmol) and 6- (2-methoxyphenyl) -5- (4-methylbenzoyloxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Compound No. 13) are added thereto. -3, 49.7 mg, 0.12 mmol) and the reaction mixture is stirred at room temperature for 1.5 hours. 100 ml of ethyl acetate are added to the reaction mixture and the whole is washed with 100 ml of water and 50 ml of saturated brine, successively, dried over anhydrous magnesium sulfate and then the solvent is removed under reduced pressure. The residue is purified by silica gel column chromatography (hexane-ethyl acetate) to provide 53.6 mg of the title compound as a light yellow amorphous product, (yield, 82%).

Example No. 23 6- [5- (l-hydroxy-2-phenylethyl) -2-methoxyphenyl] -5- (4-methylbenzoyloxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Compound No. 23 ) 6- (2-Methoxy-5-phenylacetylphenyl) -5- (4-methylbenzoyloxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline (Compound No. 22, 34.0 mg, 0.0623 mmole) is dissolved in 0.5 ml of tetrahydrofuran - 0.5 ml of methanol and sodium borohydride (6.8 mg, 0.180 mmol) is added thereto and then the reaction mixture is stirred at room temperature for 45 minutes. 0.5 ml of an aqueous solution of IN HCl and 50 ml of ethyl acetate are added to the reaction mixture, the whole is washed with water (50 ml, twice) and 50 ml of saturated brine successively, dried over sodium sulfate. Anhydrous magnesium and then the solvent is removed under reduced pressure. The residue is purified by silica gel column chromatography (hexane-ethyl acetate) to provide 31.8 mg of the title compound as a colorless amorphous product, (yield, 93%).

[Preparation Examples] Typical preparation examples of the present compound are shown below. 1) Tablet (in 100 mg) Present compound 1 mg Lactose 66.4 mg Corn starch 20 mg Calcium carboxymethylcellulose 6 mg Hydroxypropylcellulose 4 mg Magnesium stearate 0.6 mg One tablet of the formulation mentioned above is coated with 2 mg of a coating agent (for example a conventional coating agent such as hydroxypropylmethylcellulose, macrogol or a silicone resin) whereby a target tablet can be obtained. In addition, a desired tablet can be obtained by appropriately changing the kind and / or amount of the present compound and the additives. 2) Capsule (in 150 mg) Present compound 5 mg Lactose 145 mg A desired capsule can be obtained by appropriately changing the mixing ratio of the present compound to lactose. 3) Drops for the eyes (in 100 ml) Present compound 100 mg Sodium chloride 900 mg Polysorbate 80 200 mg Sodium hydroxide q.s. Hydrochloride acid c.s. Sterile purified water q.s. It is possible to obtain eye drops that are desired by appropriately changing the class and / or amount of the present compound and additives.

[Pharmacological Tests] 1. Evaluation test for glucocorticoid receptor binding activity (referred to as "GR" in the following) In order to assess GR binding activity, a receptor proficiency analysis is carried out by a Fluorescence polarization method. In the analysis, a GR competitor analysis equipment (manufactured by Invitrogen, catalog No. P2816) is used and a procedure is carried out according to the protocol attached to the equipment. Subsequently, the specific method will be described.

[Preparation of Reagents] GR Screening Damper: A buffer containing 10 mM potassium phosphate is prepared (pH 7. 4), 20 mM sodium molybdate (Na2Mo04), 0.1 mM ethylenediamine tetraacetic acid (EDTA), 5 mM dithiothreitol (DTT), 0.1 mM stabilizing peptide and 2% dimethyl sulfoxide. Solution 4 x GS1: fluormonaMR GS1, which is a fluorescent glucocorticoid ligand which is diluted with GR screening buffer so that a 4 nM solution is prepared. Solution 4 x GR: Recombinant human GR is diluted with GR screening buffer, so a 16 nM solution is prepared.

(Preparation of the Test Compound Solution) After the test compound is dissolved in dimethyl sulfoxide, the resulting solution is diluted with GR screening buffer, whereby a solution of 20 μM test compound is prepared.

(Test Method and Measurement Method) 1) The test compound solution is added in an amount of 25 μl to 10 μl into each well of a 96-well or 384-well plate and then 4 x GS1 solution is added and solution 4 x GR in an amount of 12.5 μl or 5 μl within each well, respectively. 2) The plate is incubated in a dark place room temperature for 2 to 4 hours. 3) When using a multimodal plate reader, AnalystMR HT (manufactured by LJL Biosystems), measure the fluorescence polarization of each well. With respect to the control, a well containing GR screening cushion is used instead of the test compound and solution 4 x GS1. 4) The same procedure as in previous paragraphs 1) to 3) is carried out, except that the screening buffer GR is used in place of the solution of the test compound and the result obtained is taken as the negative control . 5) The same procedure is performed as in parts 1) to 3) above, except that 2 mM dexamethasone is used instead of the solution of the test compound and the result obtained is taken as the positive control.

(Equation of Calculation of the Relationship of Union of GR) The relation of union of GR (%) is calculated from the following equation. Binding ratio of GR (%) = 100 x [1 - (fluorescence polarization of the test compound solution - fluorescence polarization of the positive control solution) / (fluorescence polarization of the negative control solution - fluorescence polarization of the positive control solution)] (Test Results and Discussion) As an example of the test results, the GR (%) binding ratio of the test compounds are shown in Table I (Compound 1-19, Compound 1-21, Compound 1-46 , compound 3-21, compound 3-22, compound 3-33, compound 3-44, compound 3-45, compound 3-48, compound 3-56, compound 3-57, compound 3-58, compound 3-59 , compound 3-61, compound 3-62, compound 3-67, compound 3-68, compound 3-69, compound 3-72, compound 3-74, compound 3-85, compound 3-91, compound 3-94, compound 3-98, compound 3-99, compound 5-3, compound 5-4, compound 6-20, compound 6-24, compound 6-27, compound 6-36, compound 6-37, compound 6-40, compound 6-43, compound 6-45, compound 6-47, compound 6-53, compound 6-57, compound 6-59, compound 6-75, compound 6-76, compound 6-77, compound 6-78, compound 6-79, compound 12-17, compound 12-19, compound 12-20, compound 12-21, compound 12-22, compound 12-25, compound 12-33, compound 1 2-42, compound 12-53, compound 12-54, compound 12-58, compound 12-67, compound 12-69, compound 12-73, compound 12-75, compound 12-76, compound 14-1, compound 14-11, composite 14-12, compound 14-13, compound 14-15, compound 14-21, compound 14-40, compound 14-41, compound 14-43, compound 14-45, compound 14-47, compound 14-48, compound 15-2 and compound 15-7).

[Table 1] Incidentally, a binding ratio of GR of 100% or greater is indicated by 100%.

Industrial Applicability As is evident from Table I, the present compounds show excellent GR receptor binding activity. Accordingly, the present compound can be used as a GR receptor modulator and is useful for a prevention or therapeutic agent particularly for diseases related to GR, ie, metabolic disorders, inflammatory diseases, autoimmune diseases, allergic diseases, central nervous system, cardiovascular diseases, diseases related to homeostasis, glaucoma and the like. an integer from 0 to 2; in the case where q is 2, each R2 can be the same or different; R3 represents a hydrogen atom, a lower alkyl group which may have at least one substituent, a lower alkenyl group which may have at least one substituent, a lower alkynyl group which may have at least one substituent, aryl group which may have at least one substituent, a lower alkylcarbonyl group which may have at least one substituent, a lower alkenylcarbonyl group which may have at least one substituent, a lower alkynylcarbonyl group which may therefore have minus one substituent or an arylcarbonyl group which may have at least one substituent; R4 and R5 may be the same or different and represent a hydrogen atom or a lower alkyl group; R4 and R5 can be combined together to form a lower cycloalkane ring of 3 to 8 members; R6 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or a carbonyl group; R7 represents OR8, NR8R9, SR8, S (0) R8 or S (0) 2R8; R8 represents a lower alkyl group which may have at least one substituent, a lower alkenyl group which may have at least one substituent, a lower alkynyl group which may have at least one substituent, a cycloalkyl group

Claims

1. Compound represented by the following general formula (1) or a salt thereof: [wherein the X ring represents a benzene ring or a pyridine ring; R1 represents a halogen atom, a lower alkyl group which may have at least one substituent, a hydroxy group, a lower alkoxy group which may have at least one substituent, a lower alkenyloxy group which may have at least one a substituent, a lower alkylcarbonyl group, an amino group, a nitro group or a cyano group; p represents an integer from 0 to 5; in the case where p is 2 to 5, each R1 may be the same or different; R 2 represents a halogen atom or a lower alkyl group which may have at least one substituent, a hydroxy group, an ester of a hydroxy group or a lower alkoxy group which may have at least one substituent; q represents lower which may have at least one substituent, an aryl group which may have at least one substituent, a heterocyclic group which may have at least one substituent, a formyl group, a lower alkylcarbonyl group which may have at least one substituent, a lower alkenylcarbonyl group which may have at least one substituent, a lower alkynylcarbonyl group which may have at least one substituent, a lower cycloalkylcarbonyl group which may have at least one substituent, an arylcarbonyl group which may have at least one substituent, a heterocyclic carbonyl group which may have at least one substituent, a carboxy group, a lower alkoxycarbonyl group which may have at least one substituent, a lower alkenyloxycarbonyl group which may have at least one substituent, a lower alkynyloxycarbonyl group which may have at least one substituent, a lower cycloalkyloxycarbonyl group which may have at least one substituent, an aryloxycarbonyl group which may have at least one substituent, a heterocyclic oxycarbonyl group which may have at least one substituent, a lower alkynylsulfonyl group which may have at least one substituent, minus one substituent, a lower alkenylsulfonyl group which may have at least a substituent, a lower alkynylsulfonyl group which may have at least one substituent, a lower cycloalkylsulfonyl group which may have at least one substituent, an arylsulfonyl group which may have at least one substituent, a heterocyclic sulfonyl group which may have at least one substituent, an aminocarbonyl group, a lower alkylaminocarbonyl group which may have at least one substituent, a lower alkenylaminocarbonyl group which may have at least one substituent, a lower alkynylaminocarbonyl group which may therefore have minus one substituent, a lower cycloalkylaminocarbonyl group which may have at least one substituent, an arylaminocarbonyl group which may have at least one substituent or a heterocyclic aminocarbonyl group which may have at least one substituent; R9 represents a hydrogen atom, a lower alkyl group which may have at least one substituent, a lower alkenyl group which may have at least one substituent, a lower alkynyl group which may have at least one substituent, lower cycloalkyl group which may have at least one substituent, an aryl group which may have at least one substituent, a heterocyclic group which may have at least one substituent, a group formyl, a lower alkylcarbonyl group which may have at least one substituent, a lower alkenylcarbonyl group which may have at least one substituent, a lower alkynylcarbonyl group which may have at least one substituent, a lower cycloalkylcarbonyl group which can have at least one substituent, an arylcarbonyl group which may have at least one substituent, a heterocyclic carbonyl group which may have at least one substituent, a carboxy group, a lower alkoxycarbonyl group which may have at least one substituent, a lower alkenyloxycarbonyl group which may have at least one substituent, a lower alkynyloxycarbonyl group which may have at least one substituent, a lower cycloalkyloxycarbonyl group which may have at least one substituent, an aryloxycarbonyl group which may have at least one substituent , a heterocyclic oxycarbonyl group which may have at least one substituent, a lower alkylsulfonyl group which may have at least one substituent, a lower alkenylsulfonyl group which may have at least one substituent, a lower alkynylsulfonyl group which may have at least one substituent, a lower cycloalkylsulfonyl group which can be to have at least one substituent, a group arylsulfonyl which may have at least one substituent, a heterocyclic sulfonyl group which may have at least one substituent, an aminocarbonyl group, a lower alkylaminocarbonyl group which may have at least one substituent, a lower alkenylaminocarbonyl group which may having at least one substituent, a lower alkynylaminocarbonyl group which may have at least one substituent, a lower cycloalkylaminocarbonyl group which may have at least one substituent, an arylaminocarbonyl group which may have at least one substituent or a group heterocyclic aminocarbonyl which may have at least one substituent; in the case where R7 is NR8R9, R8 and R9 can be combined together to form a 3 to 8 membered nitrogen containing heterocyclic ring which may have a substituent]. Compound or a salt thereof, as described in claim 1, wherein in the general formula (1), the X ring represents a benzene ring or a pyridine ring; R1 represents a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group, a lower alkenyloxy group, a lower alkylcarbonyl group, an amino group, a nitro group or a cyano group; in the case where R1 is a lower alkyl group or a lower alkoxy group, the alkyl group The lower or the lower alkoxy group may have one or a plurality of groups which are selected from a halogen atom, an aryl group, an aryl group substituted by at least one halogen atom, an aryl group substituted by at least one lower alkyl group , an aryl group substituted by at least one hydroxy group, an aryl group substituted by at least one lower alkoxy group, a hydroxy group, an ester of a hydroxy group, a lower alkoxy group, an aryloxy group, a carboxy group and an ester of a carboxy group as substituents; p represents an integer from 0 to 3; in the case where p is 2 or 3, each R1 may be the same or different; R 2 represents a halogen atom, a lower alkyl group, a hydroxy group, an ester of a hydroxy group or a lower alkoxy group; q represents an integer from 0 to 2; in the case where q is 2, each R2 can be the same or different; R3 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, an aryl group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group, a lower alkynylcarbonyl group or an arylcarbonyl group; in the case where R3 is a lower alkyl group or a lower alkylcarbonyl group, the lower alkyl group or the lower alkylcarbonyl group may have one or a plurality of aryl groups as substituents; in the case where R3 is an aryl group or an arylcarbonyl group, the aryl group or the arylcarbonyl group may have one or a plurality of groups which are selected from a halogen atom and a lower alkyl group as substituents; R4 and R5 may be the same or different and represent a hydrogen atom or a lower alkyl group; R6 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or a carbonyl group; R7 represents OR8, NR8R9 or SR8; R8 represents a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower cycloalkyl group, an aryl group, a heterocyclic group, a formyl group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group, a lower alkynylcarbonyl group, an lower cycloalkylcarbonyl group, an arylcarbonyl group, a heterocyclic carbonyl group, a carboxy group, a lower alkoxycarbonyl group, a lower alkenyloxycarbonyl group, a lower alkynyloxycarbonyl group, a lower cycloalkyloxycarbonyl group, an aryloxycarbonyl group, a heterocyclic oxycarbonyl group, a lower alkylsulfonyl group , a lower alkenylsulfonyl group, a lower alkynylsulfonyl group, a lower cycloalkylsulfonyl group, an arylsulfonyl group, a heterocyclic sulfonyl group, an aminocarbonyl group, an a lower alkylaminocarbonyl group, a lower alkenylaminocarbonyl group, a lower alkynylaminocarbonyl group, a lower cycloalkylaminocarbonyl group, an arylaminocarbonyl group or a heterocyclic aminocarbonyl group; R9 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower cycloalkyl group, an aryl group, a heterocyclic group, a formyl group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group, an lower alkynylcarbonyl group, a lower cycloalkylcarbonyl group, an arylcarbonyl group, a heterocyclic carbonyl group, a carboxy group, a lower alkoxycarbonyl group, a lower alkenyloxycarbonyl group, a lower alkynyloxycarbonyl group, a lower cycloalkyloxycarbonyl group, an aryloxycarbonyl group, a heterocyclic oxycarbonyl group , an alkylsulfonyl group, a lower alkenylsulfonyl group, a lower alkynylsulfonyl group, a lower cycloalkylsulfonyl group, an ariisulfonilo group, a heterocyclic sulfonyl group, an aminocarbonyl group, a lower alkylaminocarbonyl group, a lower alkenylaminocarbonyl group, a alquinilamin lowercarbonyl, a lower cycloalkylaminocarbonyl group, a group arylaminocarbonyl or a heterocyclic aminocarbonyl group; in the case where R8 or R9 is a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group, a lower alkynylcarbonyl group, a lower alkoxycarbonyl group, a lower alkenyloxycarbonyl group, an lower alkynyloxycarbonyl group, a lower alkylsulfonyl group, lower alkenylsulfonyl group, a lower alkynylsulfonyl group, a lower alkylaminocarbonyl group, a lower alkenylaminocarbonyl group or a lower alkynylaminocarbonyl group, the lower alkyl group, lower alkenyl group, lower alkynyl group, lower alkylcarbonyl group, lower alkenylcarbonyl group the the lower alkynylcarbonyl group, lower alkoxycarbonyl group, lower alkenyloxycarbonyl group, lower alkynyloxycarbonyl group the the lower ariisulfonilo group, lower alkenylsulfonyl group the the lower alkynylsulfonyl group, the group lower lquilaminocarbonilo, lower alkenylaminocarbonyl group or lower alkynylaminocarbonyl group may have one or a plurality of groups selected from a halogen atom, a lower cycloalkyl group, an aryl group, a heterocyclic group, a hydroxy group, an ester of a hydroxy group, a lower alkoxy group, a lower alkoxy group substituted by at least one halogen atom, a lower alkenyloxy group, a lower alkynyloxy group, a lower cycloalkyloxy group, an aryloxy group, an oxyheterocyclic group, a mercapto group, an ester of a mercapto group, a lower alkylthio group, a lower alkenylthio group, a lower alkynylthio group, a lower cycloalkylthio group, an arylthio group, a thioheterocyclic group, an amino group, an amide of an amino group, a lower alkylamino group, an amide of a lower alkylamino group, an arylamino group, an amide of an arylamino group, a heterocyclic amino group, an amide of an aminoheterocyclic group, a formyl group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group, a lower alkynylcarbonyl group, an lower cycloalkylcarbonyl group, an arylcarbonyl group, a heterocyclic carbonyl group, a carboxy group, an amide of a carboxy group, a lower alkoxycarbonyl group, a lower alkenyloxycarbonyl group, a lower alkynyloxycarbonyl group, a lower cycloalkyloxycarbonyl group, an aryloxycarbonyl group, an oxycarbonyl group heterocyclic, a lower alkylsulfinyl group, an arylsulfinyl group, a lower alkylsulfonyl group, ariisulfonilo group, an acid group Sulfinic, an ester of an acid group sulfinic, an amide of a sulfonic acid group, a sulfonic acid group, and a cyano group as substituents; in the case where R8 or R9 is a lower cycloalkyl group, an aryl group, a heterocyclic group, a lower cycloalkylcarbonyl group, an arylcarbonyl group, a heterocyclic carbonyl group, a lower cycloalkyloxycarbonyl group, an aryloxycarbonyl group, a heterocyclic oxycarbonyl group, a lower cycloalkylsulfonyl group, an arylsulfonyl group, a heterocyclic sulfonyl group, a lower cycloalkylaminocarbonyl group, an arylaminocarbonyl group or a heterocyclic aminocarbonyl group, the lower cycloalkyl group, the aryl group, the heterocyclic group, the lower cycloalkylcarbonyl group, the arylcarbonyl group, the heterocyclic carbonyl group, the lower cycloalkylcarbonyl group, the aryloxycarbonyl group, the heterocyclic oxycarbonyl group, the lower cycloalkylsulfonyl group, the arylsulfonyl group, the heterocyclic sulfonyl group, the lower cycloalkylaminocarbonyl group, the arylaminocarbonyl group or the aminocarbonyl group Eterocyclic may have one or a plurality of groups that are selected from a halogen atom, a lower alkyl group, a lower alkyl group substituted by at least one halogen atom, a substituted lower alkyl group by at least one hydroxy group, a lower alkyl group substituted by at least one lower alkoxy group, a lower alkyl group substituted by at least one amino group, a lower alkyl group substituted by at least one lower alkylamino group, a substituted lower alkyl group by at least one carboxy group, a lower alkyl group substituted by at least one lower alkoxycarbonyl group, a lower alkenyl group, a lower alkynyl group, a lower cycloalkyl group, an aryl group, a heterocyclic group, a hydroxy group, an a hydroxy group, a lower alkoxy group, a lower alkoxy group substituted by at least one halogen atom, a lower alkenyloxy group, a lower alkynyloxy group, a lower cycloalkyloxy group, an aryloxy group, an oxyheterocyclic group, a mercapto group, a ester of a mercapto group, a lower alkylthio group, a lower alkenylthio group, a lower alkynylthio group, a lower cycloalkylthio group or, an arylthio group, a heterocyclic thio group, an amino group, an amide of an amino group, a lower alkylamino group, an amide of a lower alkylamino group, an arylamino group, an amide of an arylamino group, a heterocyclic amino group , an amide of a heterocyclic amino group, a formyl group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group, a lower alkynylcarbonyl group, a group lower cycloalkylcarbonyl, an arylcarbonyl group, a heterocyclic carbonyl group, a carboxy group, an amide of a carboxy group, a lower alkoxycarbonyl group, a lower alkenyloxycarbonyl group, a lower alkynyloxycarbonyl group, a lower cycloalkyloxycarbonyl group, an aryloxycarbonyl group, an oxycarbonyl group heterocyclic, a lower alkynylsulfinyl group, an arylsulfinyl group, a lower alkylsulfonyl group, an arylsulfonyl group, a sulfinic acid group, an ester of a sulfinic acid group, an amide of a sulfinic acid group, a sulfonic acid group, an ester of an sulfonic acid group, an amide of a sulfonic acid group, a nitro group, a cyano group, an aminocarbonyloxy group, a lower alkylaminocarbonyloxy group and an arylaminocarbonyloxy group as substituents; in the case where R7 is NR8R9, R8 and R9 can be combined together to form a 5- to 6-membered nitrogen containing heterocyclic ring. 3. A compound or salt thereof, as described in claim 1, wherein in the general formula (1), the X ring represents a benzene ring or a pyridine ring; R1 represents a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group, a lower alkenyloxy group, a group lower alkylcarbonyl, an amino group or a nitro group; in the case where R1 is a lower alkyl group or a lower alkoxy group, the lower alkyl group or the lower alkoxy group may have one or a plurality of groups which are selected from a halogen atom, an aryl group, an aryl group substituted by at least one halogen atom, an aryl group substituted by at least one lower alkyl group, an aryl group substituted by at least one lower alkoxy group, a hydroxy group, a lower alkoxy group, an aryloxy group, a carboxy group and an ester of a carboxy group as substituents; p represents an integer from 0 to 3; in the case where p is 2 or 3, each R1 may be the same or different; R 2 represents a halogen atom, a lower alkyl group, a hydroxy group or a lower alkoxy group; q represents an integer from 0 to 2; in the case where q is 2, each R2 can be the same or different; R3 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, an aryl group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group or an arylcarbonyl group; in the case where R3 is a lower alkyl group or a lower alkylcarbonyl group, the lower alkyl group or the lower alkylcarbonyl group may have one or a plurality of aryl groups as substituents; in the case where R3 is an aryl group or an arylcarbonyl group, the The aryl group or the arylcarbonyl group may have one or a plurality of groups which are selected from a halogen atom and a lower alkyl group as substituents; R4 and R5 may be the same or different and represent a hydrogen atom or a lower alkyl group; Rs represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or a carbonyl group; R7 represents OR8, NR8R9 or SR8; R8 represents a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower cycloalkyl group, an aryl group, a heterocyclic group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group, a lower alkynylcarbonyl group, a lower cycloalkylcarbonyl group, an arylcarbonyl group or a heterocyclic carbonyl group; R9 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower cycloalkyl group, an aryl group, a heterocyclic group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group, a lower alkynylcarbonyl group, a lower cycloalkylcarbonyl group, an arylcarbonyl group, or a heterocyclic carbonyl group; in the case where R8 or R9 is a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower alkylcarbonyl group, an alkenylcarbonyl group lower or a lower alkynylcarbonyl group, the lower alkyl group, the lower alkenyl group, the lower alkynyl group, the lower alkylcarbonyl group, the lower alkenylcarbonyl group or the lower alkynylcarbonyl group may have one or a plurality of groups which are selected from a group aryl, a hydroxy group and a lower alkoxy group as substituents; in the case where R8 or R9 is a lower cycloalkyl group, an aryl group, a heterocyclic group, a lower cycloalkylcarbonyl group, an arylcarbonyl group or a heterocyclic carbonyl group, the lower cycloalkyl group, the aryl group, the heterocyclic group, the lower cycloalkylcarbonyl group, the arylcarbonyl group or the heterocyclic carbonyl group may have one or a plurality of groups which are selected from a halogen atom, a lower alkyl group, a lower alkyl group substituted by at least one halogen atom, an alkyl group lower substituted by at least one hydroxy group, a lower alkyl group substituted by at least one lower alkoxy group, a lower alkyl group substituted by at least one amino group, a lower alkyl group substituted by at least one lower alkylamino group, an alkyl group lower substituted by at least one carboxy group, a lower alkyl group substituted by at least one alkoxycarbonyl group lower, a lower alkenyl group, a lower alkynyl group, an aryl group, a heterocyclic group, a hydroxy group, an ester of a hydroxy group, a lower alkoxy group, a lower alkoxy group substituted by at least one halogen atom, an aryloxy group , a mercapto group, a lower alkylthio group, an amino group, an amide of an amino group, a lower alkylamino group, an amide of a lower alkylamino group, a formyl group, a lower alkylcarbonyl group, a carboxy group, an amide of a carboxy group, a lower alkoxycarbonyl group, a nitro group, a cyano group, an aminocarbonyloxy group and an alkylaminocarbonyloxy group as a substituent; in the case where R7 is NR8R9, R8 and R9 can be combined together to form a 5- or 6-membered heterocyclic ring containing nitrogen. 4. Compound or a salt thereof, as described in claim 1, wherein in the general formula (1), the X ring represents a benzene ring or a pyridine ring; R1 represents a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group, a lower alkenyloxy group, a lower alkylcarbonyl group, an amino group or a nitro group; in the case where R1 is a lower alkyl group or a lower alkoxy group, the lower alkyl group or the lower alkoxy group may have one or a plurality of groups which are selected from a halogen atom, an aryl group, an aryl group substituted with at least one halogen atom, an aryl group substituted with at least one lower alkyl group, an alkyl group substituted with at least one lower alkoxy group, an hydroxy group, a lower alkoxy group and an ester of a carboxy group as substituents; p represents an integer from 0 to 3; in the case where p is 2 or 3, each R1 may be the same or different; R 2 represents a halogen atom, a lower alkyl group or a lower alkoxy group; q represents 0 or 1; R3 represents a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkylcarbonyl group, a lower alkenylcarbonyl group or an arylcarbonyl group; in the case where R3 is a lower alkyl group, the lower alkyl group may have one or a plurality of aryl groups as substituents; in the case where R3 is an arylcarbonyl group, the arylcarbonyl group may have one or a plurality of groups which are selected from a halogen atom and a lower alkyl group as substituents; R4 and R5 both represent a lower alkyl group; R6 represents a lower alkyl group; A represents a lower alkylene group or a carbonyl group; R7 represents OR8, NR8R9 or SR8; R8 represents a lower alkyl group, a lower cycloalkyl group, an aryl group, a group heterocyclic, a lower alkylcarbonyl group, a lower alkenylcarbonyl group, a lower cycloalkylcarbonyl group, an arylcarbonyl group or a heterocyclic carbonyl group; R9 represents a hydrogen atom, a lower alkyl group, a lower cycloalkyl group, an aryl group, a heterocyclic group, an arylcarbonyl group or a heterocyclic carbonyl group; in the case where R8 or R9 is a lower alkyl group, the lower alkyl group may have one or a plurality of groups which are selected from a lower alkoxy group and an aryl group as a substituent; in the case where R8 or R9 is an aryl group, an arylcarbonyl group or a heterocyclic carbonyl group, the aryl group, the arylcarbonyl group or the heterocyclic carbonyl group may have one or a plurality of groups that are selected from a halogen atom , a lower alkyl group, a lower alkyl group substituted by at least one halogen atom, a lower alkyl group substituted by at least one hydroxy group, a lower alkyl group substituted by at least one amino group, a lower alkyl group substituted by less a lower alkylamino group, a lower alkyl group substituted by at least one carboxy group, a lower alkyl group substituted by at least one lower alkoxycarbonyl group, a lower alkenyl group, a lower alkynyl group, an aryl group, a hydroxy group, an ester of a hydroxy group, a lower alkoxy group, a lower alkoxy group substituted by at least one halogen atom, an aryloxy group, a lower alkylthio group, an amino group, an amide of an amino group, a lower alkylamino group, an amide of a lower alkylamino group, a formyl group, a lower alkylcarbonyl group, a carboxy group, an amide of a carboxy group, a lower alkoxycarbonyl group, a nitro group, a cyano group and a lower alkylaminocarbonyloxy group as substituents; in the case where R7 is NR8R9, R8 and R9 can be combined together to form a 5- or 6-membered heterocyclic ring containing nitrogen. 5. A compound or a salt thereof, as described in claim 1, wherein in the general formula (1), the X ring represents a benzene ring; R1 represents a halogen atom, a lower alkyl group, a hydrox-i group, a lower alkoxy group, a lower alkenyloxy group, an amino group or a nitro group; in the case where k1 is a lower alkyl group, the lower alkyl group may have one or a plurality of halogen atoms as substituents; in the case where R1 is a lower alkoxy group, the lower alkoxy group may have one or a plurality of groups which are selected from an aryl group, an aryl group substituted by at least one halogen atom, an aryl group substituted by less a lower alkyl group; an aryl group substituted by at least one lower alkoxy group and a lower alkoxy group as substituents; p represents 2 or 3, and in this case, each R1 may be the same or different; R 2 represents a halogen atom, a lower alkyl group or a lower alkoxy group; q represents 0 or 1; R3 represents a hydrogen atom; R4 and R5 both represent a lower alkyl group; R6 represents a lower alkyl group; A represents a lower alkylene group; R7 represents OR8, NR8R9 or SR8; R8 represents an aryl group, an arylcarbonyl group or a heterocyclic carbonyl group; R9 represents a hydrogen atom or a lower alkyl group; in the case where R8 is an aryl group, an arylcarbonyl group or a heterocyclic carbonyl group, the aryl group, the arylcarbonyl group or the heterocyclic carbonyl group may have one or a plurality of groups which are selected from a halogen atom, a lower alkyl group, a lower alkyl group substituted by at least one halogen atom, a lower alkyl group substituted by at least one hydroxy group, a lower alkyl group substituted by at least one amino group, a lower alkyl group substituted by at least one lower alkylamino group, a lower alkyl group substituted by at least one carboxy group, a lower alkyl group substituted by at least one lower alkoxycarbonyl group, a lower alkenyl group, a lower alkynyl group, an aryl group, a hydroxy group, an ester of a hydroxy group, a lower alkoxy group, a lower alkoxy group substituted by at least one halogen atom, an aryloxy group, an alkylthio group lower, an amino group, an amide of an amino group, a lower alkylamino group, an amide of a lower alkylamino group, a formyl group, a lower alkylcarbonyl group, a carboxy group, an amide of a carboxy group, a lower alkoxycarbonyl group , a nitro group, a cyano group and a lower alkylaminocarbonyloxy group as substituents. 6. Compound or a salt thereof, as described in any of claims 1 to 5, wherein in general formula (1), R7 is OR8. 7. Compound or a salt thereof, as described in claim 6, wherein R8 represents a phenyl group, a phenylcarbonyl group or a thiophenecarbonyl group. 8. Compound or a salt thereof, as described in any of claims 1 to 5, wherein in general formula (1), R7 is NR8R9. 9. Compound or a salt thereof, as described in claim 8, wherein R8 represents a phenyl group. 10. Compound or a salt thereof, as described in any of claims 1 to 5, wherein in general formula (1), R7 is SR8. 11. Compound or a salt thereof, as described in any of claims 1 to 10, wherein in the general formula (1), the X ring is a benzene ring. 1

2. Compound or a salt thereof, as described in any of claims 1 to 11, wherein in the general formula (1), A is a lower alkylene group. 1

3. Compound or a salt thereof, as described in claim 12, wherein A represents a methylene group. 1

4. Compound or a salt thereof, as described in any of claims 1 to 13, wherein in the general formula (1), R3 is a hydrogen atom. 1

5. Compound or a salt thereof, as described in any of claims 1 to 14, wherein in the general formula (1), R4, R5 and R6 are a lower alkyl group. 1

6. Compound or a salt thereof, as described in claim 15, wherein R4, R5 and R6 represent a methyl group. 1

7. Compound or a salt thereof that is selected from: 5-acetoxymethyl-6- (2-methoxyphenyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 5-benzoyloxymethyl-6- (2-methoxyphenyl) -2,2,4-trimethyl-1, 2-dihydroquinoline 6- (2-methoxyphenyl) -5 - [(thiophen-2-yl) carbonyloxymethyl] 2,2,4-trimethyl-1,2-dihydroquinoline 5- (4-tert-butylbenzoyloxymethyl) -6- (2-methoxyphenyl) ) -2,2, 4-trimethyl-1,2-dihydroquinoline 5-benzoyloxymethyl-6- (4-fluoro-2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro) -2-methoxyphenyl) -5- (3-methoxybenzoyloxymethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-Fluoro-2-methoxyphenyl) -5- (2-methoxybenzoyloxymethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (4-methoxybenzoyloxymethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- [(thiophen-2-yl) carbonyloxymethyl] -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) - 5- (4-methylbenzoyloxymethyl) 2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (3-methylbenzoyloxymethyl) 2,2,4-trimethyl-2, -dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (2-methylbenzoyloxymethyl) -2, 2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5-phenoxymethi1-2, 2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (4-methoxyphenoxymethyl) -2 , 2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (4-fluorophenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4- fluoro-2-methoxyphenyl) -5- (3-fluorophenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (2-fluorophenoxymethyl) -2, 2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (3-methoxyphenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro) -2-methoxyphenyl) -5- (2-methoxyphenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4,5-difluoro-2-methoxyphenyl) -5- (3-fluorophenoxymethyl) -2 2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (4-methylphenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4- fluoro-2-methoxyphenyl) -5- (3-methylphenoxymethyl) -2, 2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (2-methylphenoxymethyl) il) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (2-hydroxymethylphenoxymethyl) -2, 2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (5-fluoro-2-methylphenoxymethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5 - (5-chloro-2-methylphenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4,5-difluoro-2-methoxyphenyl) -5- (5-fluoro-2-methylphenoxymethyl) - 2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (2-methoxy-5-nitrophenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- [2- (2-hydroxyethyl) phenoxymethyl] -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) - 5- (2-methyl-5-nitrophenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (2-allylphenoxymethyl) 2, 2,4-trimethyl-1,2-dihydroquinoline 6- (5-chloro-2-methoxyphenyl) -5- [2- (2-hydroxyethyl) phenoxymethyl] -2,2,4-trimethyl-1,2-dihydroquinoline 5- (5-fluoro-2-methylphenoxymethyl) -6- (4-hydroxy-2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline 5- (5-fluoro-2-methylphenoxymethyl) -6 - (5-hydroxy-2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-hydroxy-2-methoxyphenyl) -5- (4-methylbenzoyloxymethyl) 2,2,4-trimethyl -l, 2-dihydroquinoline 6- (2-methoxyphenyl) -5-phenylaminomethyl-2, 2, 4- trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5-phenylaminomethyl-2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (4-methoxyphenylaminomethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (4-fluorophenylaminomethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (3-fluorophenylaminomethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-Fluoro-2-methoxyphenyl) -5- (2-fluorophenylaminomethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (3-methoxyphenylaminomethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (2-methoxyphenylaminomethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4,5-difluoro-2-methoxyphenyl) -5- (2-methoxyphenylaminomethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (2-hydroxymethylphenylaminomethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (2- methoxy-5-methylphenylaminomethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (5-fluoro-2-methylphenylaminomethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (5-chloro-2-methoxyphenyl) -5 - (2- methoxyphenylaminomethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (5-chloro-2-methoxyphenyl) -5- (5-fluoro-2-methylphenylaminomethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (2-methoxyphenyl) -5-phenylthiomethyl-2 , 2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5-phenylthiomethyl-2, 2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2- methoxyphenyl) -5- (2-methoxyphenylthiomethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5 - [(5-methylthiophen-2-yl) carbonyloxymethyl] -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5 - [(4-methylthiophen-2-yl) carbonyloxymethyl] -2,2,4-trimethyl-1 , 2-Dihydroquinoline 5- [(5-chlorothiophen-2-yl) carbonyloxymethyl] -6- (4-fluoro-2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro) -2-methoxyphenyl) -5- [(3-methylthiophen-2-yl) carbonyloxymethyl] -2,2,4-trimethyl-1,2-dihydroquinoline 5- [(5-bromothiophen-2-yl) carbonyloxymethyl] -6 - (4-fluoro-2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5 - [(5-methoxythiophen-2-yl) carbonyloxy methyl] -2, 2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- [(thiophen-3-yl) carbonyloxymethyl] -2,2, 4-trimethyl-1 , 2-dihydroquinoline 6- (4,5-difluoro-2-methoxyphenyl) -5 - [(5-methylthiophen-2-yl) carbonyloxymethyl] -2,2,4-trimethyl-1,2-dihydroquinoline 6- (5-chloro-2-methoxyphenyl) -5- (5-methylthiophen-2-ylcarbonyloxymethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (5-chloro-2-methoxyphenyl) -5 - (4-methoxybenzoyloxymethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (5-Chloro-2-methoxyphenyl) -5- (2-methyl-5-nitrophenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (5-chloro-2-methoxyphenyl) -5 - (5-fluoro-2-methylphenoxymethyl) -2,2, -trimethyl-1,2-dihydroquinoline 6- (5-chloro-2-methoxyphenyl) -5- (2-methoxy-5-nitrophenoxymethyl) -2,2 , 4-trimethyl-1,2-dihydroquinoline 6- (5-chloro-2-methoxyphenyl) -5- (5-chloro-2-methylphenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- ( 5-chloro-2-methoxyphenyl) -5- (5-fluoro-2-methoxyphenoxymethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (5-chloro-2-methoxyphenyl) -5- (2 , 5-dimethylphenoxymethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 5- (2-allylphenoxymethyl) -6- (5-chloro-2-methoxyphenyl) -2,2,4-trimethyl-2, -dihydroquinoline 5- (5-fluoro-2-methylphenoxymethyl) -6- (2-methoxy-5-nitrophenyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-allyloxy-2-methoxyphenyl) -5- (5-Fluoro-2-methylphenoxymethyl) -2, 2,4-trimethyl-1,2-dihydroquinoline 6- (5-allyloxy-2-methoxyphenyl) -5- (5-fluoro-2-methylphenoxymethyl) - 2,2, 4-trimethyl-1,2-dihydroquin nolina 6- (5-amino-2-methoxyphenyl) -5- (5-fluoro-2- methylphenoxymethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 5- (2-fluorobenzoyloxymethyl) -6- (4-fluoro-2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline - (3-fluorobenzoyloxymethyl) -6- (4-fluoro-2-methoxyphenyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 5- (4-fluorobenzoyloxymethyl) -6- (4-fluoro-2-methoxyphenyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro- 2-methoxyphenyl) -5- (4-methylphenylaminomethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (3-methylphenylaminomethyl) -2,2, 4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2-methoxyphenyl) -5- (2-methylphenylaminomethyl) -2,2,4-trimethyl-1,2-dihydroquinoline 6- (4-fluoro-2) -methoxyphenyl) -5- (2-methylphenylthiomethyl) 2,2,4-trimethyl-1,2-dihydroquinoline. 1

8. Pharmaceutical composition, comprising the compound or a salt thereof as described in any one of claims 1 to 17. 1

9. Glucocorticoid receptor modulator, comprising the compound or a salt thereof as described in any of the claims. 1 to 17 as an active ingredient. 20. Method for preventing or treating a glucocorticoid receptor-related disease, comprising administering a therapeutically amount to a patient of the compound or a salt thereof as described in any one of claims 1 to 17. 21. Method of prevention or treatment as described in claim 20, wherein the glucocorticoid receptor related disease is a metabolic disorder such as diabetes or obesity, an inflammatory disease such as enteritis or a chronic obstructive pulmonary disease, an autoimmune disease such as congenital tissue disease, an allergic disease such as asthma, atopic dermatitis or allergic rhinitis, a central nervous system disease such as a psychiatric disorder , Alzheimer's disease or a drug use disorder, a cardiovascular disease such as hypertension, hypercalcemia, hyperinsulinamia and hyperlipidemia, a disease related to homeostasis that causes an abnormality of the neuro-immunological-endocrine balance or glaucoma.